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Summary
The aims of this thesis were to investigate and build on recent reports 
implicating the complement (C) system in tumour growth and progression. 
The respective contributions of specific C components and regulators to this 
effect were assessed by the use of two tumour induction protocols.
Firstly, the chemical carcinogen 3-methylcholanthrene (3-MCA) was used to 
induce tumours in wild type mice and in animals deficient in C1q, C3 or 
double deficient in CD55 and CD59. Deficiency in the classical pathway of 
activation (C1 q'/_) or in the central component (C3'7') conferred a statistically 
significant protective effect against 3-MCA-induced tumourigenesis, 
suggesting that a fully functional C system was important for promotion of 
tumour progression in vivo. Additionally, a protective effect was observed in 
CD55‘7'.CD59‘7' mice indicating an important role for C-regulatory proteins 
(CRegs) in tumour progression.
In the second approach, novel fibrosarcoma lines were generated from 3- 
MCA-induced tumours. WT, C1q‘7‘, C3‘7' and CD55‘7'.CD59 lines were cloned 
and tested for specific characteristics including CReg expression, synthesis of 
C3 and susceptibility to C-attack. Few differences were observed between 
lines of different genotypes though expression of terminal pathway regulator 
CD59 was observed in C3‘7' lines only. Re-inoculation of WT and C3 lines 
showed no differences between the groups with comparable tumour incidence 
and growth rates observed.
Additionally, the effect of C on progression of a pre-characterised WT 
fibrosarcoma line was tested by inoculation into WT and C-deficient mice. 
Tumours inoculated into C1q'7', C3'7' and CD55'7'.CD59'7' mice were shown to 
exhibit comparable growth characteristics to those in WT controls. However, 
depletion of the terminal pathway component C5 using a monoclonal antibody 
(mAb) was shown to inhibit tumour progression. Treatment of mice with anti- 
05 mAb conferred a statistically significant protective effect to these mice and 
suggests a role for C in driving tumour pathology.
In conclusion, work in this thesis demonstrates an important pro-tumour role 
for C whereby activation of C can result in enhanced tumour progression. 
Additionally, expression of the CRegs CD55 and CD59 on host cells rather 
than tumour cells contributes to tumour proliferation. A pro-tumour role for C 
is contrary to current dogma but supports an alternative hypothesis whereby 
cell activating effects may provide a selective advantage to tumour cells 
following C-activation.
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1. INTRODUCTION
The aims of the work described in this thesis were to investigate the 
relationship between tumours and the complement (C) system. This system 
forms a crucial branch of innate immunity with numerous roles including host 
defence against infection, clearance of immune complexes and contribution to 
optimal antibody responses. C is known to target and kill cells and it would 
seem logical to assume that C poses an obstacle against tumour cell survival 
and proliferation. However, the relationship between C and tumours remains 
poorly understood and an alternative hypothesis is emerging suggesting that 
C may actually elicit pro-tumour effects and contribute to enhanced tumour 
cell survival and proliferation. Whilst this hypothesis remains unproven and 
appears to contradict dogma, nucleated cells are known to be resistant to lysis 
by C and are able to withstand C activation and deposition. Various 
stimulatory effects have been attributed to C activation and deposition on cells 
which are not lysed. Therefore, it has been suggested that tumour cells may 
be able to ‘harness’ the C system and use it to their advantage. In this way, C 
activation could promote tumour growth and survival rather than contribute to 
anti-tumour immune responses.
A detailed knowledge of the C system is important to identify key steps and 
their effects in relation to tumour cells. Three C activation pathways exist and 
are shown in Figure 1.1:
1.1 The Complement system: Overview
The C system comprises a family of plasma proteins that interact via a 
cascade mechanism. A crucial effector mechanism of innate immunity, C also 
provides an important link between innate and adaptive immune responses. 
Although initially discovered as a bacteriolytic pathway, C has many wide- 
ranging effects which do not culminate in lysis of target cells. A plethora of 
proteins exist which contribute to one or more of the activation pathways, or 
possess regulatory functions able to control autologous C attack (reviewed in
14
two parts (Walport, 2001a; Walport, 2001b)). Primarily, C components are 
synthesized by hepatocytes in the liver and circulate in blood plasma (Alper et 
ai. 1969). However, local C biosynthesis by numerous cell types is also well 
documented and is known to be significant in tissue homeostasis and immune 
defence (Morgan and Gasque 1997).
An important characteristic of C is the ability to discriminate between self and 
non-self cells and limit attack to foreign/invading cells whilst causing minimal 
damage to host tissue. This is partly achieved by tightly controlled activation 
mechanisms that prevent the inactive ‘zymogen’ forms of C proteins from 
depositing until specifically activated. Three separate activation pathways 
exist (Figure 1.1), each converging at a shared terminal pathway which leads 
to deposition of the Membrane Attack Complex (MAC), capable of lysing 
target cells. Upon activation of any of the pathways, precursor C proteins are 
enzymatically cleaved causing deposition of active protein fragments and 
localising attack to the activating target.
The enzymatic nature of these pathways means that a relatively small-scale 
trigger can be readily amplified to elicit a large-scale and rapid C response.
1.1.1 Classical pathway activation
The classical pathway of C activation is antibody-dependent and provides a 
link between innate and adaptive immunity. ‘Foreign’ antigens are recognised 
by specific antibodies to form immune complexes whereupon the Fc portions 
of IgM and IgG antibodies can then initiate the classical pathway through 
interaction with the globular domains of the initiator complex C1 (Sim and 
Reid 1991). C1 is a large multimeric complex made up of 3 different sized 
subunits: two C1r, two C1s and a single C1q molecule. The C1q protein 
comprises 18 polypeptide chains that form 6 globular ‘heads’ each consisting 
of 3 independently interacting chains (Reid and Porter 1976).
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Figure 1.1: The complement system.
Schematic representation of the three activation pathways of complement: classical, alternative and 
mannose binding lectin. Each pathway converges to a shared terminal pathway leading to insertion 
of a lytic pore into target cell membranes, the membrane attack complex (MAC). The classical 
pathway is initiated by either C1q binding to antibodies, or lectin binding to mannose residues. By 
contrast, the alternative pathway has no specific activation step and instead is centred around 
spontaneous low level hydrolysis or cleavage by proteases at inflammatory sites.
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For activation, 2 of the 6 C1q heads must bind to immunoglobulin Fc (lgG1, 
lgG2, lgG3 or IgM only) inducing a conformational change in the complex.
This change causes a C1r sub-unit to spontaneously activate via autocatalytic 
cleavage, this activated C1r molecule then cleaves and activates the other 
C1r sub-unit. The activated C1r molecules then cleave the two C1s sub-units 
respectively activating serine esterase activity of C1s and enabling cleavage 
of the next protein in the cascade, C4 (Cooper 1985).
The activated C1s enzyme can cleave numerous C4 molecules making this 
step capable of rapid amplification of the pathway. The C4 molecule 
comprises 3 polypeptide chains linked by three disulphide bonds (Schreiber 
and MUIIer-Eberhard 1974). Cleavage of this protein yields a weak 
anaphylatoxin (C4a) (Hugli et al. 1983), which is released, and an unstable 
C4b intermediate (Dodds and Law 1990). The larger C4b fragment contains a 
highly labile internal thioester bond which is either rapidly inactivated via 
aqueous hydrolysis or can bind covalently with amine or hydroxyl groups on 
the target cell membrane. Surface bound C4b provides a Mg2+-dependent 
binding site for the next component C2 which binds in an inactive form and 
releases C2b upon cleavage (Nagasawa and Stroud 1977). This cleavage is 
also mediated by activated C1s and allows formation of a C4b2a complex 
known as the ‘C3 convertase’ of the classical pathway. This enzyme is highly 
unstable and rapidly loses its function if it cannot immediately bind C3 The 
short half-life of the C3 convertase and the lability of activated C4b confers a 
high level of self-regulation upon the pathway and helps to prevent 
unnecessary activation and autologous attack. Hydrolysis occurs very rapidly 
in non-bound proteins confining deposition, and therefore attack, to the 
immediate vicinity of the activation site.
The C3 molecule is common to all three pathways and is the central 
component of the entire C system. Following classical pathway activation, C3 
is cleaved by the serine protease domain of C2a which makes up part of the 
classical C3 convertase, C4b2a. The C3 molecule comprises 2 protein chains 
covalently linked via disulphide bonds, while the alpha chain contains a 
thioester loop buried within the inactive molecule and protected inside a
17
hydrophobic ‘pocket’ (de Bruijn and Fey 1985). Upon cleavage of C3 by the 
C2a portion of the convertase, a small anaphylactic fragment (C3a) is 
released (Lambris 1988). Like cleavage of C4, once the C3a fragment is 
removed, the internal thioester loop is exposed and highly susceptible to 
nucleophilic attack. The unprotected loop is highly reactive, although unstable, 
and may bind to any nearby antigenic surface. Deposition of the larger 
fragment C3b with the C4b2a convertase forms a C4b2a3b complex (Kozono 
et al. 1990), the C5 convertase of the classical pathway and the initiator 
enzyme of the terminal pathway. Deposited C3b also serves to ‘focus’ further 
C attack to the area and it is estimated that approximately 240 C3b molecules 
are deposited for each activated C1 complex highlighting the amplification 
potential of classical pathway activation (Ollert et al. 1994).
1.1.2 MBL pathway activation
Another activation pathway closely resembles the classical pathway, sharing 
many of the components but differing in the initial activation step and thus is 
not antibody dependent. The mannan-binding lectin (MBL) pathway involves 
the recognition of mannose and N-acetylglucosamine residues abundant on 
surfaces of pathogenic micro-organisms via a serum protein known as 
Mannan Binding Lectin (MBL) (Epstein et al. 1996). This protein, like C1q of 
the classical pathway, is part of a family known as collectins or collagenous 
lectins. MBP binds to mannose on bacteria and interacts with two associated 
serine proteinases MASP-1 and MASP-2, analogous to C1r and C1s of the C1 
initiation complex (Matsushita and Fujita 1992). Activation of these enzymes 
leads to cleavage of C4 and C2 as in the classical pathway and formation of 
the classical C3 convertase. Another closely related protein, known as MASP- 
3, is formed by alternative splicing of the MASP-1 gene and has been shown 
to down-regulate the cleavage capacity of MASP-2 (Dahl et al. 2001).
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1.1.3. Alternative pathway activation
C activation can also occur via a third pathway known as the ‘alternative 
pathway’, an antibody-independent process based on a ‘tickover’ mechanism 
(Nicol and Lachmann 1973). No specific activation step exists in this pathway 
which instead centres around the spontaneous activation of serum C3 via 
aqueous hydrolysis of the internal thioester bond of the native molecule. This 
process is outlined in Figure 1.2. In addition to aqueous hydrolysis, any 
mechanism by which C3 is cleaved and activated may lead to deposition of 
C3 fragments and continuation of the alternative pathway. In this way, C3 
cleavage enzymes produced locally following inflammatory stimuli can 
activate the alternative C pathway and lead to C deposition. Cleavage by 
these mechanisms creates an activated molecule analogous to the C3b 
cleavage product formed by the classical pathway. Following aqueous 
hydrolysis, the activated C3(H20) reveals a Mg2+-dependent binding site for a 
93kDa plasma protein Factor B (fB). This forms a C3(H20)B complex 
susceptible to cleavage by a 26kDa serine proteinase, Factor D (fD) 
(Volanakis and Narayana 1996). A small fragment of the fB molecule (Ba) is 
released, while the larger portion is retained in a C3(H20)Bb molecule to form 
an unstable but active C3 convertase. This convertase is able to bind and 
cleave further C3 molecules via the serine protease domain of fB. This 
releases the C3a fragment and yields an active C3b fragment. However, as 
this convertase is in the fluid phase, the vast majority of C3b formed is rapidly 
inactivated via hydrolysis of the labile thioester bond. As previously stated, 
this process is spontaneous and occurs ubiquitously in a random and non­
specific manner. Continuation of the alternative pathway, or cleavage of C3b 
to iC3b by inactivating enzymes is dependent on surface properties of the 
target cell. Such properties include glycosylation patterns, charge and 
sialation on cell surfaces (Fearon 1979). Surfaces exhibiting low levels of 
sialic acid are less able to bind the regulatory protein factor H (fH), thus 
provide an ‘activating’ surface allowing un-hindered binding of fB and 
subsequent cleavage by fD to release Ba. This forms the membrane bound 
C3bBb complex capable of further C3 cleavage.
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Figure 1.2: The alternative pathway of C activation
Schematic representation of the alternative activation pathway of complement. Spontaneous ‘tickover1 
activation occurs due to hydrolysis of C3 in the fluid phase. An unstable C3 convertase is formed in the 
fluid phase able to yield C3b fragments capable of depositing on cell membranes.
The C3bBb convertase dissociates rapidly but is effectively stabilised in the 
presence of properdin, a glycoprotein which acts as a positive regulator on the 
alternative pathway (Pillemer et al. 1954). This step of the alternative pathway 
represents an effective amplification mechanism whereby one convertase 
molecule can cleave numerous further C3 molecules and rapidly amplify the 
response. As subsequent C3 molecules are cleaved, the larger C3b fragment 
may associate with C3bBb to form C3bBbC3b which is the alternative 
pathway C5 convertase and allows initiation of the terminal pathway. A key 
feature of the alternative pathway is that cleavage of C3 yields a C3b 
molecule capable of forming another C3 convertase enzyme (through 
interaction with fB). In this way, the amplification capacity of the alternative 
pathway is not restricted only to alternative pathway activation and will
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effectively amplify activation following initial deposition of C3b via classical, 
alternative or MBL pathways.
1.1.4 Terminal pathway & MAC formation
Cleavage of C5 by either the classical (C4b2a3b) or alternative (C3bBbC3b) 
C5 convertase initiates the terminal pathway of C. The C5 molecule is 
homologous to C3 and C4, but lacks the internal thioester bond. Cleavage of 
C5 releases the small anaphylactic fragment C5a and exposes a labile 
binding site on C5b (Cooper and Muller-Eberhard 1970). Additionally, the 
activated C5b possesses an acceptor site for spontaneous binding of C6 
followed by C7 causing a conformational change in the complex. The resulting 
C5b67 complex is released from the C5 convertase, exposing a hydrophobic 
region in C7 able to penetrate the target cell membrane (Preissner, Podack 
and Muller-Eberhard 1985). C8 is able to bind the C5b67 complex and inserts 
into the lipid bilayer, numerous hydrophobic C9 molecules may then 
polymerise into the complex (Podack and Tschopp 1982). Up to 14 C9 
molecules insert into the membrane forming a ring structure resulting in a lytic 
pore through the membrane, abbreviated as C5b-9, or the MAC. 
Immunochemical studies have demonstrated that MAC deposited on lysed 
cell surfaces comprise on average 3 or 4 C9 molecules (Stewart et al. 1984). 
MAC integrated into a membrane results in a channel of approximately 100A 
diameter which compromises the homeostatic capabilities of the cell and may 
lead to cell death (Podack and Tschopp 1982). The mechanism of pore 
insertion is thought to be similar to that of perforin insertion by CD8+ T- 
lymphocytes (Young et al. 1986).
1.2 Biological effects of C other than lysis
Whilst C activation may lead to formation of the MAC and cytolysis of target 
cells, a number of other biologically important effects also result from C 
activation. In many cases of C activation, lysis does not occur. However, in
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these cases, C remains important to mediate powerful effects independent of 
continuation of the lytic pathway. Such consequences include the release of 
anaphylatoxins and deposition of opsonins each of which contribute to 
enhanced immune responses. A summary of the various responses attributed 
to C activation is shown in Figure 1.3.
Clq
MASP1
MASP2
>  Clearance of 
apoptotic cells
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apoptotic cells
Phagocytosis Opsonisation
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B-cell activation 
T-cell activation
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products
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Figure 1.3: The diverse functions of C activation
The C system has numerous wide-ranging and import effects attributed to different C 
components. The best known effects caused by different C stages are summarised.
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1.2.1 Anaphylatoxins
The smaller cleavage products of C activation do not contribute to direct lysis 
of a target cell. They can be, however, potent anaphylatoxins (ATs) with roles 
in recruitment and activation of numerous inflammatory cells around the site of 
C activation (e.g. C3a, C4a, C5a). The ATs are short-lived to avoid excessive 
inflammatory responses damaging host tissue and are rapidly inactivated by 
the enzyme carboxypeptidase-N. This specific plasma inhibitor cleaves an 
arginine residue from the C-terminal end of C3a, C4a or C5a to yield a 
‘desArg’ form of the AT with reduced function. ATs can interact with G-protein 
coupled receptors (C3aR, C5aR) on various cell types to induce chemotaxis 
and mediate effector mechanisms of recruited cells.
C3a is released upon cleavage of C3, the central step in the C system and as 
such is found at higher concentrations than other cleavage products of C 
activation. This 9kDa fragment has been shown to mediate a number of pro- 
inflammatory responses (Lambris 1988). Binding of C3a to its receptor C3aR 
has been demonstrated to induce vascular permeabilisation and stimulate 
contraction of smooth muscle cells (Ember et al. 1992). Respiratory burst and 
subsequent production of reactive oxygen species is another major contributor 
to the inflammatory response and is triggered by C3a in macrophages 
(Murakami, Imamichi and Nagasawa 1993), and neutrophils (Eisner et al. 
1994). Mast cells and basophils can also be recruited (Kretzschmar et al. 
1993), and subsequently activated to release vasoactive amines such as 
histamine (el-Lati, Dahinden and Church 1994). Mouse cells transfected with 
human C3aR were shown to migrate in response to C3a but show no 
migratory activity in response to C3adesArg (Zwirner et al. 1998). However, 
C3desArg has been shown to mediate comparable effects on cytokine 
production by monocytes expressing the C3aR (Martin et al. 1997). This 
suggests that C3desArg may induce cellular responses through receptor 
independent mechanisms, however, no in vivo evidence is available to 
support this. Whilst the majority of C3a mediated effects are pro-inflammatory, 
a role for C3a interaction with C3aR in control of inflammatory responses has 
been shown via suppression of the pro-inflammatory cytokines TNFa and IL-1
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(Takabayashi et al. 1996). Additionally, an anti-inflammatory role for C3a 
independent of C3aR signalling has been shown, resulting in secretion of 
pituitary hormones such as growth hormone (Francis et al. 2003).
Cleavage of C5 yields a C5a product (11kDa) and, like C3a, induces pro- 
inflammatory effects. Both C3a and C5a have been shown to trigger 
vasodilation (Schumacher et al. 1991), and induce contraction of smooth 
muscle cells (Ember et al. 1992). Two receptors have been identified to bind 
with high affinity to C5a. The vast majority of effects are mediated through 
binding to C5aR, a G-protein coupled receptor. The role of the alternative 
receptor, C5L2, remains unclear, with no signalling effects initially associated 
with this protein (Okinaga et al. 2003). As such, C5L2 is often referred to as 
the ‘decoy’ receptor for C5a. However, an in vitro study found a strong anti­
inflammatory role for C5L2 and further work is needed to elucidate the in vivo 
relevance of this receptor (Gao et al. 2005). In this study, a clear role for C5L2 
up-regulation in response to inflammation was shown, and a role in balancing 
IL-6 secretion was observed. In contrast to C 3 a deSArg, the C 5 a desArg fragment 
remains active and functions akin to C5a via binding to 5aR. A wealth of 
evidence exists supporting an important role for C5a in infiltration of 
inflammatory cells through chemotaxis (Gerard and Gerard 1994), and as 
such C5a is heavily implicated in allergic diseases and inflammatory disorders 
e.g. asthma. Degranulation of mast cells can be triggered by C5a release, 
leading to release of histamine, matrix metalloproteinases and inflammatory 
cytokines (el-Lati et al. 1994, Takafuji et al. 2003). Other cells expressing the 
C5aR and shown to be subject to chemoattractant effects include neutrophils 
(Ehrengruber, Geiser and Deranleau 1994), macrophages (Aksamit, Falk and 
Leonard 1981), activated B-lymphocytes (Ottonello et al. 1999) and T- 
lymphocytes (Nataf et al. 1999). Native C5a is more resistant than C3a to 
carboxypeptidase-N cleavage, and also retains biological activity in its desArg 
form making it the principal C derived AT in vivo (Burgi, Brunner and 
Dahinden 1994).
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C4a (Clark and Klebanoff 1978) and Ba (Hamuro, Hadding and Bitter- 
Suermann 1978) possess only weak anaphylotoxic effects and are likely to be 
of little significance in vivo.
Complement activation leading to enzymatic cleavage of C3 and C5 therefore 
contributes to inflammation via release of C3a and C5a. This may be 
important in the tumour microenvironment where inflammatory mediators can 
contribute to enhanced tumour growth e.g. TNFa and IL-6 (Lin, 2007).
1.2.2. MAC deposition
The MAC is primarily responsible for disruption of target cell membranes 
leading to loss of homeostasis and cell death. However, C activation does not 
always result in lysis of a target cell and MAC deposition can be tolerated by 
cells which continue to function normally. This ‘sub-lytic’ attack occurs when 
MAC is deposited in insufficient quantities to cause lysis. In these cases, 
activation may be low level or cells may be protected from C e.g. through 
expression of inhibitory molecules such as CD55 or CD59 (Kim and Song, 
2006). Additionally, nucleated cells have been shown to possess intrinsic 
membrane repair mechanisms capable of preventing MAC deposition from 
resulting in lysis (Ohanian and Schlager 1981). Nucleated cells were also 
shown to release membrane vesicles in response to C attack (Richardson and 
Luzio 1980) suggesting these cells to be capable of ‘shedding’ the C5b-9 
complex from the surface via exocytosis, a theory that was later proved using 
monoclonal antibodies to visualise vesiculation (Campbell and Morgan 1985). 
Importantly, sub-lytic attack has also been shown to confer enhanced 
protection to subsequent C attack (Reiter, Ciobotariu and Fishelson 1992), 
trigger protein synthesis and phosphorylation (Reiter et al. 1995) and 
stimulate cell proliferation (Niculescu, Badea and Rus 1999). Such effects are 
particularly significant when considering the effects of C on tumour cells and 
are discussed in depth in subsequent sections.
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1.2.3 Opsonisation
C can also cause destruction of the target cell via another, distinct process in 
response to the deposition of ‘opsonic’ C fragments. These are C3b, C4b and 
associated inactivation products: iC3b, C3d and C3dg. Deposition of C3b on a 
cell surface is an essential step common to all 3 activation pathways but this 
molecule (or associated fragments) can also be recognised, and elicit a 
response in various cells expressing receptors specific for the opsonins (e.g. 
CR1, CR3). In this way opsonisation ‘labels’ the cell and allows enhanced 
adherence of many immune cell types which possess a C3b receptor 
(Lambris and MGIIer-Eberhard 1986, Fearon 1983). These receptors are found 
on immune effector cells and lead to enhanced phagocytosis i.e. engulfment 
and digestion of opsonised targets. Opsonisation provides a distinct pathway 
for clearance of cells independent of lysis through MAC deposition. A similar 
opsonic effect is mediated by C4b fixation although this effect is significantly 
weaker (Clark and Klebanoff 1978).
1.3. Complement Receptors
As previously described, opsonisation of surfaces by C activation products 
can result in adherence of various immune cell types. A number of cell surface 
proteins have been identified which bind to activation fragments of the C 
system. Four such receptors are termed ‘Complement Receptor’ (CR) and are 
numbered CR1 to CR4:
1.3.1. CR1
CR1 (CD35) is a large transmembrane protein with strong binding affinity for 
C3b and C4b as well as a weak interaction with iC3b. Binding of CR1 to these 
ligands mediates a range of functions. CR1 can act as an extrinsic co-factor 
to factor I facilitating cleavage of C3b to iC3b and further inactivation by 
cleavage to C3c and C3dg fragments (Fearon 1979). This protein is principally 
expressed on erythrocytes but may also be found on other cells of myeloid 
lineage e.g. B-cells, T-cells and neutrophils (Wilson, Tedder and Fearon 1983,
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Fischer et al. 1986). A crucial mechanism for removal of immune complexes 
involves interaction between CR1 and C3b whereby erythrocytes ‘collect’ 
opsonised immune complexes from tissues and transport them via the 
bloodstream to phagocytic cells for degradation in the spleen (Cornacoff et al. 
1984). CRs expressed by phagocytic cells detects opsonins on cell surfaces, 
and targets the cell for endocytosis (Fearon, Kaneko and Thomson 1981).
1.3.2. CR2
CR2 (CD21) was originally shown to be the receptor for the Epstein-Barr Virus 
(Fingeroth et al. 1984), and has been targeted to block EBV binding to 
lymphocytes (Nemerow, McNaughton and Cooper 1985). Human CR1 and 
CR2 are products of separate genes while murine CR1 and CR2 are products 
of a single, alternatively spliced gene. The CR2 protein is shorter and does 
not possess the C3b/C4b-binding site therefore cannot act as a co-factor for fl 
mediated cleavage. Instead, the CR2 receptor binds C3dg and C3d strongly 
and has only weak affinity for iC3b (Kalli and Fearon 1994). CR2 was initially 
isolated from Raji cells (Barel, Charriaut and Frade 1981) and is found 
predominantly on B-cells and follicular dendritic cells (Reynes et al. 1985).
1.3.3. CR3
CR3 (CD18/11b) is part of the integrin family of adhesion molecules but also 
has a distinct role in mediating phagocytosis of opsonised particles (Hogg 
1992). Expressed predominantly on macrophages, CR3 binds to iC3b 
resulting in phagocytosis of the labelled cell.
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1.3.4. CR4
CR4 (CD18/11c) also functions as an adhesion molecule and was isolated 
from neutrophils as a novel CR type protein capable of binding iC3b, C3dg 
and C3d (Vik and Fearon 1985). The primary ligand for CR4 is the C3dg 
molecule through a distinct binding mechanism to that of CR2. CR4 is found 
predominantly on neutrophils, platelets, macrophages, monocytes and 
erythrocytes (Myones et al. 1988). Interaction with opsonic fragments allows 
enhanced localisation of coated immune complexes and particles by cells of 
the myeloid and lymphoid lineage.
1.4. The central component C3: links to adaptive immunity
Native C3, a 185 kDa protein, is present in high concentration in the serum (1- 
2mg/ml) and comprises two polypeptide chains linked by a disulfide bond 
(Tack and Prahl 1976). C3 is central to the entire C system and common to all 
three activation pathways. Unsurprisingly, recurrent bacterial infection is 
associated with C3 deficiency through inability to cause CDC (Walport and 
Lachmann 1984). Outside of C activation, C3 has key roles in phagocytosis, 
inflammatory responses and forms important links between innate and 
adaptive immunity. Effects of the anaphylotoxic fragment C3a, as well as 
opsonic effects of C3 cleavage products have previously been described in 
this Chapter. Targeted disruption of the murine C3 gene generated mice 
lacking the majority of the functions elicited by C and has allowed better 
understanding of the diverse roles of C3 over the past decade (Wessels et al. 
1995, Pekna et al. 1998). An overview of the diverse roles of C activation, 
including the contribution of C3 activation is shown in Figure 1.3.
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1.4.1 C3 and the B cell response
The observation that a lack of C3 caused sub-optimal antibody responses first 
suggested a link between C and humoral immunity. An in vivo study in mice 
showed that depletion of C3 caused impairment of T-cell dependent antibody 
production (Pepys 1974). A role for the CR2 protein was initially demonstrated 
in enhancement of B-cell proliferation following ligation with a polyclonal 
antibody. This effect was only observed in the presence of T-cell factors 
(Frade et al. 1985). Later, an antibody targeted against murine CR2 was 
shown to suppress 99% of primary B-cell antibody responses in vivo through 
blocking of the binding site for opsonic fragments iC3b and C3dg (Heyman, 
Wiersma and Kinoshita 1990). A synergistic mechanism for enhanced B-cell 
responses was first described following the observation of increased Ca2+ 
influx and thymidine incorporation following cross-linkage of CR2 and 
membrane-bound IgM molecules on B-cells (Carter et al. 1988). The 
membrane localised CD19 protein was also shown to co-precipitate with CR2 
and another protein CD81, with this complex shown to contribute to enhanced 
signal transduction (Matsumoto et al. 1991). Co-ligation of this complex with 
the B-cell receptor (BCR) was shown to significantly decrease the threshold 
for stimulation (Carter and Fearon 1992). The CR1 protein also contributes to 
this synergistic mechanism via co-factor activity for fl mediated cleavage thus 
facilitating conversion of deposited C3b to C3dg fragments and providing the 
ligand for CR2 attachment. This mechanism is depicted in Figure 1.4.
Therefore when antigens bind to B-cells through the BCR, opsonic C 
fragments (C3dg / C3d) on antigen surfaces can also bind CR2 expressed on 
B-cells. CR2 forms part of the CR2/CD19/CD81 complex and contributes to 
enhanced B-cell signalling and activation resulting in a more efficient antibody 
response. Further work by Dempsey et al (1996) demonstrated a role for CR2 
binding to antigen opsonised with C3d in lowering the threshold for B-cell 
activation. In this study, immunisation of mice using C3d fusion proteins 
lowered the amount of antigen required to elicit a secondary response by 
10,000 fold through co-ligation with CR2 and was shown to be dependent on 
amount of C3d attached to antigen.
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Figure 1.4: Antigenic opsonisation contributes to B-cell responses
Antigen opsonised with the C3dg fragment can bind with CR2 in a complex with CD19 and CD81. Co­
stimulation of this complex with the B-cell receptor results in a synergistic response and contributes to 
optimal humoral immune responses.
30
1.4.2. C3, dendritic cells and the T-cell response
A role for C as an accessory molecule in the adaptive immune system has 
been the subject of much recent research with evidence available to 
demonstrate a modulatory role for C3 in T-cell activation and migration. 
Dendritic cells (DCs) are heterogeneous bone marrow derived cells crucial to 
the adaptive immune response as antigen presenting cells. Mature DCs are 
responsible for recognition and phagocytosis of pathogens, whereby antigenic 
fragments of degraded particles are presented on their surfaces. Subsequent 
activation of na'fve T-lymphocytes leads to differentiation and proliferation of 
T-cells (both CD4+ and CD8+) and B-cells (Behrens et al. 2004). C has long 
been thought to play a role in T-cell responses and antigen-bound C3b was 
initially shown to enhance DC function and human T-cell activation (Arvieux, 
Yssel and Colomb 1988). In mice, CR1 and CR2 are expressed on activated 
T-cells and bind directly to C3 fragments on DCs enhancing proliferation of 
antigen-specific T lymphocytes (Kerekes et al. 1998). These receptors are not 
expressed on naive T-cells, further suggesting a role in activation (Kinoshita 
et al. 1988). The presence of iC3b on apoptotic cells leads to enhanced 
engulfment by DCs (Verbovetski et al. 2002), with further studies on this 
mechanism showing important roles for CR3 and CR4 binding to iC3b (Morelli 
et al. 2003). Mouse DCs have been shown to secrete C3 both in vivo and in 
vitro with DCs derived from C3'7' mice shown to down-regulate MHC 
molecules and elicit reduced T-cell responses to stimulation (Peng et al.
2006).
A role for C3 in murine CD4+ and CD8+ T-cell responses to viral infection has 
also been demonstrated, with deficiency of C3 associated with delayed 
clearance of influenza virus in mice, along with increased viral titres in the 
lung (Kopf et al. 2002). The study also noted reduced T-cell priming of virus- 
specific CD4+ and CD8+ effector T cells. Importantly, these effects were not 
seen in CR1/CR2 deficient mice suggesting this effect was not mediated 
through the enhanced B-cell response described above. Instead, a C3- 
mediated effect independent of CR1 and CR2 was shown. An alternative 
receptor for this interaction has yet to be proven but may be linked to C3a and
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C5a release in WT but not C3‘7' mice. T-cell recruitment, effector function and 
priming were found to be sub-optimal in C3*/_ hosts implicating C in 
enhancement of anti-viral adaptive immune responses.
1.5 C1q: A molecule with numerous functions
C1q, a sub-unit of the initiation molecule of the classical pathway also 
possesses important and wide-ranging functions unrelated to CDC. Deficiency 
in this protein has long been associated with autoimmune disease, with cases 
often leading to development of systemic lupus erythrematosus (SLE). Of 32 
cases of human C1q deficiency assessed by Slingsby et al (1996), 30 went on 
to develop SLE while another presented with an SLE-like disease. A role for 
C1q in clearance of dying cells was initially proposed through stimulation of 
phagocytosis of opsonised cells by monocytes, mediated via the collagen-like 
portion of C1q (Bobak et al. 1987). A later finding showed impaired clearance 
of apoptotic cells (ACs) leading to SLE-like symptoms and autoimmunity 
though increased autoantibody production (Mevorach et al. 1998). A human 
keratinocyte model was used to show direct binding of C1q specifically to ACs 
in an antibody independent manner (Korb and Ahearn 1997). In this in vitro 
study, human keratinocytes were rendered apoptotic through UV irradiation or 
infection with virus. C1q binding directly to apoptotic keratinocytes was 
visualised using immunofluorescent microscopy and shown to be localised to 
apoptotic blebs implicating C1q in clearance of these cells in healthy 
individuals. One proposed mechanism for the clearance is through activation 
of the classical pathway on these cells leading to opsonisation and enhanced 
phagocytosis. This hypothesis is supported by the in vivo observation by a 
separate group that C3 activation products are deposited on apoptotic 
keratinocytes in human skin biopsies (Rauterberg, Jung and Rauterberg 
1993).
Additionally, a role for C1q in directly labelling (i.e. not through classical 
pathway activation) these cells for phagocytosis was postulated through
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interaction with C1q receptors. The generation of a murine C1q knock-out 
mouse colony via gene targeting has allowed rapid progress in the field (Botto 
1998). Mice of this genotype showed increased mortality with 
glomerulonephritis and immune deposits common. A further investigation 
found high titres of autoantibodies and multiple apoptotic bodies in these 
animals (Botto et al. 1998). Activation of the CP by C1q binding was 
demonstrated in these mice following direct association between ACs and 
C1q (Nauta et al. 2002). Taylor et al demonstrated a hierarchical role for C1q 
and C4 in AC clearance, and found impaired phagocytosis in vivo (Taylor, 
2000). C1q and C4 deficiencies caused significant and comparable delays in 
AC clearance indicating a key role for opsonisation via CP activation. 
However, the observation that phagocytic uptake was less impaired in C4_/' 
animals compared to those lacking C1q suggested that C1q was in fact more 
important in this model, thought to be mediated through direct binding to the 
C1qR receptor (Taylor et al. 2000). A direct mechanism for C1q binding and 
phagocytosis was elucidated as macrophage engulfment of apoptotic cells. 
This was demonstrated to be C independent and to be mediated by 
interaction with the membrane expressed C1q receptor calreticulin (cC1qR) 
and CD91 (Ogden et al. 2001). MBL has also been shown to have a similar 
effect on AC uptake through binding to calreticulin. Interestingly, C1q was 
shown to bind to both viable and apoptotic cells in this study, however only 
ACs stimulated macrophage engulfment. This difference is surprising and is 
thought to be due to localisation patterns of C1q on ACs compared to viable 
cells. Previous studies corroborate the authors’ suggestion that ‘clustered’ 
(rather than diffuse) C1q binding in blebs is required for macrophage binding 
and subsequent phagocytosis (Korb et al. 1997, Navratil et al. 2001). An 
alternative receptor for C1q was proposed with antibody targeted against the 
molecule shown to inhibit enhanced phagocytosis mediated by C1q (Guan et 
al. 1994). This receptor was designated C1qRp and later demonstrated to be 
CD93 (Steinberger et al. 2002). However, transfection of CHO cells with 
C1qRp was shown not to confer enhanced C1q binding. Additionally, the 
same study found little evidence for expression on macrophages, and argues 
against a direct association mediating enhanced phagocytosis (McGreal et al.
2002). The same protein was later shown to enhance removal of ACs in an in
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vivo murine model though this phenomenon was shown to be C1q 
independent and the role of this receptor remains controversial (Norsworthy et 
al. 2004).
Binding of C1q to CR1 has been demonstrated in humans (Klickstein et al. 
1997), thought to aid clearance of immune complexes via binding to 
erythrocytes (Tas et al. 1999). C1q can also recruit, activate and cause 
degranulation of mast cells, central in allergic and inflammatory responses 
(Marshall and Bienenstock 1994). These effects were shown to be mediated 
through interaction with a novel C1q receptor molecule, a2p1 integrin 
(Edelson et al. 2006). Antibody production by B-cells and modulation of 
platelet behaviour are other reported functions of C1q (Peerschke and 
Ghebrehiwet 1992).
Unlike the majority of C components, the primary site of synthesis for C1q is 
not the liver. Instead C1q has been shown to be produced locally by immune 
cell types, most notably macrophages on which C1q has been shown to have 
multiple effects (Muller, Hanauske-Abel and Loos 1978). Macrophage 
cytotoxicity can also be regulated by C1q through regulation of TNF-a 
synthesis and Nitric Oxide production (Jiang et al. 1996). C1q synthesis and 
secretion was up-regulated in response to stimulation in this study, while an 
antibody to C1q abrogated the effects. The receptor for C1q binding in these 
experiments was not identified. The recruitment of fibroblasts is a relevant role 
of C1q of particular note in this thesis. A chemotactic function of this protein 
has been demonstrated with human neutrophils and mouse mast cells shown 
to migrate in response to soluble C1q, mediated through the collagen tail 
(Ghebrehiwet et al. 1995, Leigh et al. 1998). C1q is also implicated in the 
migration of fibroblasts to injury sites (Oiki and Okada 1988), i.e. those of C 
activation and inflammation while an alternative effect of C1q on fibroblasts is 
the induction of apoptosis (Bordin and Whitfield 2003).
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1.6 Regulation of C
The C system represents a powerful effector mechanism mediating numerous 
inflammatory effects, with the capability to destroy cells and contribute to 
disease. Inappropriate activation of C can have severe consequences for host 
tissue and is implicated in many autoimmune diseases such as rheumatoid 
arthritis. Rapid hydrolysis and inactivation of active fragments serves to limit 
the harmful effects of C activation to the vicinity of an activating surface. 
However, the nature of the cascade, and the possibility of active components 
diffusing from the site of activation has the potential to damage host cells in 
the vicinity, or ‘bystander cells’. The classical pathway of C is antibody 
dependent and as such is activated only on cells which elicit a humoral 
(antibody) immune response. In addition, the ‘tickover’ of the alternative 
pathway and the great potential for amplification necessitates that additional 
protective mechanisms are in place to guard against autologous attack. A 
plethora of proteins exist, both membrane bound and fluid phase, with the 
primary function of protecting host cells from C-mediated damage. These 
proteins are collectively termed complement regulators (CReg) and are 
summarized in Table 1.1.
1.6.1 Serpins
The serpin family of proteins derives its name from the activity of its members 
as serine grotease inhibitors. There are a huge number of serpins, wide- 
ranging in function and localisation. One such protein, known as C1 inh, is able 
to prevent CP activation.
1.6.1.1 C1inh
The initiation step of the classical pathway can be inhibited by C1 inhibitor 
(C1inh). This enzyme inhibitor is a single chain polypeptide with variable 
glycosylation and like C components, is primarily synthesised in the liver 
(Johnson et al. 1971). However multiple other cell types have been shown to
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CReg Location Ligand Function
C1inh Plasma C1 Dissociates activated C1 
complex
CD55
(DAF)
Membrane C3bBb,
C4b2a
Accelerates decay of 
convertases
CD46
(MCP)
Membrane C3b, C4b Co-factor for fl.
CR1
(CD35)
Membrane C3b, C4b, 
iC3b (weak)
Cofactor for fl, accelerates 
decay of convertases
C4bp Plasma C4b, C4b2a Cofactor for fl, accelerates 
CP convertase decay
Factor H Plasma C3b, C3bBb Co-factor for fl, 
accelerates AP 
convertase decay
Crry Membrane C3b. iC3b, 
C4b, C4b2a, 
C3bBb
Cofactor for fl, accelerates 
convertase decay
Factor I Plasma C3b, iC3b, 
C4b
Inactivates C3b and C4b 
fragments
CD59 Membrane C5b-8 Prevents C9 
polymerisation by binding 
to C5b-8
Clusterin Plasma C5b-7 Prevents C8 binding to 
C5b-7
S-
Protein
Plasma C5b-7 Prevents C8 binding to 
C5b-7
Table 1.1: Summary of complement regulators
Activity and function of the complement regulatory proteins described in this Chapter.
36
secrete local C1inh in response to cytokine stimuli, including fibroblasts (Katz 
and Strunk 1989), and monocytes (Lotz and Zuraw 1987). The mode of action 
for C1inh is through binding to the proteases C1r and C1s causing 
dissociation of these molecules from C1q. This removes the enzymatic activity 
of C1 and prevents CP activation (Bos, 2002). C1 and C1inh proteins are both 
found in the fluid phase and as such, the inhibitor in circulating plasma has 
been shown to ‘chaperone’ C1 and prevent unnecessary activation (Tenner, 
1986).
1.6.2 Regulators of Complement Activation
The genes encoding an important family of proteins are found in the 
‘Regulators of Complement Activation’ (RCA) gene cluster localized on 
chromosome 1. Members of this family comprise varying numbers of 
consecutive domains known as Short Consensus Repeats (SCRs) (Hourcade, 
Holers and Atkinson 1989). These repeating units contain approximately 60 
amino acids each and are highly conserved. Integral to the SCR structure are 
4 conserved cysteine residues, these form two disulphide bridges and hold 
the SCR in a compact, globular conformation. The number of SCRs varies 
between proteins but it is these common repeating units which are 
responsible for interaction with activation products of C3 and C4 and thus the 
regulatory effects of these proteins. Early work in this field concentrated on 
RCA family members in humans and found the genes encoding these proteins 
to be closely linked and localized within an 800kb segment on chromosome 
1q21 (Lublin et al. 1987, Rodriguez de Cordoba et al. 1985). The various 
proteins appear to be the result of gene duplication, all derived from the same 
ancestral gene. Investigations of RCA proteins in mice found significant 
sequence homology to corresponding human proteins including conservation 
of the SCR structures. The genes for these proteins were found located on 
mouse chromosome 1 (Seldin et al. 1988). However, a number of differences 
were also identified including designation of a new, murine specific CReg 
(Crry, described in section 1.6.2.6).
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Human CReg which belong to this family include: complement receptor 1 
(CR1; CD35), membrane co-factor protein (MCP; CD46), decay accelerating 
factor (DAF; CD55), C4b binding protein (C4bp) and factor H (fH).
1.6.2.1 Decay accelerator factor (DAF, CD55)
CD55 (DAF) was first described as a membrane-bound protein of human 
erythrocytes comprising 4 SCR domains and a molecular weight of ~70kDa 
(Hoffmann 1969). CD55 was purified and shown to integrate into other 
erythrocyte membranes and protect from C, suggesting a hydrophobic portion 
(Medof, Kinoshita and Nussenzweig 1984) later identified as a 
glycophosphatidylinositol (GPI)-anchor (Davitz, Low and Nussenzweig 1986). 
CD55 had previously been shown to bind the human C3 and C5 convertases 
of both classical and alternative pathways and accelerate their decay (Medof 
et al. 1984) thus regulating all three pathways of C activation, preventing 
further C3 deposition and initiation of the terminal pathway. Recombinant 
CD55 proteins deficient in individual SCRs have been used to locate areas of 
activity with the SCR2 and SCR3 domains shown to inhibit the classical C3 
convertase and the SCR4 domain also necessary for alternative pathway 
inhibition (Brodbeck et al. 2000).
A functional mouse homologue for human CD55 was later identified as a 
~65kDa glycoprotein (Kameyoshi, Matsushita and Okada 1989). The CD55 
gene encodes a GPI-anchored form of the protein and is designated Daf-1. 
This protein has been found widely distributed on most tissues (Song et al. 
1996). A duplicate gene is found only in mice and encodes a transmembrane 
form of CD55 with 78% homology to Daf-1 (Spicer, Seldin and Gendler 1995). 
Expression of the Daf-2 transmembrane form is restricted to the testis and 
spleen only (Lin et al. 2001). Targeted deletion of Daf-1 in the mouse was not 
sufficient to cause spontaneous lysis of erythrocytes, despite elevated levels 
of C3 deposition (Sun et al. 1999), although deficiency in another RCA, Crry, 
did cause cells to be lysed through C (Miwa et al. 2002b). However, an 
important regulatory function for CD55 was shown through exacerbated
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phenotype in murine models of autoimmune disease (Miwa et al. 2002a, Liu et 
al. 2005). CD55 expression has also been shown to be up-regulated in 
response to cytokine stimuli and important in the protection of vascular tissue 
against C deposition in an inflammatory environment (Ahmad et al. 2003).
1.6.2.2 Membrane co-factor protein (MCP, CD46)
MCP was first purified from a human T-cell line (Lublin et al. 1988), and was 
found ubiquitously expressed except on erythrocytes (Liszewski, Post and 
Atkinson 1991). MCP does not exhibit decay accelerating action on either CP 
or AP convertases. Instead MCP possesses co-factor activity for cleavage 
and inactivation of deposited C3b and C4b by the serine protease factor I 
(Seya and Atkinson 1989). Expression of the murine MCP protein is confined 
to the testis (Tsujimura et al. 1998) with the role postulated to be unrelated to 
C regulation and important in sperm-egg interactions (Mizuno et al. 2004).
1.6.2.3. CR1
Complement receptor 1 (CD35) has previously been described in this thesis 
as mediating binding to C3 activation products by various immune cell types. 
Various forms of this protein exist with the most common variant comprising 
30 SCRs and with a molecular weight of 190kDa (Klickstein et al. 1987). CR1 
regulates both the classical and alternative pathways by accelerating decay of 
C3 and C5 convertases. An additional function of CR1 is as a co-factor for fl- 
mediated cleavage of C3b and C4b to inactive forms e.g. iC3b, C3dg, iC4b, 
C4d (Fearon 1980). In humans, the majority of CR1 is found expressed on 
erythrocytes and is responsible for clearance of immune complexes from the 
bloodstream (previously described in section 1.3.1.)
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1.6.2.4. C4 binding protein (C4bp)
C4 binding protein (C4bp) is a larger plasma protein which possesses decay 
accelerating activity through binding to the classical pathway C3 and C5 
convertases (Gigli, 1979). The protein also acts as a co-factor for fl-mediated 
cleavage of both surface bound and fluid phase C4b to inactive fragments 
(Fujita, 1978). In this way, C4bp regulates the classical and MBL activation 
pathways only.
1.6.2.5. Factor H (fH)
Factor H (fH) is a monomeric fluid phase protein of ~150kDa found at 
relatively high levels (~0.5mg/ml) in human and murine plasma. fH inhibits the 
alternative pathway via binding to C3b and preventing association with fB. 
Additionally, fH can bind to the pre-formed convertase and accelerate it’s 
decay (Whaley and Ruddy 1976). In a similar fashion, fH promotes decay of 
both the classical and alternative C5 convertases (Ollert et al. 1995). As a co­
factor for fl, fH also promotes the cleavage of C3b to iC3b (Harrison and 
Lachmann 1980).
An important splice variant of the fH gene exists, known as fH-like protein 1 
(FHL-1) also with the ability to regulate the alternative pathway. Like fH, FHL- 
1 possesses decay accelerating activity and acts as a co-factor for fl mediated 
cleavage of C3b (Fontaine et al. 1989, Zipfel and Skerka 1999).
1.6.2.6. Complement receptor related protein y (Crry, 5I2 antigen)
Crry is a potent CReg found only in rodents. Initially identified during a search 
for a murine CR1 molecule, the 65kDa protein, initially named p65, was 
shown to inhibit both the classical and alternative pathways (Wong and 
Fearon 1985). Murine Crry is ubiquitously expressed (Funabashi et al. 1994), 
and provides effective protection against unwanted C attack. The molecule 
comprises 5 SCR domains in addition to a transmembrane and cytoplasmic
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domain (Kurtz et al. 1989), and was hypothesised to function akin to MCP and 
CD55 (Li et al. 1993). Further study demonstrated both a C3-convertase 
decay-accelerating role, and fl co-factor activity for Crry (Kim et al. 1995). Crry 
combines the regulatory activities of MCP and CD55 and as such is of vital 
importance in rodents. Blockade of the protein in vitro caused increased AP 
activation with significant cytotoxicity in mesangial and endothelial ceils 
(Quigg et al. 1995), while systemic administration of Crry neutralising mAbs is 
associated with increased C3b deposition, enhanced inflammation and 
significant cell death (Matsuo et al. 1994, Nomura et al. 1995). While CD55 
retains important roles in rodents, MCP is reduced to a minimal role and is 
present in the testes alone (Tsujimura et al. 1998). Mice bred to be deficient in 
Crry died in utero following activation of maternal C. This embryonic lethality 
could be rescued by breeding to C3-deficient mice with tissue damage 
mediated by C deposition at the foetomaternal interface responsible for foetal 
death (Xu, 2000). Further evidence of the importance of Crry is provided from 
observations that this molecule, but not CD55 or CD59, is crucial in protection 
of erythrocytes from spontaneous lysis in the circulation (Miwa et al. 2002b), 
while rat T-cells depend solely on Crry to protect from autologous CDC 
(Hanna et al. 2002).
1.6.2.7. Factor I (fl)
As previously described, several of the CRegs (CR1, MCP, C4bp, fH) interact 
with another protein, factor I (fl). This protein is a plasma serine protease 
capable of regulating both activation pathways by inactivating C3b or C4b via 
cleavage within the alpha chain (Davis and Harrison 1982). fl can only 
function in conjunction with these specific co-factors but is crucial for 
regulation of C, in particular the amplification capacity of the AP (Nicol and 
Lachmann 1973). Cleavage of C3b (bound to fH, MCP or CR1) renders an 
inactive C3b molecule (iC3b) and another fragment C3f (Harrison et al. 1988). 
Further cleavage of iC3b yields C3c and membrane bound C3dg (Ross et al. 
1983). Additionally, fl (in association with C4bp, MCP or CR1) can also 
regulate the classical pathway via cleavage of C4b to release C4c and leave
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C4d attached to the membrane (Shiraishi, 1975, Fujita, Gigli and 
Nussenzweig 1978)). This protein is a crucial CReg and contributes to the 
efficacy of the ubiquitously expressed membrane-bound CReg.
1.6.3 Terminal pathway regulation
The majority of CReg exhibit inhibitory activity on the activation pathways of C 
whereas just one membrane bound protein has been identified able to 
regulate the terminal pathway. This protein, and two fluid phase proteins 
inhibit the terminal pathway to prevent MAC integration into target cell 
membranes.
1.6.3.1 CD59 (protectin)
CD59 is a member of the lymphocyte antigen 6 (Ly-6) superfamily, a number 
of related proteins of which only one is involved in regulation of C. Ly-6 family 
members are cysteine-rich GPI-anchored cell surface proteins forming 5 
disulphide bonds within the molecule (Kieffer et al. 1994). CD59 is a small 
protein (19kDa) and was first purified from human erythrocyte cells (Sugita, 
Nakano and Tomita 1988). The activity of CD59 was shown to differ from 
other CReg through its action to regulate specifically the terminal pathway 
(Davies et al. 1989). CD59 regulates the terminal pathway by binding with the 
C5b-8 complex through the alpha chain of C8 (Meri et al. 1990). Whilst one 
C9 molecule can then bind, the polymerisation of C9 and subsequent 
formation of MAC is inhibited by CD59 providing a potent regulatory 
mechanism against MAC-induced lysis. Non-nucleated cells are more 
susceptible to C lysis and have been shown to express in the region of 25000 
CD59 molecules per cell (Meri et al. 1990).
Murine CD59 was identified and has also been shown to be widely expressed 
(Powell et al. 1997). Like CD55, a duplicate gene for CD59 is present in the 
mouse, shown to be 63% and 85% identical in protein and gene sequence
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respectively (Qian et al. 2000). CD59a is the widely distributed GPI-anchored 
form and is associated with the vast majority of CD59 effects. Expression of 
the transmembrane form of this protein, CD59b, is restricted to the testis 
(Harris et al. 2003).
Targeted deletion of the CD59a gene is associated with paroxysmal nocturnal 
haemoglobinuria (PNH)-like disease and spontaneous haemolysis in mice 
(Holt et al. 2001). In PNH, a stem cell mutation results in erythrocytes unable 
to express GPI-anchored proteins. The erythrocytes are highly sensitive to C 
attack leading to haemoglobinuria and anaemia in sufferers, proven to be 
caused by lack of terminal pathway regulation (Motoyama et al. 1992). An 
induced encephalomyelitis model of autoimmune disease was used to show 
exacerbated phenotype in CD59a'/‘ mice compared to WT characterised by 
rapid demyelination, inflammation and MAC deposition (Mead et al. 2004).
1.6.3.2 Clusterin (complement lysis inhibitor, CLI)
Clusterin is a ~80kDa serum glycoprotein with diverse functions. It is 
synthesised locally and secreted at times of cellular stress where it is involved 
with clearance of apoptotic cells and acts as a chaperone or may serve to 
inhibit apoptosis. However, a further association with C5b-9 complexes has 
long been demonstrated (Murphy, 1988), and shown to inhibit haemolysis in a 
dose dependent manner (Murphy, 1989). Further studies cast doubt on the in 
vivo relevance of this function by the observation that concentrations required 
to inhibit lysis were non-physiological (Hochgrebe, 1999). However, 
convincing evidence for a role for clusterin in Alzheimer’s disease is available 
(reviewed in (Holtzman 2004)), with MAC deposition known to contribute 
heavily to the pathology of Alzheimer’s disease (Shen et al. 1998). This area 
has been the subject of significant renewed interest following a recent 
landmark study identifying clusterin as a genetic risk factor for Alzheimer’s 
disease (Harold et al. 2009). Additionally, clusterin is thought to contribute to 
progression of cancers (Trougakos and Gonos 2002), and has been 
suggested as a potential target for immunotherapy (Gleave and Chi 2005).
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1.6.3.3 S-Protein (vitronectin)
S-Protein is a 75kDa serum glycoprotein able to bind fluid phase C5b-7, a 
precursor complex to MAC formation. Interaction between S-protein and C5-7 
prevents C8 binding and insertion into the membrane. Additionally, S-Protein 
can interact with membrane bound C5b-8 and prevent C9 polymerisation 
(Podack, 1984).
1.7 Alternative roles for CRegs
Whilst the primary function of CRegs is to inhibit C and protect host tissues 
from autologous attack, there are numerous other roles associated with these 
proteins. In particular, various human and murine CRegs have been shown to 
have an important function in regulation of adaptive T-cell responses, signal 
transduction and cell proliferation.
Three CRegs of particular interest in this thesis are CD55, CD59 and Crry.
1.7.1 CD55
CD55 is an inhibitor of the activation pathways of C through action on both the 
classical and alternative C3 convertases. A role for this protein has also been 
demonstrated in T-cell responses to antigens. This was first observed in 1988 
when human T-cells, incubated with phorbol esters were stimulated to 
proliferate via CD55 cross-linking (Davis et al. 1988). Work involving mice 
deficient in Daf-1, the common GPI form of the protein, demonstrated more 
vigorous T-cell responses to antigen than those isolated from Daf-1+/+ mice 
(Heeger et al. 2005). Additionally in this study, the proliferation of CD4+ T-cells 
was enhanced in the Daf-1'7' mice suggesting CD55 to have a potent down- 
modulatory on CD4+T-cells. Reconstitution of CD55 expression on Daf-1'7' T-
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cells abrogated these effects showing CD55 on the T-cells themselves to 
contribute to the down-modulatory phenotype. However, a further observation 
that Daf-1"7' APCs stimulated stronger responses to antigen suggests that 
CD55 on APCs also contributes to T-cell regulation. The T-cell effects 
associated with CD55 were shown to be dependent on C activation through 
the alternative pathway since the augmented responses by Daf-1"7’ cells were 
abrogated in the absence of fD. Depletion of C5 also caused partial 
abrogation of the enhanced phenotype with a role for C5aR in optimal T-cell 
responses previously reported (Kim et al. 2004).
A parallel study confirmed stronger T-cell responses to antigen in Daf-1"7" mice 
and also showed more vigorous responses to re-stimulation (Liu et al. 2005). 
This effect was also shown to be dependent on C activation and deposition of 
C3b and was abolished in the absence of C3. A notable difference in this 
study compared to the previous report was the finding that effects were 
elicited through CD55 expression on the lymphocytes only. Data provided by 
Liu et al. showed that APCs from Daf-1"7" and Daf-1+7+ were able to stimulate 
comparable T-cell responses to antigen rather than the augmented responses 
elicited by Daf-1’7' APCs noted by Heeger et al.
The role of CD55 as a potent CReg appears critical to the observed effects in 
these studies whereby inhibition of convertase assembly, and inactivation of 
C3b by CD55 is mediating the effects on T-cells. In the absence of CD55, C- 
activation is enhanced leading to elevated levels of MAC deposition and C5a 
release which are able to augment T-cell responses to antigen. Further work 
in CD55"7" mice has supported a C-dependent down-modulatory role for CD55 
in CD8+ T-cell responses (Fang et al. 2007).
Originally, NK-cells were thought to not express CD55 making them unusual 
amongst circulating lymphocytes (Nicholson-Weller, Russian and Austen 
1986). However, CD55 expression was later observed at low levels on human 
NK-cells and a distinct sub-population identified expressing significant levels 
of CD55 (Solomon, Chan and Finberg 1995). NK-cell responses have been
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shown to be down-regulated by CD55 (Finberg, White and Nicholson-Weller 
1992, Kusama et al. 2003).
1.7.2 CD59
CD59 is a potent CReg with ability to regulate the terminal C pathway. The 
molecule has long been thought to play a role in human T-cell activation with 
various effects observed following cross-linking of CD59 with antibody. Influx 
of Ca2+, production of IL-2, increased proliferation and tyrosine 
phosphorylation have been demonstrated (Korty et al. 1991, Stefanova et al.
1991). CD59 expressed on human T cells was shown to be co-stimulatory 
with the T-cell receptor (TCR) leading to important downstream effects 
including T cell proliferation. However, the same study showed an additional 
role for CD59 in signalling independent of the TCR (Decked et al. 1995). 
Incorporation of CD59 into CD59-negative U937 cells conferred a signalling 
capacity through association with tyrosine kinases (van den Berg et al. 1995). 
More recent studies have shown roles for CD59 in enhancing human NK-cell 
cytotoxicity whereby CD59 expressed on NK-cells themselves was shown to 
have a co-stimulatory role with the natural cytotoxicity receptor (Marcenaro et 
al. 2003). Additionally, transfection of U937 cells with CD59 enhanced NK cell 
responses following antibody cross-linking due to signalling via its GPI-anchor 
(Omidvar et al. 2006). These described roles are in direct contrast to CD55 
which inhibits NK-cell cytotoxicity. A further role for CD59 has also been 
demonstrated in enhanced proliferation and cytokine secretion by neutrophils 
(van den Berg et al. 1995).
A murine model of CD59 deficiency was generated using targeted deletion of 
the mouse CD59a gene (Holt et al. 2001). Using these animals, Longhi et al 
(2005) demonstrated a down-modulatory role for CD59 on CD4+ (but not 
CD8+) lymphocytes. T-cell activity was enhanced through increased 
proliferation following CD3 stimulation. The effect was shown to require the 
presence of APCs but was independent of C activation and unaffected by the 
absence (C3-depleted and C3'A) of C3. This finding is of great significance
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and suggests a role for CD59a in binding to APCs without engagement of C- 
derived ligands.
The role of CD59 as a negative regulator of murine T-cells is difficult to 
reconcile with the co-stimulatory role for this protein described in humans 
(Korty et al. 1991). However, a more recent study on human CD4+ T-cells 
found enhanced responses to antigen following blockade of CD59 (Sivisankar, 
2009). Although the mechanism underlying this effect is unclear, this study 
highlights a down-modulatory role for CD59 on CD4+ lymphocytes supporting 
the findings in murine T-cells.
Both CD55 and CD59 have been shown to possess down-modulatory roles 
when expressed on murine T-cells. In both cases, deficiency of the CReg 
allowed more vigorous T-cell responses with APCs required to observe these 
effects. However, a significant difference between the molecules is revealed 
by the C-dependent nature of CD55 modulated T-cell immunity. No effects 
were seen in the absence of C activation in CD55-/-.C3-/- mice. This is in 
contrast to enhanced T-cell responses in CD59-/- mice, which were shown to 
be C-independent. This observation suggests the existence of an alternative 
ligand for CD59, which remains as yet un-identified.
An area of controversy regarding CD59 and cell signalling is the potential 
interaction with CD2, a signalling molecule found on both naive and activated 
T-cells. Initial observations were that monoclonal antibodies targeted against 
CD59 restricted resetting between T-cells and CD59+ erythrocytes and that 
CD59 was directly responsible for the resetting of human T-cells with CHO 
cells transfected with CD59 (Decked et al, 1992, Decked, Kubar and Bernard
1992). A binding site was later mapped for the CD59/CD2 interaction, 
overlapping with a site for binding with CD58 (unrelated), known to have a co­
stimulatory role with CD2 (Hahn et al. 1992). However, Chinese Hamster 
Ovary (CHO) cells were later transfected with human CD59 and blocking 
mAbs used to rule out an interaction between CD59 and CD2 (Arulanandam 
et al. 1993). Fudher evidence against CD2 and CD59 interaction is provided 
by sudace plasmon resonance (SPR) techniques which also identified no
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CD2/CD59 association (Aruianandam et al. 1993, van der Merwe et al. 1994). 
Several further studies have been published with no irrefutable proof provided 
suggesting other molecules in a complex may be needed to facilitate the 
stimulation. It seems likely that interaction and co-stimulation may be 
dependent on other proteins involved in a complex and further work is 
required to elucidate the precise mechanism and functions of this interaction.
1.7.3 Crry
As described in section 1.5.2.4., Crry is an ubiquitously expressed CReg in 
rats and mice but is not found in humans. This protein has been shown to be 
the sole CReg protecting rat T-cells from autologous C attack (Hanna et al.
2002) and is also thought to have roles in modulation of T-cell responses. A 
co-stimulatory role for Crry has been demonstrated for the activation and 
proliferation of CD4+ T-cells (Fernandez-Centeno et al. 2000). In these 
studies, in vitro co-stimulation of Crry along with CD3 antigen (ligand for the T- 
cell receptor) induced proliferation of a subset of CD4+ primary splenocytes. In 
addition, co-stimulation specifically induced IL-4 secretion, with no effect 
observed on IFN-y production suggesting a role in selective development of 
certain T-celi subsets. An independent study at the same time confirmed 
these findings using a different Crry-specific monoclonal antibody to co- 
stimulate CD3 on rat thymocytes (Arsenovic-Ranin et al. 2000). A further role 
for Crry is provision of resistance to NK cell-mediated cytotoxicity when 
expressed by target cells (Caragine et al. 2002). In this study, transfection of 
adenocarcinoma cells with Crry conferred added resistance to NK-cell killing 
in a C-independent manner.
As previously described, deficiency of Crry is embryonically lethal in mice and 
Crry"7' mice could only be generated via breeding to C3'7' mice (Xu et al.
2000). However, Crry"7" mice have recently been generated in C sufficient 
mice by inhibition of the terminal pathway via a specific mAb (Ruseva et al. 
2009). This knock-out colony will allow further investigation of the T-cell 
related effects attributed to Crry and their in vivo relevance. However, C3
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consumption occurs spontaneously in these mice and native C3 is present at 
markedly reduced levels in serum. Therefore, while these mice are deficient in 
Crry, T-cell responses could be expected to be impaired in vivo through 
reduced C3 serum levels and sub-optimal opsonisation (section 1.3.2.2).
1.8 Tumour Immunity
Tumour cells differ from normal tissue cells due to a multitude of genetic and 
epigenetic alterations. These mutations can be spontaneous or induced 
through exposure to carcinogenic chemicals or radiation, while others arise 
following viral infection. The changes undergone by transforming cells mark 
tumour cells as distinct from normal host cells. They are characterised by a 
loss of regulation, rapid proliferation and in some cases, the ability to 
metastasise. Mutations in specific genes are common in numerous tumour 
types, one such example being the p53 suppressor gene. The protein 
encoded by this gene is a pro-apoptotic regulator, which binds to damaged 
DNA labelling the cell for apoptotic clearance. However, a mutation in this 
gene results in an inactive p53 protein and allows the tumour cell to evade 
apoptosis (Levine 1997). Mutation of this particular gene is highly prevalent in 
transformed cells and is seen in over 50% of all human cancers (Poremba, 
1996).
1.8.1 Immunosurveillance of tumours
The concept of host immune system protecting against tumourigenesis has 
long been considered. The idea was first conceived by Ehrlich in 1909 who 
suggested that ‘aberrant germs’ arose continuously in our bodies but were 
recognized and eradicated by the immune system before becoming clinically 
apparent. The concept was elaborated in the 1950s through the work of 
Burnet and Thomas, who developed the ‘immune surveillance’ theory after 
showing immune control of transplanted tumours. The basis of the hypothesis 
was a constant role for the immune system in surveying the body for presence 
of transformed cells and destroying neoplastic cells at an early stage. Burnet
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hypothesised that antigenic alterations allowed this recognition and 
consequent elimination by immune cells (Burnet 1957).
The use of chemical carcinogens to investigate developing tumours and the 
immune system gave rise to a wealth of information, both contradictory and 
supportive of the controversial immunosurveillance hypothesis. Evidence 
opposing the hypothesis was provided by a study which described nude mice 
(deficient in T and B-lymphocytes) which did not develop tumours more 
rapidly than wild type mice and that the immunocompromised mice showed no 
increased susceptibility to tumourigenesis (Stutman 1979). However these 
mice were later shown to have some limited T-lymphocyte activity, and also to 
possess NK cells, also implicated in tumour rejection (Hunig and Bevan 
1980). The past decade has seen a resurgence of the immunosurveillance 
hypothesis with numerous studies supporting a role for the immune system in 
controlling tumour cell growth. A study involving Rag-2'7' mice, deficient in T- 
cells and B-cells showed that immunodeficient mice were at greater risk for 
spontaneous adenoma development (Shankaran et al. 2001). Using a 
selection of tumour cell lines, the authors found that 100% of tumours 
generated in WT mice grew in WT and Rag-2'7' recipients while <50% of those 
generated in Rag-2'7' mice grew when transplanted into WT recipients. This 
finding supported a previous study whereby tumours passaged in WT mice 
showed higher tumourigenic potential and grew faster than those derived from 
nude mice (Urban et al. 1982). A role for ‘immunoselection’ is supported by 
these studies whereby tumour cell populations subjected to positive selection 
pressures (i.e. a full immune response) are better adapted to in vivo growth in 
immunocompetent hosts than populations that have not undergone such a 
selection process.
The first human tumour antigen (MZ2-E) was identified almost 20 years ago 
(van der Bruggen et al. 1991), since then numerous antigens recognised by 
the immune system have been described. Such proteins may be specific to 
tumours, or up-regulated compared to normal tissues (reviewed in Pardoll
2003). In addition to antigenic differences, glycosylation patterns are altered in 
many tumours giving rise to novel carbohydrate patterns which may be
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recognisable to the immune system (reviewed in (Hakomori 1996)). However, 
important to the immunoselection process is the preferential survival of tumour 
cells, which do not elicit strong anti-tumour responses. Consequently, tumour 
antigens are often expressed at low levels or elicit weak immune responses 
when expressed on clinically apparent tumours.
Studies identifying increased susceptibility to tumour development in 
immunocompromised mice have given further credibility to the concept of 
immunosurveillance (Cretney et al. 2002, Crowe, Smyth and Godfrey 2002, 
Street et al. 2002). Further, a refined model for the hypothesis defined as 
‘cancer immunoediting’ has been proposed (Dunn et al. 2002). This 
hypothesis outlines three stages by which tumour cells are either eliminated, 
or undergo immune selection before gaining the ability to escape from 
immune attack:
1) Elimination. Nascent neoplastic cells are targeted and 
destroyed by T-cells and NK cells.
2) Equilibrium. Immune selection of tumour cells with increased 
resistance to immune effector cells. Contains but does not 
extinguish tumour cell population.
3) Escape. Surviving tumour cells develop effective 
mechanisms for immune evasion and proliferate 
uncontrollably.
Natural selection dictates that only those tumour cells best able to evade 
immune responses will go on to proliferate therefore giving rise to more 
aggressive malignancies. A recent study provided strong evidence to support 
the existence of these phases, and showed a role for T-cells and the adaptive 
immune system in maintaining tumours in the equilibrium phase (Koebel et al.
2007). Cells escaping immunosurveillance in this study were shown to exhibit 
enhanced proliferation and reduced immunogenicity compared to those 
remaining in the equilibrium phase. A multitude of factors influence the ability
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of tumour cells to escape immunosurveillance. Strategies by which tumour 
cells avoid elimination by the immune system are termed ‘immune evasion’.
1.8.2. Immune evasion and suppression
Mechanisms of immune evasion exhibited by tumours are wide-ranging and 
effective. The means by which transformed cells escape immunosurveillance 
represent a crucial area to be targeted in cancer therapy.
Suppression of the immune response is a crucial characteristic of tumours 
and is achieved by many different mechanisms, while few are well 
understood. T regulatory cells (TReg) are one potent cell-type harnessed by 
tumour cells to provide protection from host immune responses. Early work in 
the TReg field remained controversial until Sakaguchi et al (2005) showed a 
role for a CD25+ subset of CD4+ lymphocytes in regulating autoimmunity. 
This suppressive T-cell subset exists primarily to regulate T-cell activation and 
protect against autoimmunity (reviewed by Sakaguchi, 2004). However, a role 
in suppressing innate immune responses via production of cytokines has also 
been demonstrated with impaired recruitment and activity of neutrophils, 
macrophages and NK-cells observed following adoptive transfer of TRegs 
(Maloy et al. 2003). Cells of this type are best characterised via expression of 
the transcriptional regulator FoxP3 which is crucial for development of these 
cells (Fontenot, Gavin and Rudensky 2003). A role for TRegs has been 
proposed in suppression of anti-tumour immune responses in the tumour 
micro-environment with a previous report demonstrating a suppressive 
population of T-cells contributing heavily to tumour growth (Berendt and North 
1980). TRegs have been found to accumulate within tumours and can be 
shown to correlate with reduced life expectancy in some studies (Woo, 2001, 
Petersen, 2006). Partial depletion of Tregs using CD25-specific depleting 
mAbs has been shown to aid immune clearance of many different tumour cell 
lines, including fibrosarcomas (Onizuka et al. 1999). These findings were 
corroborated by several other groups with cytotoxic (CD8+) T-cells shown to 
be responsible for the tumour rejection (Shimizu, Yamazaki and Sakaguchi 
1999, Sutmuller et al. 2001). Immunosuppressive effects of TReg were
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subsequently shown to be mediated through endogenous production of the 
immunoregulatory cytokine TGF-p (Chen et al. 2005).
An alternative mechanism for immune regulation in tumours involves 
recruitment of myeloid derived suppressor cells (MDSCs). These cells provide 
pro-tumour signals and exert strong inhibitory effects on tumour infiltrating T- 
cells (Serafini, Borrello and Bronte 2006). MDSCs have been shown to 
accumulate in tumours and mediate down-modulation of immune responses, 
in particular the suppression of CD8+ T-cells (Kusmartsev, 2005). In this 
study, MDSCs collected from tumour bearing mice were able to reduce CD8+ 
T-cell responses with no effect mediated by MDSCs from naive counterparts. 
The suppressive effect of these cells is mediated through production of 
reactive oxygen species (ROS) which act directly on CD8+ T-cells impairing 
their function (Kusmartsev, 2004)
1.9 Induction of fibrosarcomas using chemical carcinogen
Induction of tumours by chemical carcinogens has been invaluable in 
delineating roles for numerous immune cell types, cytokines and signalling 
pathways in tumour development. Injection of the chemical carcinogen 3- 
methylcholanthrene (3-MCA) is a widely used tumour induction model and has 
contributed heavily to the verification and refinement of the 
immunosurveillance hypothesis described in previous sections. 3-MCA is an 
insoluble poly-cyclic aromatic hydrocarbon (PAH) and causes severe tissue 
damage and inflammation at the site of injection. The precise mechanism of 
3-MCA induced carcinogenesis is a complex and controversial subject. Whilst 
the toxification of PAHs in vivo is poorly understood, it has been shown that 
metabolic activation by cytochrome P450 enzymes is required to form 
‘genotoxic’ metabolites capable of forming DNA adducts (Moorthy, 2002). The 
covalent attachment of these metabolites causes damage to DNA and 
induces significant cell death. In addition to causing severe tissue damage, 3- 
MCA products are highly mutagenic and can disrupt DNA in surrounding cells. 
As part of the wound healing response, fibroblast cells are recruited to the site
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of injury and have been shown to surround 3-MCA crystals following injection 
(Qin et al. 2002). These cells encapsulate 3-MCA and are thus subjected to 
the mutagenic activity of the carcinogen. Consequently, injection of 3-MCA 
gives rise to fibrosarcoma tumour populations. The random mutagenic activity 
of 3-MCA induces highly heterogeneous cell populations which may ultimately 
escape immunosurveillance and form progressively growing tumours 
consisting of tightly compacted fibroblast-like cells. Extra-cellular matrix (ECM) 
secreted by fibroblasts is thought to provide a protective environment around 
the MCA crystals, shielding other cells from carcinogenesis as part of the host 
foreign-body reaction (Kovacs, 1991). It is thought that the immune system is 
able to recognise and eliminate some tumour cells and should insufficient 
mutagenesis occur before ECM encapsulation of MCA, mice remain tumour 
free though the carcinogen persists in encapsulated form (Qin, 2002).
Numerous factors influence tumour induction following 3-MCA injection. The 
dose of carcinogen administered is predictably important while different 
strains of mice also show different susceptibilities to tumour induction in this 
model (Blankenstein and Qin 2003). However, the reasons for differences 
observed between apparently similar studies are less clear. Identical doses of 
3-MCA induced tumours in 80-100% C57BI/6 mice in some studies (Takeda 
2002, Van den Broek 1996), yet others reported far lower incidences: 40% by 
Smyth et al. 2000, and 20% by Cretney et al. 2002. Environmental factors 
specific to different animal housing facilities are likely to contribute to these 
observed differences. Additionally, levels of metabolising enzymes will play a 
role and links to gender and growth hormone have been described for these 
enzymes (Sharma et al. 1998, Pampori and Shapiro 1999). Other local events 
linked to interferon-y responses such as inflammation, angiogenesis and T- 
cell responses are also important (Qin and Blankenstein 2000, Qin et al.
2003). Following a 400pg MCA dose, tumours develop with high incidence 
(>80%) in C57BI/6 mice after a period of 90-150 days (Gareth Betts, personal 
communication, November 2005).
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1.10 Activation of complement by tumour cells
As previously described, some tumour antigens may be recognised as foreign 
and stimulate the immune system, with one effect being production of 
antibodies raised against these antigens (Lloyd 1991, Houghton 1994). Such 
antibodies may have the potential to activate the classical pathway of C, 
possibly leading to CDC and destruction of the tumour cells. Due to the 
spontaneous activity of the alternative pathway, and the inherent C-resistance 
of nucleated cells, evidence for C-targeting of tumours is scant. However, 
support to this claim is provided by a number of reports demonstrating 
deposition of C activation products on various tumour cell types in humans. 
Antibodies targeted against C opsonins have been used to identify C 
deposition with persistent classical pathway activation (IgG, C3b, C4b 
deposition) shown in thyroid carcinoma (Lucas et al 1996), and breast cancer 
(Niculescu et al. 1992). Alternative pathway activation by human lymphoma 
(Okada and Baba 1974), and renal carcinoma has been demonstrated 
(Magyarlaki et al. 1996). Additionally, MBL has been shown to bind directly to 
human colorectal carcinoma (Ma et al. 1999), and glioma cells (Fujita et al. 
1995). In these in vitro studies, MBL binding was demonstrated with both C3 
and C4 fragments found deposited on tumour surfaces.
Activation of C classical pathway on tumour cells represents an appealing 
possibility for anti-tumour therapy through ability to specifically target cancer 
cells via monoclonal antibodies and leave normal host tissue unharmed. Over 
the past 5 years, the identification of suitable tumour antigens has advanced 
significantly and remains a priority in cancer immunotherapeutic research. 
However, difficulties in obtaining high titre and specificity antibodies has 
proved a major limitation in vivo, while the immunogenicity of both pAbs and 
murine mAbs has also proved problematic for over a decade. A promising 
advance was made via the development of chimeric mouse/human mAbs with 
reduced yet still significant immunogenicity and still further by ‘humanisation’ 
of Ab binding variable regions (Cobleigh et al. 1999). In most cases, Abs that 
can be effectively targeted to tumour surfaces have been used to direct
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chemical agents or to block cell surface protein function. The use of C as an 
effector system to clear tumours is attractive due to the diverse adaptive and 
innate immune functions mediated by C activation. However for a variety of 
reasons discussed in this Chapter, C remains an inefficient mechanism for 
clearance of clinically apparent tumours. The majority of early anti-tumour 
mAbs possessed poor C-fixing capacity (Macor and Tedesco 2007), although 
promising evidence to support further research in this area was provided in 
the C-dependent control of ovarian carcinoma in humans (Macor et al. 2006). 
Further, it has been demonstrated that a ‘cocktail’ of anti-tumour mAbs could 
be used to significantly enhance C deposition and reduce growth of a human 
breast cancer line compared to treatment with individual mAbs both in vitro 
and in vivo (Spiridon et al. 2002). A growing number of both human/mouse 
chimeric and humanised anti-tumour antibodies are now available for clinical 
use (reviewed by Gelderman et al. 2004), and provide a potential mechanism 
for C-activation targeted to tumour cells. Whilst the primary anti-tumour effects 
of these antibodies are not C-mediated in the majority of cases, CDC has 
been shown to contribute heavily to tumour regression in vivo in some cases. 
The mouse/human chimeric anti-CD20 mAb Rituximab has been shown to 
promote CDC and ADCC in a mouse lymphoma model transfected with 
human CD20 (Di Gaetano et al. 2003), while Rituximab has achieved 
considerable success in vivo and is widely used in the treatment of non- 
Hodgkins lymphoma (Plosker and Figgitt 2003)
A current aim in C research involves harnessing the powerful effects of C to 
control cancer. Several anti-tumour antibodies have been shown to activate C 
in vitro (Sliwkowski et al, 1999, Trikha et al. 2002). However, the expression of 
CRegs remains a major obstacle and has been shown to limit the efficacy of 
anti-tumour therapeutic mAbs (Golay et al. 2001). Further progress in this 
area may be achieved through modification of C-fixing capacity of antibodies 
to optimise C activation e.g. by preferentially engineering lgG1 or lgG3 mAbs 
will increased C activation efficacy (Idusogie et al. 2001). An extremely 
attractive mechanism to circumvent this problem is through the use of bi­
specific Abs which co-target a tumour antigen and CReg. In this way, a 
therapeutic Ab could simultaneously target a tumour cell, and partially
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neutralise the ability to regulate C. The use of a chemically engineered 
construct, able to simultaneously bind tumour cells and neutralise CD59 
allowed efficient killing of Raji cells in vitro (Harris et al. 1997). A further bi- 
specific Ab directed against renal tumour antigen G250 and the CReg CD55 
was shown to cause enhanced tumour cell lysis compared with anti-G250 
alone with increased C3b deposition demonstrated (Blok et al. 1998). Further 
demonstrations of the use of bivalent Abs incorporating an anti-tumour moiety 
and capacity to neutralise a CReg have been provided in vitro using a human 
and rat model of colorectal cancer (Gelderman et al. 2002b, Gelderman et al.
2004). This technique may be applicable to many tumour cell types and 
remains a promising mechanism in tumour immunotherapy. Bi-specific anti- 
CD20 with either human CD55 or CD59 has been suggested as an adjuvant 
to conventional Rituximab anti-lymphoma therapy with a two-fold increase in 
CDC demonstrated in vitro (Ziller et al. 2005).
1.11 Protection of tumour cells from complement
All host cells require effective mechanisms to protect them from the damaging 
effects of autologous C. Tumour cells may also utilise and selectively regulate 
these protective mechanisms to confer added resistance.
1.11.1. Membrane bound CReg
A major limitation to the efficacy of C in tumour immunosurveillance is 
provided by the presence of CReg expressed by tumour cells. As previously 
described, these proteins are secreted or expressed on host cell membranes 
to protect from autologous C and autoimmunity. The presence of these CReg 
on the tumour cell surface will afford effective protection against C mediated 
attack, providing a significant obstacle to the use of C in anti-tumour therapy. 
In addition to the levels of protective molecules expressed by normal tissue, a 
wealth of evidence exists to support modulation of expression patterns of 
these proteins on tumour cells (Reviewed by Fishelson, 2003). In the majority
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of cases, CRegs are over-expressed in transformed cells conferring enhanced 
protection against C effector systems. A proposed explanation for this is that 
CDC or opsonisation may lead to clearance of poorly protected cells, and 
select for high CReg expressors. Alternatively, CReg expression has been 
shown to depend on differentiation stage in vivo with CD59 expression 
increased in well differentiated human carcinomas as compared to little or no 
CD59 expression in poorly differentiated cells (Koretz et al. 1993). In order to 
exploit C as a potential effector system in tumour immunotherapy, neutralising 
antibodies to CReg have been used with variable success. A wealth of 
evidence exists demonstrating that blockade of various CReg to effectively 
sensitise in vitro cell lines to CDC. Examples of this include neutralisation of 
CD59 on human neuroblastoma cells (Qasque et al. 1996), and both CD55 
and CD59 on human breast carcinoma and leukaemic cells (Golay et al.
2001). Neutralisation of CD55 and CD59, but not CD46, has also been used 
to sensitise erythroleukaemic K562 cells to CDC (Harris et al. 1997, Jurianz 
et al. 2001), while blockade of CD55 or CD59 significantly enhanced C3 
deposition on human cervical carcinoma cells (Gelderman et al. 2002a). An 
important development in this area was provided by the use of bi-specific 
neutralising antibodies (described in section 1.10). In this way, cells can be 
co-targeted with an anti-tumour effector antibody alongside a CReg 
neutralising antibody. This therapeutic technique inhibits CReg only on tumour 
cell surfaces and prevents significant damage to bystander cells. Co-targeting 
of tumour antigens with anti-CD55 or anti-CD59 antibodies have been shown 
to significantly enhance killing of both mice and human tumour cells in vitro 
(Harris et al. 1997, Blok et al. 1998). This technique was also utilised in a rat 
model of lung metastasis whereby tumour-specific blockade of Crry 
significantly decreased metastases in the lung, with enhanced C3b deposition 
observed (Gelderman et al. 2004). Further in vivo work in this area is required 
to assess the feasibility of modifying current mAb immnunotherapies to 
incorporate CReg blocking moieties and increase CDC and opsonisation. In 
addition to Ab blockade of CReg, anti-sense oligonucleotides can be used to 
sensitise tumour cells to in vitro CDC by decreasing CReg expression (Zell et 
al. 2007). However, a major obstacle to this technique is the current lack of 
method for specifically targeting CReg down-regulation to tumour cells.
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The over-expression of CReg by tumours has been shown to correlate with 
poor patient prognosis in colorectal cancer patients (Durrant et al. 2003, 
Watson et al. 2006). Additionally, CD55 has been linked to proliferation rates 
with over-expression of this CReg by colorectal cancer cells shown to exhibit 
enhanced proliferation. In direct contrast to this observation, loss of CD55 was 
demonstrated on advanced stage breast carcinomas and the lack of CD55 
was shown to correlate with poor prognosis (Hofman et al. 1994, Madjd et al. 
2004). Despite these seemingly contradictory reports, CD55 has been 
implicated in discriminating tumour grade i.e. stage and suggested as a 
potential cancer vaccine for T-cell immunotherapy (Spendlove et al. 1999). 
Initially, CD55 appears a poor candidate for tumour immunotherapy due to its 
widespread expression in humans and important role in regulating C 
activation. However, a tumour associated antigen was identified in an 
osteosarcoma cell line by a mAb raised in mice immunised against this cell 
line (Embleton et al. 1981). This antigen, designated 791Tgp72, has been 
described as a 72kDa glycoprotein commonly found over-expressed in 
various tumour cell types including osteosarcomas and colorectal carcinomas 
(Pimm et al. 1982, Durrant et al. 1986). The mAb recognising this antigen, 
791T/36, has been used to effectively and selectively image tumour cells and 
predict patient prognosis (Powell et al. 1987, Buckley 1989, Austin, 1989). 
One such mAb, named 105AD7, mimics the 791Tgp72 antigen and has been 
used in colorectal carcinoma patients to prolong survival by stimulating anti­
tumour T-cell responses. CD4+, CD8+ T-cell and NK-cell responses appeared 
higher in those patients vaccinated with 105AD7 and delayed tumour growth 
(Buckley, Robins and Durrant 1995). The 791Tgp72 was later identified as 
showing 100% sequence identity to CD55 and specifically binds anti-CD55 
antibodies (Spendlove et al. 1999). This discovery was unexpected given the 
ubiquitous expression of CD55 in humans and the non-toxic effects of 
immunising with 105AD7 which effectively mimics 791Tgp72 i.e. CD55.
The reasons underlying the unlikely identification of CD55 as a tumour antigen 
is due to differential antigen density and expression patterns in the tumour 
microenvironment compared with normal tissue. The enhanced T-cell
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mediated cytotoxicity specific to tumour cells in patients immunised with 
105AD7 is likely caused by the over-expression of CD55 (< 100-fold) observed 
on tumour cells compared to normal cells (Li et al. 2001). In this way, tumour 
cells may express low levels of CD55 thus being more susceptible to CDC, or 
over-express CD55 and present a promising target for vaccination and T-cell 
immunotherapy.
A number of different isoforms of CD55 exist, shown to result from different 
glycosylation patterns in colorectal carcinomas (Nakagawa et al. 2001). This 
results in heterogeneous molecular weights observed for this protein and 
these tumour-specific isoforms also provide therapeutic targets. The SC-1 
mAb is known to bind a high molecular weight (~82kDa) isoform of CD55, 
preferentially expressed by stomach carcinoma cells. SC-1 binding induces 
cell phosphorylation and apoptosis (Hensel et al. 1999). Such effects are 
independent of CDC and ADCC and have negligible detrimental effects on 
normal immune responses making this an attractive anti-tumour therapy 
(Vollmers et al. 1998, Beutner, 2008).
1.11.2. Soluble CReg
In addition to up-regulation of membrane-bound regulatory proteins, tumour 
cells may secrete soluble CReg to inhibit C in the tumour micro-environment. 
Fluid phase regulators have been associated with secretion by tumours 
including C1inh by a neuroblastoma line (Gasque et al. 1996). fH, a potent 
inhibitor of the alternative pathway, can be secreted by certain types of 
tumours including human ovarian cancer cells and this secretion and 
subsequent binding was shown to provide a novel mechanism aiding 
resistance to C and contributing to the strong resistance of glioblastoma cells 
to CDC (Junnikkala et al. 2000, Junnikkala et al. 2002). Expression of fH has 
also been put forward as a possible marker for bladder cancer (Kinders et al. 
1998). Binding of fH to phosphoproteins up-regulated in certain tumour types 
has been shown to directly contribute to tumour cell resistance to CDC of 
mouse erythroleukaemic cells and human breast carcinoma lines (Fedarko et 
al. 2000), while down-regulation of fH by siRNA caused retarded in vivo
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growth of human lung carcinoma cells through a C-dependent manner (Ajona 
et al. 2007). Factor I has been detected in the supernatant of a sarcoma line 
(Legoedec et al. 1995), and shown to effectively cleave deposited C3b and 
C4b when secreted by non-small cell lung carcinomas (Okroj et al. 2008).
Soluble forms of membrane bound CReg can also be released from cells to 
supplement membrane bound CRegs. The released forms may be 
synthesised without the GPI anchor or may be enzymatically cleaved from the 
surface. Increased soluble CR1 has been observed in leukaemic patients and 
elevated soluble MCP levels observed in several tumour types (Seya et al. 
1995, Sadallah et al. 1999). Both CD55 and CD59 were observed at high 
levels in tumour stroma of various carcinomas (Niehans et al. 1996). Further 
studies found that CD59 can also be secreted by melanoma cells 
(Brasoveanu et al. 1997), while CD55 was found to be deposited into extra­
cellular matrix at levels proportional to surface levels in osteosarcoma and 
colorectal carcinoma (Li et al. 2001).
1.11.3. Ecto-proteases
Other proteins have been demonstrated to influence C activation and cleave 
opsonic fragments on cell surfaces. This may result in activation of C through 
the amplification loop of the alternative pathway, or, inactivation of opsonins 
leading to protection from C and phagocytosis. Amongst these secreted 
proteins are a group known as ecto-protease enzymes with the capability to 
cleave C components, in most case the activation products of the central 
component C3. These proteases are not specific to tumours and can be 
secreted by various cell types (Hermann, Barel and Frade 1994). Human 
melanoma cells expressing one such protein, p65, have been shown to be 
highly resistant to CDC, with antibody blockade of p65 abrogating this 
resistance and sensitising cells to lysis (Panneerselvam et al. 1986, Ollert et 
al. 1990). A C3-cleaving cysteine proteinase was identified in another human 
melanoma study, termed p41. Expression of this proteinase was found to 
coincide with secretion of tumour derived C3 and this co-secretion to correlate
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with a high metastatic potential (Jean, 1997). A further C3-cleaving proteinase 
(p39) was identified in mouse melanoma cells and shown to share sequence 
identity with procathepsin-L (Jean, 1995), also demonstrated to confer high 
tumourigenicity in human melanoma lines (Frade et al. 1998). The enzymes 
described in this study cleave native C3 with C3b and C3dg fragments 
detectable in supernatants. These fragments may deposit on antigenic 
surfaces leading to opsonisation and/or continuation of the C pathway, or may 
interact with various receptors to regulate cellular functions.
1.11.4. Sialic Acid
Cell surfaces expressing high levels of polyanionic molecules are protected 
from C activation through enhanced binding of fH to C3b. This binding 
competes with fB binding and enhances inactivation by fl-mediated cleavage 
in the presence of polyanions (Pangburn and Muller-Eberhard 1978). 
Therefore, high levels of sialic acid confer enhanced resistance against 
amplification of the alternative pathway and CDC (Meri and Pangburn 1990). 
Sialylation is implicated in protection of many host cell types from excessive 
C3b deposition and protection from autologous attack. Unsurprisingly, sialic 
acid is also important in tumour resistance to CDC and bladder cancer cells 
can be markedly sensitised to C-mediated lysis following removal of sialation 
by neuraminidase enzyme (Jacobsen et al. 1982). Further, three human 
carcinoma cell lines have been shown to express high levels of sialation 
correlating with resistance to CDC (Donin et al. 2003). Protection of tumour 
cells from C by high expression levels of sialic acid has also been observed in 
murine leukaemic lines (Shi et al. 1996). In each of these studies, removal or 
blocking of sialic acid binding was shown to sensitise tumour cells to CDC 
showing an important role for the non membrane-bound CReg fH in tumour 
protection from C and suggest a possible mechanism for targeting of tumour 
cells.
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1.12 Sublytic effects of C
The major effector molecule of CDC is the C5b-9 MAC complex which forms a 
transmembrane channel and compromises homeostatic capabilities of target 
cells. Whilst C is able to lyse bacterial cells and erythrocytes effectively, 
nucleated cells possess additional mechanisms to prevent MAC-mediated 
lysis and are significantly more resistant to CDC (Ohanian and Schlager 
1981). This was evidenced by a study on nucleated cells which required co­
operative channel formation in a multi-hit manner to cause lysis (Koski et al. 
1983). Demonstration of cellular responses to MAC deposition was provided 
by the initial observation of Ca2+ influx and inhibition of cyclic AMP formation 
in the absence of cell lysis (Campbell et al. 1981, Hallett et al. 1981). Further, 
U937 cells were shown to be capable of rapidly eliminating MAC molecules 
from their surface in a process not observed on erythrocytes (Ramm et al. 
1983). The mechanism for this process was elucidated via the use of a mAb 
specific for C9 which showed vesiculation and removal of MACs from 
leukocyte cell surfaces (Campbell and Morgan 1985). This effect was shown 
to be temperature dependent and associated with increased metabolism. A 
later study found that human neutrophils rapidly eliminate all MAC molecules 
from cell membranes with both vesiculation and internalisation processes 
observed (Morgan et al. 1987).
A variety of effects have been associated with sub-lytic deposition of MAC on 
nucleated cells. However the mechanisms underlying these effects, and the 
specific functions attributed to the changes remain poorly understood. The 
immediate influx of Ca2+ is critical to mediate these effects and protect 
nucleated cells from CDC (Morgan and Campbell 1985). Additionally, lipid 
metabolism has also been shown to contribute to cell survival following MAC 
deposition (Ohanian and Schlager 1981, Papadimitriou et al 1991). The 
protein kinase C family (PKC) is known to play a role in cellular activation 
events following the abrogation of protection after treatment with PKC 
inhibitors (Kraus and Fishelson 2000). Cell signalling events associated with 
these enzymes were shown to involve the ERK mitogen-activated protein
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kinases (Kraus, Seger and Fishelson 2001). Phosphorylation of these kinases 
can regulate numerous downstream effects including regulation of gene 
expression, apoptosis and cell proliferation (Pearson et al. 2001). In addition 
to this signalling cascade, activation of the Ras GTPase (Niculescu, Badea 
and Rus 1999), and c-Jun families has also been demonstrated (Rus et al. 
1997), with roles in cell proliferation and cell cycle phase transition 
respectively. Sublytic MAC has been shown to trigger de novo protein 
synthesis in both normal (Benzaquen, Nicholson-Weller and Halperin 1994), 
and tumour cells (Reiter, Ciobotariu and Fishelson 1992). The above 
observations, and the presence of intrinsic cell repair mechanisms, have led 
to the hypothesis that sublytic MAC deposition is capable of activating cells 
and providing supplementary resistance to basal C-protective mechanisms.
A further observation following sublytic MAC deposition on nucleated cells is a 
phenomenon known as ‘C-induced protection’. This in vitro effect was 
described following treatment of human leukemic lines with a sublytic C dose. 
Following recovery of cells, subsequent treatment of cells with a lytic dose 
was unable to cause lysis (Reiter et al. 1992). Thus, cells surviving initial MAC 
deposition were conferred an elevated level of resistance against further C- 
activation with the effects shown to be associated with Ca2+ influx and 
increased protein synthesis. The induced protection was shown to be 
independent of MAC deposition levels and was lost after 10-12 hours. In 
addition to enhanced protection from C, cells are also rendered resistant to 
lysis by other pore-formers e.g. perforin (Reiter et al. 1995). A later study 
showed negligible lysis of K562 cells treated with 16-fold higher C dose than 
that required to lyse >70% cells prior to sublytic attack (Marchbank, van den 
Berg and Morgan 1997). Importantly, Experiments performed in this study 
ruled out differential binding of C-fixing Ab and CReg expression as potential 
contributors to the protected phenotype. A weaker but still significant effect 
was found on U937 cells in the same study. An additional consequence of 
sublytic MAC deposition on K562 cells (and other human leukaemic lines) is 
the rapid production of a large C induced protein (L-CIP)(Reiter and Fishelson 
1992). This protein is related to the heat shock protein family and is thought to 
play a role in tumour cell escape from CDC (Fishelson et al. 2001). The
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mechanism for C-induced protection remains unclear. However, the 
consequences of C-activation failing to lyse targets may be of considerable 
significance in vivo. In particular, tumour ceils which are known to activate C 
and deposit activation products may be subjected to the various stimulatory 
effects associated with MAC deposition and gain acquired resistance to C and 
associated immune mechanisms.
Aside from MAC deposition, C3 activation fragments are able to increase the 
proliferation of B-cells by association with CR2 (see section 1.4.2.1). 
However, direct binding of C3 products has also been implicated in promoting 
cellular proliferation. Lewis lung carcinoma cells have been shown to bind C3 
fragments independent of CRs (di Renzo et al. 1999). The fragments were 
internalised and were shown to contribute to enhanced proliferation of the 
cells in vitro. The authors suggested that C3 fragments are translocated from 
the surface and provide a stimulatory growth signal. The effects were shown 
to be independent of MAC deposition and were abrogated in the presence of 
anti-C3 Abs. Further study by the same group found that C3 fragment 
internalisation was mediated by PKC activity (Longo et al. 2005), and 
postulated the enhanced proliferation to be mediated through previous 
correlations between PKC and ceil growth rate in tumours (Matsuzaki et al. 
2004). Proliferative effects were abrogated in the presence of PKC inhibitors 
while initial C3b binding to cell membranes was un-affected suggesting a role 
for PKC in the internalisation process rather than initial binding.
Whilst the majority of studies involving C and tumours have involved targeting 
basal resistance mechanisms e.g. CReg, induced effects remain an important 
consideration and an area requiring significant further investigation. Effects by 
which C activation on cellular surfaces may contribute to enhanced survival or 
proliferation crucial to the emerging hypothesis by which C, below the 
threshold of killing, may represent a pro-tumour stimulus and promote tumour 
progression.
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1.13 Secretion of complement components by tumours
As described previously, the vast majority of C proteins are synthesised in the 
liver, though numerous cell types have been reported to synthesise C 
components locally (Morgan et al. 1997). A number of reports over the past 
20 years have identified C component synthesis by transformed cells, in the 
majority of cases this involves the central C component C3. Unsurprisingly, 
hepatoma cells from humans (Falus et al. 1990), rats (Stapp et al. 2005), and 
mice (Lin et al. 1993), have all been shown to secrete C3. However, further 
reports of C3 secretion by alternative cell types may indicate a pro-tumour role 
for C3 secretion. The strongest evidence for this is provided by a study in 
which secretion of C3 was found to correlate with increased metastasis in 
human melanoma cells (Jean et al. 1997). Important to this study was the 
identification of a C3-cleaving enzyme, p41, found to be co-secreted with C3 
(Section 1.11.3). Whilst expression of p41 alone may be sufficient to promote 
metastasis of these cells, a selective advantage to tumour cells secreting their 
own C3 may also contribute. Co-secretion of C3 and a p41 may represent a 
tumour mechanism able to harness the stimulatory effects of C3b deposition 
(as described in Section 1.12) whilst avoiding CDC. Human gastric cell lines 
(Kitano et al. 1993), colorectal carcinoma (Andoh et al. 1998) and myoblasts 
(Legoedec et al. 1995) have all been shown to up-regulate C3 synthesis in 
comparison to normal cells derived from the same tissue. Production of 
various pathway components have been demonstrated in astroglioma cells 
(Barnum et al 1992), and activation of C3, C5 and C9 genes observed 
following treatment of lung carcinomas treated with photodynamic therapy 
(Stott et al. 2007). A clear role for tumour derived C components is yet to be 
defined and may be simply be a result of loss of gene control common in 
tumour cells. However, tumour-derived C may be significant to the emerging 
hypothesis that tumour cells can ‘harness’ the C-system to provide stimulatory 
and proliferative effects whilst avoiding CDC. Further investigation into the 
contribution of C-derived C components in tumour progression is needed.
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1.14. Aims of this thesis
The relationship between the C system and tumour immunity is poorly 
understood. Whilst C components can undoubtedly be activated and 
deposited on tumour cell surfaces, this does not lead to clearance either by 
CDC or phagocytosis following opsonisation with C products. The 
conventional role of C, and the described reports of deposited C activation 
fragments on tumour cell surfaces have previously suggested a role for C in 
immunosurveillance and in anti-tumour responses. However, an alternative 
hypothesis is now emerging whereby C activation on tumour cell surfaces 
may lead to enhanced C-resistance, proliferation and metastasis. Deposition 
of C3b and MAC on nucleated cells has been shown to mediate various 
stimulatory effects including cell activation. In this way, C may actually 
contribute to tumour progression.
Mice deficient in specific C components provide an invaluable tool allowing 
detailed investigation of the respective roles played by individual proteins in 
tumour rejection or progression. The chemical carcinogen, 3-MCA, can be 
used to induce fibrosarcomas in wild type and C knock-out mice unable to 
elicit specific C-mediated effects. Differences in tumour survival and growth 
are expected dependent on whether the C component is contributing to 
tumour immunosurveillance or progression. From tumours induced in WT and 
C-deficient mice, novel tumour lines can be generated ex vivo, and 
characterised in vitro. The re-inoculation of cells sufficient or deficient in 
synthesis of C components or regulators into WT and C-deficient hosts 
provides a powerful model by which the role of cell-derived and systemic 
protein can be investigated. A protein of particular significance is the central C 
component C3. Table 1.2 outlines a typical experiment designed to address 
this issue:
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Tumour Line Recipient Animal Complement Source
C3- C3_/* No C3
C3+ C3_/' Local (tumour C3 only)
C3- C3+/+ Systemic C3
C3 + o CO + + Local & Systemic C3
Table 1.2: Control over host/tumour derived C3 secretion.
Mice sufficient and deficient in C3 are injected with fibrosarcoma cells with and without the 
ability to synthesise C3. In this way, the effects of systemic and tumour-derived C3 on 
fibrosarcoma incidence or growth can be assessed.
Aims:
In order to investigate the relationship between C and tumour growth, the 
specific aims of this thesis were:
1) To optimise a method for, and to investigate the effect of a deficiency in 
a C component or regulator on in vivo growth of a pre-characterised WT 
fibrosarcoma line. This work is described in Chapters 3 and 4.
2) To investigate the effect of a deficiency in a C component or regulator on 
tumour induction by the chemical carcinogen 3-MCA. Differences in tumour 
survival, progression and phenotype are described in Chapter 5.
3) To excise tumours induced in WT and C-deficient mice, and to generate 
and characterise novel fibrosarcoma lines in vitro from these tumours. To 
assess in vivo growth of these lines and to examine the effect of C produced 
by the tumours themselves, or systemic C, on tumour growth. This work is 
described in Chapter 6 and is illustrated in Table 1.2 above.
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2. Materials and Methods
Coomassie Brilliant Blue Stain: 0.2% Coomassie Blue R250 in 45% Methanol, 
10% Acetic acid in dH20.
Destain: 20% Methanol, 7% CH3COOH in dH20.
Gel Drying Buffer: 4% Glycerol, 20% Methanol in dH20
Flow Cytometry Buffer: PBS, 1% BSA (Sigma), 1% NaN3, pH 7.4.
Phosphate Buffered Saline (PBS): 8.1mM Na2HP04, 1.5M KH2P04, 137nM 
NaCI, pH 7.4.
PBS-BSA: PBS, 1% w/v Bovine Serum Albumin (BSA).
PBS-Milk: PBS, 5% w/v dry skimmed milk powder.
PBS-Tween: PBS, 0.1% Tween 20 (Acros Organics).
SDS-PAGE Stacking Gel Buffer: 0.5M Tris, 0.4% (w/v) SDS, pH6.8. 
SDS-PAGE Resolving Gel Buffer: 1.5M Tris, 0.4% (w/v) SDS, pH8.8.
SDS-PAGE Running Buffer: 25mM Tris, 191mM glycine, 1% (w/v) SDS.
SDS-PAGE Loading Buffer (reduced): 0.1 M Tris (pH6.8), 10% (v/v) Glycerol, 
2% (w/v) SDS, 0.01% Bromophenol Blue, 2% (v/v) p-mercaptoethanol (p-ME). 
P-ME omitted for non-reduced samples.
Transfer Buffer: 25mM tris, 191mM glycine, 20% methanol.
ELISA Coating Buffer: 0.2M Na2C03, pH9.6.
ELISA Development Solution: 4x OPD tablets (Dako) added to 12ml dH20, 
5pL 33% H20 2.
Complement Fixation Diluent (CFD): 2.8mM Barbituric acid, 145.5mM NaCI, 
0.8mM MgCI2, 0.8mM CaCI2, 0.9mM Sodium Barbital, pH 7.2.
Erythrocyte Lysis Buffer: 8.3g NH4CI, 1g KHCO3, 37mg potassium-EDTA, pH 
7.4
Table 2.1: Buffer compositions for methods detailed in Chapter 2
69
2.1. Mice
Mice were bred in Specific Pathogen Free (SPF) conditions and maintained in 
filter-top cages in Biomedical Services Unit, Cardiff University, Heath Park. 
Clq^', C3'/_ and CDSS '^.CDSST7" mice were previously back-crossed onto 
C57BL/6 background at least 10 times (Morgan et al. 2006). Knock-out mice 
were controlled with age-matched C57BL/6 WT mice. Adult mice between 6- 
10 weeks of age were used for all experiments. All experiments were 
performed under license and in compliance with Home Office regulations.
2.2.3-Methylcholanthrene tumour induction
Four hundred pg 3-MCA (Sigma-Aldrich) was injected in a 100pL dose sub- 
cutaneously on the mouse hind leg to induce fibrosarcoma tumours. 3-MCA 
was dissolved in olive oil immediately prior to use. Mice were monitored 
weekly for tumour development using callipers (Jencons) to measure tumour 
width and length. Tumour volumes were estimated according to the formula: 
( t t  x length x width2) / 6 (Jones et al, 2002). Mice were sacrificed when tumour 
diameter reached 1cm.
2.3. Cell culture
Fibrosarcoma cell lines were grown in RPMI-1640 (Gibco) supplemented with 
10% (v/v) heat inactivated foetal calf serum, 50U penicillin/streptomycin, 
2mM L-glutamine, 1mM sodium pyruvate and 1% non-essential amino acids 
(Invitrogen) unless otherwise specified. Cells were maintained with 30ml 
media in T175 tissue culture flasks (Nunc) unless otherwise stated and 
incubated at 37°C, 5% CO2. When confluent, flasks were washed twice with 
sterile 0.9% NaCI solution (Fresenius Kabi Ltd) and incubated (10 minutes, 
room temperature) with 0.5ml Versene (1:1000 EDTA, Invitrogen), per flask to 
lift adherent cells. Cells were re-suspended in 10ml fresh media and 
centrifuged (800g, 3 minutes) to pellet. Resulting pellet was re-suspended in 
5ml media, mixed briefly and 1ml removed to seed a new T175 flask.
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Antibody Specificity Isotype Application Dilution Source
Mel4 Rat anti­
mouse CD59 
mAb
igGl WB, FC, IHC 10pg/ml In house
MD1 Rat anti­
mouse CD55 
mAb
lgG2c WB, FC, IHC 10pg/ml In house
5D5 Rat anti­
mouse Crry 
mAb
lgG1 WB, FC, IHC 10pg/ml M.V. Holers
Apa5 Rat anti­
mouse
CD140a mAb
lgG2a WB, FC 10pg/ml e-bioiscience
11H9 Rat anti­
mouse C3, 
C3b, iC3b, 
C3dg mAb
lgG2a FC, IHC, 
ELISA
10pg/ml 
5pg/ml IHC
Hycult
Anti-C3 Rabbit anti­
mouse C3 pAb
Affinity
purified
ELISA 2pg/ml Hycult
Anti-C9 Rabbit anti-rat 
C9 pAb
Affinity
purified
IHC 1/50 In house
Anti-MsE Rabbit anti­
mouse 
erythrocyte 
pAb
serum FC, KA As defined In house
BB5.1 Mouse anti­
mouse C5 
mAb
lgG1 depletion 10mg/ml Hycult
Anti-C4 Mouse anti­
human C4 
mAb
lgG1 depletion 10mg/ml In house
Isotype
Control
Rat lgG1 lgG1 IHC 10pg/ml Caltag
Isotype
Control
Rat lgG2a lgG2a IHC 5pg/ml
10|jg/ml
Caltag
Isotype
Control
Rat lgG2b lgG2b IHC 5pg/ml
10|jg/ml
Caltag
Isotype
Control
Rat igG2c lgG2c IHC 10pg/ml Caltag
Anti-CD4 Rat anti­
mouse CD4 
mAb
lgG2a IHC 5pg/ml BD-
bioscience
Moma-2 Rat anti­
mouse 
macrophage 
mAb
lgG2b IHC 5pg/ml Abeam
Table 2.2: FC: flow cytometry, WB: Western blot, IHC: Immunohistochemistry, ELISA: Enzyme-linked 
immunosorbent assay, KA: Killing assay.
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2.3.1. Cell storage
For storage, one T175 flask at ~80% confluency was used. Cells were lifted, 
washed and re-suspended in freezing solution (10% DMSO (Sigma), 90% 
FCS (Invitrogen)) and placed in 1ml cryovials (Greiner). Cryovials were placed 
into Cryo 1°C Freezing Container (Nalgene) and incubated at -80°C for 24 
hours. Cryovials were removed from the Container and stored in liquid 
nitrogen until required. Upon retrieval, cells were thawed quickly, centrifuged 
(800g, 3 minutes), re-suspended in 30ml media and passaged once in vitro 
prior to inoculation.
2.3.2. Fibrosarcoma cell inoculation
Cells were cultured as described to 70-80% confluency, washed with 0.9% 
NaCI solution, lifted with Versene (0.5ml, 10 minutes, room temperature), 
strained through 40pm filter (SC Lab Supplies) and counted. An estimation of 
cell number was performed using a haemocytometer (MarienField) with cells 
pre-mixed 1:1 with Trypan blue solution (Fluka). Dead (blue stained) cells 
were not counted, and cultures were discarded if <90% viable. 105 cells were 
re-suspended per 100pL sterile PBS and injected sub-cutaneously into the 
flank. Mice were monitored three times per week, with tumour volumes 
measured as described in section 2.2.
2.3.3. Cloning of fibrosarcoma lines
Freshly excised tumours were disaggregated using forceps, scissors and 
repetitive syringing. The resulting cell suspension was washed three times 
(800g, 3 minutes) in 10ml culture media and passed through a 40pm cell 
strainer (SC Lab Supplies). Heterogeneous fibrosarcoma populations were 
incubated as described (section 2.3). Media was removed daily, cells washed 
once with 0.9% NaCI solution (Fresenius Kabi Ltd) to remove cell debris and 
media replaced. Initially, 20% FCS media was used, reverting to 10% when 
cultures became established (~ 1 week). Cells were harvested and re­
suspended 900 cells/ml in fresh media. Cells were then titrated by 100pl
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limiting dilution into a 96 well plate. Wells containing a single, localised cell 
population were identified, and cells allowed to divide several times before 
lifting with Versene and re-plating into T25 flask in 5ml culture media. This 
process was repeated 3 times, with populations screened by flow cytometry 
for uniform expression of CD140a following each cloning step.
2.3.4. Alamar blue proliferation assay
15000 cells were seeded in triplicate into 6 well plates with 1ml culture media. 
Cells were allowed to adhere for 2 hours before removing media and 
replacing with 0.5ml media supplemented with 10% (v/v) Alamar Blue solution 
(AbD Serotec). Plates were incubated at 37°C for 2 hours before 50pL 
supernatant was removed and placed into a flat-bottomed 96 well plate. Cells 
were washed using 0.9% NaCI solution (Fresenius-Kabl Ltd) and 1ml culture 
media replaced. Plates were re-incubated at 37°C. This procedure was 
repeated at 24 hour intervals. Supernatants in 96 well plates were read using 
a Fluostar Otima (530 nm excitation, 590 nm emission wavelength).
2.4. Haemolysis assays
2.4.1 Sensitisation of rabbit erythrocytes
Rabbit blood was harvested and mixed with an equal volume Alsever’s 
solution to preserve cells and prevent clotting. Cells were centrifuged (900g, 5 
minutes, 4°C) and diluted to 4% v/v in CFD. Polyclonal mouse anti-rabbit 
erythrocyte Ab was diluted to 0.5% v/v in CFD and incubated 1:1 with 
erythrocyte suspension for 30 minutes at 37°C. Cells were washed to remove 
unbound Ab (900g, 5 minutes, 4 °C) and re-suspended to 2% in CFD.
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2.4.2. Serum collection
Normal mouse serum was harvested from C57BI6 mice following sacrifice 
under Schedule 1 protocol. Blood was collected and clotted on ice for 15 
minutes. The resulting clot was spun at 8000g for 10 minutes at 4°C. Upper 
serum fraction was removed and used immediately or stored at -80°C.
2.4.3. Haemolysis
Mouse serum (50pl) was plated with 50pl CFD in column 1 of a 96-well round 
bottomed plate and titrated with further CFD via Vz serial dilution. 50pl of 
antibody coated rabbit erythrocytes were added to each well. Control wells 
were included in which 50pl dH20  or CFD was added in place of serum to 
provide 100% and 0% lysis controls respectively. Duplicate wells were 
prepared for each serum dilution and control. Following incubation at 37°C for 
30 minutes, intact erythrocytes were pelleted by centrifugation (900g, 5 
minutes). Flat-bottomed plates were prepared with 100pL dH20  per well, and 
50pL erythrocyte supernatant added per well. Absorbance of the supernatant 
was read at 415nm using a Dynex MRX II plate reader. Percentage lysis was 
calculated at each serum dilution according to the following equation:
% lysis = (A4i5sample - A4150%) / (A415100% - A4150%) X 100
2.4.4. in vitro C5 depletion
To assess C-inhibitory effects of BB5.1, sensitised erythrocyte cells were 
prepared as described in section 2.4.1 and lysed using a range of serum 
dilutions. The concentration of serum giving 60% lysis was noted. Antibody 
(BB5.1 or isotype control) was diluted in CFD and 50pl plated at lOpg/ml in 
duplicate. Further dilutions were prepared by ten 1:1 serial dilutions in CFD. 
50pl of the appropriate dilution of mouse serum (to give -60% lysis) was 
added and plates shaken briefly to mix. 50pl antibody coated erythrocytes 
were added per well and haemolysis performed and measured as described 
above.
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2.4.5. In-vivo C5 depletion
2.4.5.1. Titration
Monoclonal mouse anti-mouse C5 antibody (BB5.1) in sterile PBS was 
injected (200pL, 10mg/ml) intra-peritoneally per mouse at 6-day intervals. 
Serum was harvested regularly via tail tipping and allowed to clot on ice for 20 
minutes. The resulting clot was centrifuged (8000g, 5 minutes, 4°C) and 
serum fraction (top layer) removed. Sera were assayed for C activity via 
haemolysis assay (as above). Haemolytic activity was plotted and used to 
determine period over which sera were C5-depleted i.e. non-haemolytic. This 
was used to select an appropriate in vivo dosage for further experiments.
2.4.5.2. Tumour inoculation
To deplete C5, 2 mg BB5.1 or isotype control antibody (mouse anti-human 
C4) was administered intra-peritoneally on day -1. Fibrosarcoma cells were 
injected sub-cutaneously (as in section 2.3.2) on day 0 (10s cells, 100pL 
PBS). Repeat antibody doses (2mg) were administered at 6-day intervals.
2.5. Antibody preparation
Antibody producing hybridoma cells were maintained in CELLine 1000 Integra 
flasks (Integra Biosciences). These flasks comprise a lower (small) and upper 
(large) compartment separated by a 10kDa semi-permeable membrane. Cells 
were inoculated at initial density of ~2x107 cells suspended in 15ml media 
(15% v/v heat-inactivated low-bovine IgG FCS) (Gibco) in RPMI-1640 (Gibco), 
50U penicillin/streptomycin, 2mM L-glutamine, 1mM sodium pyruvate and 1% 
non-essential amino acids (Invitrogen) . 1L RPMI-1640 supplemented with 
50U penicillin/streptomycin, 2mM L-glutamine and 1mM sodium pyruvate was 
added in the upper compartment. To harvest cells, the upper compartment 
was drained, 20ml medium removed from lower compartment and 1ml cells 
replaced with 15ml fresh media. Remaining supernatant was spun to pellet
75
cells (800g, 3 minutes) supernatant removed and frozen at -20°C. This 
process was repeated as required (~6 day intervals).
2.5.1. Antibody purification
Hybridoma supernatant was thawed and pooled before high speed 
centrifugation (6000g, 30mins, 4°C) to remove cell debris. The s/n was filtered 
through a 0.2pm Stericup filter unit (Millipore). An equal volume of saturated 
ammonium sulphate was added to the s/n and left overnight at 4°C with 
stirring. Precipitate was collected by centrifugation (6000g, 30mins, 4°C) and 
re-suspended in AnalaR H20  until dissolved. Precipitate was collected by 
centrifugation (6000gt 30min, 4°C) before re-suspension in minimum volume 
of AnalaR H2O. The resulting antibody solution was dialysed three times into 
sterile PBS.
2.5.2. 'Endotoxin-low’ antibody purification
Reagents for all buffers used were highest molecular grade available (>99% 
purity) and were kept sterile. To prepare buffers, solids were weighed in 
sterile boats in a fume cabinet and were not allowed to contact any other 
object e.g. a spatula. Prior to protein purification, the AktaPrime protein 
purifier (GE Life Sciences) and all lines were pre-washed 3 times with 0.5M 
NaOH to remove all traces of endotoxin. All lines were thoroughly rinsed using 
PBS running buffer (Gibco) to remove NaOH. The purifier was equilibrated 
and fitted with an unused 5ml protein G column (Hi-Trap), able to bind ~30mg 
Ab per purifier run. Pooled tissue culture supernatant containing Ab was 
thawed, filtered through a 0.2pm Stericup filter unit and passed over the 
column until saturation i.e. maximum Ab amount bound to column. This 
volume was determined to be ~40ml per run. To elute protein from the 
column, 0.1M Glycine (Acros) was prepared using AnalaR H2O and was 
acidified to pH 2.5 with HCI (Sigma). Fractions were collected in sterile (pre­
packed) Facs tubes (BD-Falcon). Those fractions containing Ab were 
identified using the absorbance trace via Primeview software and neutralised 
using 100pl 1M Tris/HCI pH9. The column was cleaned using HCI in AnalaR
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H2O pH1.5, before repeating load cycle. Neutralised Ab fractions were pooled 
and placed into dialysis tubing pre-boiled in 0.5M NaOH. Ab solution was 
dialysed twice into sterile PBS (16 hours, 4 °C) using the original PBS 
packaging and a stirrer pre-washed with 0.5M NaOH. Ab in PBS was 
aliquoted stored at -20°C until required.
2.5.3. Endotoxin testing
Endotoxin contamination was quantified using the QCL-1000 Chromogenic 
LAL test (Lonza) according to kit instructions. Screening of ‘endotoxin-low’ 
antibody preparations was performed by the Endotoxin screening lab, Medical 
Microbiology, Cardiff University.
2.5.4. Protein concentration & quantification
Following purification of antibody preparations, solutions were concentrated to 
10mg/ml using Amicon pressure ultrafiltration systems, through a 100kDa 
filter. A Jenway Genove or Nanodrop ND1000 (Labtech) spectrophotometer 
was first used to set a baseline ‘zero’ absorbance reading at 280 nm ( A 2 8 0 n m )  
using buffer only (PBS). Ab containing samples were then tested and A280nm 
reading noted. The Beer-Lambert Law (A=e.c.l) was used to calculate protein 
concentration whereby the extinction co-efficient (e) for Ab = 1.4 and the 
length (i) = 1 cm.
2.6. SDS-Polyacryiamide gel electrophoresis (SDS-PAGE)
The Hoefer gel electrophoresis system was used for all experiments. 10pl 
protein containing samples were boiled for 2 minutes with an equal volume or 
greater of loading buffer (under reducing or non-reducing conditions). Gels 
were prepared according to Table 2.5 and submerged in SDS-PAGE running 
buffer. 20pl protein solution was loaded per well and gels subjected to 200V 
for 60-75 minutes. Resolved gels were stained or Western blotted as 
described below. Pre-stained broad range markers were co-loaded to allow 
size estimation (New England Biolabs).
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2.6.1. Cellular lysates
K6 cells were grown until 80% confluent, washed, lifted using Versene and 
used to make three fibrosarcoma lysates as described in Table 2.4. All steps 
were performed on ice with resulting lysates centrifuged (15000g, 4 minutes, 
4°C) to remove cell debris. Lysates were made fresh and used immediately.
1 2 3
Detergent 3% NP40 3% NP40 5% Triton X-100
PMSF 0.001 M 0.001 M 0.001 M
EDTA 10mM 10mM 10mM
SDS 0.05% (w/v) 0.05% (w/v) 0.05% (w/v)
Protease Inhibitor 
Cocktail (Sigma)
5% (v/v) 5% (v/v) 5% (v/v)
Cells 20x10° per ml 10x10° per ml 10x10B per ml
Incubation 30 mins 60 mins 30 mins
Table 2.3: Cell lysis buffers. Lysates prepared and adjusted to pH 7.4
2.6.2. Coomassle Stain
In order to detect 2-8pg of protein, SDS PAGE gels were immersed in R250 
Coomassie blue solution with agitation for 30 minutes following by repeated 
immersion in destain solution until non-specific staining was removed. Gels 
were submerged in gel drying buffer (30 minutes) and dried overnight 
between two sheets of gel drying film (Promega) stretched in a gel drying 
frame.
2.6.3. Western Blot
Resolved gels were submerged in transfer buffer and blotted (100V, 1 hour) 
onto 0.2pm nitrocellulose (VWR International) sandwiched between blotting 
paper and sponges pre-soaked in transfer buffer and placed in a cassette. 
Following transfer, nitrocellulose was removed and blocked in PBS-milk (1 
hour, room temperature) before incubation with primary antibody (see Table
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2.2) (14 hours, 4°C). Blots were washed 3 times (10 mins, room temperature) 
in PBS-Tween solution before re-blocking with PBS-milk (30 minutes, room 
temperature). Blots were stained with 1/1000 v/v donkey anti-rat IgG-HRPO 
(Jackson Immunoresearch) (1 hour, room temperature) before washing three 
times with PBS-Tween solution and once with PBS. Bound Ab was visualised 
using Enhanced Chemiluminesce kit (GE Healthcare), subjected to light 
sensitive hyperfilm (GE Healthcare) and developed using Compact X-2 X- 
Ograph developer machine.
Percentage gel 5%
(stacking)
7.5%
(resolving)
10% 12.5%
Stacking gel Buffer 
(ml) pH6.8
2.4 - - -
Resolving gel Buffer 
(ml) pH8.8
- 7.5 7.5 7.5
40% Acrylamide (ml) 1.3 5.6 7.5 9
10% Ammonium 
Persulphate(APS) (pi)
100 300 300 300
dH20 (ml) 6.1 16.4 14.5 13.0
TEMED (pi) 10 30 30 30
Table 2.4: Gel compositions for SDS-PAGE. Acrylamide, APS and Temed all sourced from Sigma- 
Aldrich.
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2.7. Flow Cytometry
2.7.1. Cell staining
Cells were characterised for protein expression using a 2 step staining 
process. Cells were lifted, strained and counted as described in Section 2.3.2. 
Cells were re-suspended to 106/ml in FACS buffer and 100pl incubated with 
the same volume of primary Ab (60 minutes, 4°C) in a 96-well plate (Abs used 
are detailed in Table 2.2). Cells were pelleted (800g, 4 minutes) and washed 
three times in FACS buffer. 100pl re-suspended cells were incubated 1:1 with 
1/100 v/v species-specific R-Phycoerythrin labelled secondary antibody (60 
minutes, 4°C ) in 96-well plate (Table 2.2, Jackson Immunoresearch). Cells 
were pelleted (800g, 4 minutes) and washed three times in FACS buffer.
2.7.2. Flow cytometric analysis
Cell events were collected using a FACSCalibur and analysed using 
CellQuest Pro software (BD Biosciences). A minimum of 15000 ‘events’ were 
collected per sample, and 106 erythrocytes were analysed for controls. Data 
were gated to remove cellular debris and analysed for fluorescence in the FL- 
2 channel using Summit v3.1 (Dakocytomation).
Antibody Conjugate Application Dilution Source
Donkey anti­ RPE FC 1/100 Jackson
rat IgG HRPO WB 1/1000
Donkey anti­
rabbit IgG
RPE FC 1/100 Jackson
Goat anti­
rabbit IgG
HRPO ELISA 1/1000 Jackson
Donkey anti­
rat IgG
Alexa-fluor-
594
IHC 1/200 Molecular 
Probes Inc.
Goat anti- 
rabbit IgG
Alexa-fluor-
594
IHC 1/200 Molecular 
Probes Inc.
Table 2.5: FC: flow cytometry, WB: Western blot, IHC: Immunohistochemistry, ELISA: Enzyme-linked 
immunosorbent assay.
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2.7.3. Killing assay: propidium iodide
Cells were grown until 80% confluent, lifted using 0.5ml Versene, washed and 
re-suspended at 2x106/ml in CFD. 50pl polyclonal rabbit anti-mouse 
erythrocyte antibody (in CFD) was added to 50pl cells with final antiserum 
concentrations from 10% to 0.5% v/v in a 96-well plate. Cells were incubated 
with heat inactivated (30minutes, 56°C) antiserum (45 minutes, 4°C) before 
washing twice in CFD. Cells were transferred to FACS tubes after re­
suspension in 100pL of a range of fresh mouse serum (100% to 2% final 
concentrations v/v in CFD). After 1 hour at 37°C, 200pl of 2pl/ml propidium 
iodide (PI) was added to FACS tubes and fluorescence measured by flow 
cytometry as described above. PI is an intercalating agent which penetrates 
cells with disrupted membranes (i.e. dead/dying) and binds to DNA. PI emits a 
fluorescent signal which can be used to differentiate healthy cells (non- 
fluorescent) from lysed cells (PI fluorescent).
2.7.4. Killing assay: calcein-AM loading
Cell viability can be assayed by pre-loading with a compound and quantifying 
release of the compound following sensitisation and treatment with serum. For 
this assay, the cell permeable compound calcein acetoxymethyl ester 
(calcein-AM) was incubated with cells and is readily taken up to ‘load’ cells 
with the non-fluorescent dye. Intracellular esterases cleave the compound by 
hydrolysis to yield the fluorescent dye calcein. Release of free calcein by dead 
cells can be detected and used to quantify cell death following sensitisation 
and treatment with C. Intact cells can then be lysed with detergent allowing 
calculation of the proportion of cells lysed through C as a percentage of the 
total population.
Cells were seeded to 30-40% and grown overnight to obtain 50-60% 
confluence in 24 well plates. 50pg calcein-AM (Molecular Probes) was 
dissolved in 50pl DMSO (Sigma) + 50pl methanol. 25pl 2M KOH (H20) was 
added and the calcein solution (1 hour, room temperature), diluted to 2pg/ml 
in 5% FCS-RPMI and the solution was adjusted to pH7. Cells were loaded by
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incubation with 200|jI per well calcein (2pg/ml, 5% FCS-RPMI) for 1 hour at 
37°C and washed with 1 % BSA/ CFD. Cells were sensitised for 45 minutes at 
4°C with 7% v/v heat inactivated (56°C, 35 minutes) pAb in 175pL BSA/CFD. 
Cells were washed before incubation (37°C, 30 minutes) with 200pl of a range 
of fresh mouse serum concentrations (100% to 2% v/v in BSA/CFD). This and 
subsequent steps were performed in the dark to avoid quenching of 
fluorescent signal. Supernatants were transferred to a 96-well plate. 
Remaining calcein was released from non-lysed cells using 200pl 0.5% Triton 
X-100 (Sigma-Aldrich)/CFD v/v for 15 minutes and s/n was transferred to a 
96-well plate. Fluorescence was read using a Fluostar Optima (excitation 
485nm, emission 530nm) and plotted using Graphpad Prism. % C-mediated 
lysis was calculated according to the below formula whereby A0% refers to 
background calcein release in wells untreated by C or detergent:
% |ygjg =  ^C-mediated _ ^0%^ j ^C-mediated + detergent-mediated _ ^0%^ ^ 100
2.7.5. Complement C3b/iC3b deposition assay
K6 cells were grown until 80% confluent, lifted as described in Section 2.3.2 
and re-suspended at 106/ml. 100pl cells were sensitised in 96-well plates 
using 2% v/v heat inactivated (30minutes, 56°C) rabbit anti-mouse erythrocyte 
pAb in CFD (45 minutes, 4°C). Cells were washed in CFD and 100pl cells 
incubated (30 minutes, 37 °C) with a range of fresh mouse serum (final 
concentrations 50%-0.5% v/v). Cells were washed three times (800g, 3 
minutes) into FACS buffer. Mouse C3b/iC3b deposition was detected by flow 
cytometry using 10pg/ml 11H9 rat anti-mouse C3 mAb by incubation at 4°C 
for 45 minutes. Cells were washed three times (800g, 3 minutes) before 
incubation with 1/100 (v/v) donkey anti-rat IgG-RPE (cross-adsorbed against 
rabbit Ig to prevent binding to sensitising pAb). Shift in fluorescence was 
measured using a FACSCaliber and analysed using Summit v3.1 
(Dakocytomation).
2.8. Immunohistochemistry
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Excised tumours were snap frozen in -20°C iso-pentyl alcohol and stored at - 
80°C. Tumour sections of 10pm thickness were collected using a Thermo 
Shandon cryotome and fixed in acetone (15 minutes, 4°C). Sections were 
blocked using 2% BSA in PBS (w/v) and stained (1 hour, room temperature) 
for C deposition / regulator expression using in-house monoclonal antibodies 
(Table 2.1). Appropriate isotype control antibodies were included alongside 
each staining procedure. Following incubation with antibody, sections were 
washed 3 times in PBS to remove non-specific binding. Sections were re­
blocked for 30 minutes with 2% BSA in PBS. Fluorescent (Alexa-594 
conjugated) secondary antibodies (Table 2.3, Molecular Probes Inc.) were 
used (1 hour, room temperature) to detect binding of primary Abs. Fluorescent 
images were taken using a Leica microscope and Hamamatsu C4742-95 
digital camera. Images were de-compressed using Velocity.
2.8.1. Fluorescence quantitation
Images were captured from non-overlapping random positions per tumour 
section and assessed for C3b/iC3b deposition, C9/MAC deposition or CD4+ 
infiltrating cells. A total of 8 tumours was selected per genotype, with 6 frames 
recorded from each tumour section.
2.8.1.1. C3b I C9 deposition
Images were loaded into Image-Pro Analyser 6.3 software. This software 
allows determination of fluorescence within an image by assessing 
fluorescent signal relative to a user-defined standard. A background threshold 
for fluorescence was set to recognise areas stained positive by eye and 
maintained for all photos analysed. Area of field stained positive was 
measured automatically and expressed relative to the entire frame area. % 
fluorescence was then recorded and analysed using Graphpad Prism.
2.8.1.2. CD4* cell infiltration
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Images were captured from non-overlapping random positions per tumour 
section. Sections were counted blind to avoid bias, and verified by an 
independent blinded observer. Cells were visible as a defined ring of 
fluorescence. The total number of single cells stained positive for CD4 antigen 
were recorded and analysed using Graphpad Prism.
2.9. Quantitative real-time PCR analysis
2.9.1. RNA Extraction
Total RNA was extracted and purified from fibrosarcoma cell lines using the 
GenElute Mammalian Total RNA Miniprep kit according to the manufacturer’s 
instructions (Sigma-Aldrich). Additionally, RNA from 1g homogenised fresh 
(WT) liver sample was extracted and purified using the same kit. All protocols 
involving RNA extraction were carried out using DEPC-treated H20, pipette 
tips and tubes to prevent RNA degradation. Briefly, cells were lysed in 
guanidine thiocyanate and p-mercaptoethanol to release RNA and inactivate 
RNases before centrifugation (12000g, 10 minutes, 4°C) through a filtration 
column to remove cell debris and DNA. RNA was then precipitated using 
isopropanol and spun (12000g, 10 minutes, 4°C) to produce an RNA pellet. 
RNA was re-suspended and washed twice in 70% ethanol (8000g, 5 minutes, 
4°C) before re-suspending in DEPC-H2O. RNA concentration was assessed 
using Nanodrop ND1000 (Labtech).
2.9.2. qPCR
1pg cDNA from each cell line was prepared from RNA using 
random hexamers and multiscribe reverse transcriptase according to the 
manufacturer’s instructions (Applied Biosystems, Warrington, U.K.). The 
Platinum SYBR Green qPCR Super-Mix-UDG kit was used for real-time 
qPCR including Taq DNA polymerase. Primer RNA strands were designed 
specifically to hybridise to genes of interest (mouse C3, CD55, CD59 and p-
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actin). Forward and reverse primers were included as described in Table 2.6 
and PCR conditions were as follows:
12.5pL Platinum SYBR Green qPCR Supermix
0.5pL Forward primer (10pM)
0.5pL Reverse primer(10pM)
50ng cDNA template
6.5pL DEPC-treated H20
PCR conditions:
Activation: 95°C 3 minutes
Repeat40 f  Denaturation: 95°C 15 seconds
cycles |
L Annealing: 58°C 30 seconds
Reactions were carried out in 48 well plates, with each cell line assessed in 
triplicate. qPCR was performed on the ABI PRISM 7000 (Applied Biosystems) 
and analysed using the sequence detection system software version 1.9 
(Applied Biosystems). SYBR Green uptake was normalised using p-actin 
expression levels to control for differences in cDNA loading. Results were 
calculated and expressed relative to results from lines deficient in C3, CD55 
or CD59.
Primer sequence
B-actin forward ACGGCCAGGTCATCACTATTG
B-actin reverse AGTTT CAT GGAT GCCACAGGAT
CD55 forward T GT GATGCT CTTACT CACT GG
CD55 reverse GTAT CCATT CTT CCTGGACATT C
CD59a forward GCCGGAATGCAAGTGTATCA
CD59a reverse GT CCCCAGCAAT GGT GT CTT
C3 forward AGAAGACTGCCTGACCTTCA
C3 reverse TTTT CTCCCCAGAGGT CAGA
Table 2.6: Forward and reverse primer sequences for real-time qPCR.
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2.10. ELISA
96-well ELISA plates (MP Biochemicals) were coated with 90pl rat anti-mouse 
C3 mAb (11H9) at 10pg/ml in ELISA coating buffer (1 hour, 37°C). Plates 
were then washed 3 times with 150pl 0.1% Tween-20 (Acros Organics)/PBS. 
Plates were then blocked with 5% milk/PBS (w/v) (1 hour, 37°C) and 
incubated with 90pl purified C3 from WT mice or tissue culture supernatant in 
triplicate. For some assays, supernatant was concentrated using 0.22pm 
centrifugal concentrator (Millipore). After washing, 90pl polyclonal rabbit anti­
mouse C3 was used at 2pg/ml to detect bound C3 (1 hour, 37°C) followed by 
washing and detection using HRPO-conjugated 1/1000 goat anti-rabbit IgG (1 
hour, 37°C). Plates were washed and signal developed using OPD solution 
and stopped by addition of 45pl 10% H2SO4. Absorbance was read at 490nm 
in Dynex Technologies MRXII.
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3. Characterisation of a WT fibrosarcoma line for in vivo inoculation
3.1. Introduction
The aims of experiments described in this Chapter were to characterise the in 
vitro behaviour and confirm in vivo growth of a fibroblast cell line available in 
house. This was done in order to later use the cell line to investigate the 
impact of the C system on tumour growth and progression. As described in 
Chapter 1, tumours can be induced by administration of the chemical 
carcinogen 3-MCA. Injection of this substance results in recruitment and 
subsequent mutation of fibroblasts at the site of injury. A progressively 
growing tumour is formed which may be excised and cultured in vitro. A cell 
line derived in vitro from a 3-MCA induced fibrosarcoma was obtained from Dr 
Maries van den Broek (University Hospital, Zurich). This cell line, named K6, 
was found to grow aggressively when re-inoculated into WT mice (G.J.Betts 
personal communication, November 2005). No work using this cell line has 
previously been published, however, it was surmised that inoculation of these 
cells into various hosts could be used to identify differences in tumour 
progression between WT and C-deficient host mice. As such, this cell line is 
expected to provide a robust model for the growth of established tumours in 
vivo.
In order to achieve this goal, it was first considered important to perform a 
detailed characterisation of this cell line with respect to relevant in vitro 
properties and in vivo growth rates. Thus, this Chapter describes assessment 
of fibrosarcoma phenotype and expression of 3 important CRegs by these 
cells. Such properties were examined via the use of monoclonal antibodies 
(mAbs) against CD140a (a fibroblast marker), CD55, CD59 and Crry (CRegs) 
proteins. Expression of CReg provides effective protection from C-mediated 
lysis and may be important for assessment of in vivo survival and progression.
Additionally, the possibility that these cells synthesise and secrete C3 in vitro 
was investigated. This hypothesis is based on previous reports detailing co­
secretion of melanoma-derived C3 along with a C3 cleaving enzyme (Jean et
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al. 1997), and C3 secretion by human gastric cancer derived cells (Kitano and 
Kitamura 1993). Fibroblast cells have also been shown to produce local C3 
following cytokine stimulation (e.g. IL-1, IL-6, IL-13) suggesting that 
fibrosarcoma cells may be good candidates to investigate the possibility and 
effects of C3 secretion by transformed cells (Katz, Revel and Strunk 1989).
3.2. Results
3.2.1. Characterisation of K6 line for fibrosarcoma phenotype
K6 cells cultured in vitro were found to be extremely adherent and showed 
similar morphology to normal fibroblasts. In order to further characterise these 
cells, the CD 140a antigen was considered an appropriate marker to confirm 
the fibroblastic origin of the K6 line. This 170kDa antigen is also known as 
Platelet Derived Growth Factor Receptor a (PDGFRa, CD140a), is expressed 
on fibroblasts and implicated in cell migration (Yu et al. 2001). A rat mAb 
specific for this protein was used to detect expression via flow cytometry and 
visualised using an RPE-conjugated donkey anti-rat secondary Ab.
Flow cytometry data shown in Figure 3.1 indicates a relatively homogeneous 
population as evidenced by a defined population in terms of forward and side 
scatter (Panel A). Panel B shows fluorescence exhibited upon staining for 
CD140a expression. Cells were gated to fall within the region marked R1 in 
Panel A. Gating to this region included approximately 90% of the entire 
population and excluded dead/dying cells which may distort fluorescence 
measurements. Displayed in panel B is a control population (shaded area) 
stained with secondary Ab only, while the test population treated with anti- 
CD140a Ab is also shown and caused an increase in fluorescence. This 
indicates detectable levels of CD140a expression on K6 cells. Data shown is 
representative of 5 experiments performed at different times on K6 
populations. In each case, a shift in median fluorescence intensity (MFI) was 
recorded and found to range between 15-22 MFI units. This value was 
calculated in reference to the control population not exhibiting fluorescence 
and provided a measure of relative protein expression.
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Figure 3.1: Expression of CD140a on cultured K6 cells.
K6 cells were lifted, dis-aggregated and stained for CD140a expression using a two step 
staining protocol. Apa5 rat anti-mouse CD140a mAb was used and detected by donkey anti- 
Rat IgG-RPE. Panel A depicts forward and side scatter gated to region 1 (R1). Panel B depicts 
shift in fluorescence following staining for CD140a. Blue shaded area represents control cells, 
red line indicates shift in fluorescence following staining for CD140a antigen. Panel C depicts 
control (untreated cells) and those treated with isotype control Ab. 15000 cells were analysed. 
Data shown are representative of 5 separate experiments.
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3.2.2. CReg characterisation of K6 cells
3.2.2.1. Flow cytometry
CReg expression by tumour cells is a key mechanism by which cells are 
protected from C-mediated lysis and are important considerations when 
investigating the relationship between C and fibrosarcoma lines. Protein 
expression levels were analysed using flow cytometry. A rat mAb specific for 
Crry (5D5) was used and detected a significant increase in fluorescence when 
compared to a control population. However, rat mAbs specific for CD55 (MD1) 
and CD59 (Mel4) did not bind to cells at detectable levels with no shift in 
fluorescence observed. These data are shown in Figure 3.2 and suggest that 
high levels of Crry, but no CD55 or CD59 are expressed on K6 cells. As 
previously, these data are representative of 5 independent experiments. In 
order to exclude a problem with Ab binding and detection in the assay, mouse 
erythrocyte cells were also included as a positive control. Non-nucleated cells 
(e.g. erythrocytes) are prone to C-mediated lysis and are known to express 
high levels of CReg (Miwa et al. 2002b). As shown in Figure 3.3, a clear shift 
in fluorescence was observed following staining for Crry, CD55 and CD59 on 
erythrocytes. These data indicate that the lack of CD55 and CD59 on K6 cells 
is a genuine observation and is due to lack of expression and not a problem 
with the detection method.
Flow cytometry analysis of these cells was performed on several occasions 
using freshly thawed cells passaged only once or twice in vitro. Collated data 
from 5 separate experiments are summarised in Figure 3.4. This Figure 
shows little variation between experiments and confirms a consistent lack of 
CD55 and CD59 but high expression of Crry on K6 cells. The CD140a protein 
was also detected on all populations analysed.
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Figure 3.2: Expression of CReg by K6 cells.
K6 cells were lifted, disaggregated and stained for CReg expression using a two step staining 
protocol. 5D5, MD1 and Mel4 rat anti-mouse Crry, CD55 and CD59 respectively were used and 
detected by donkey anti-Rat IgG-RPE (red line). Control (unstained) cell populations are shown 
in blue, with isotype control treated populations in green. 15000 cells were analysed. Data 
shown are representative of 5 separate experiments.
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Figure 3.3: Expression of CReg by mouse erythrocytes
Mouse erythrocyte cells were stained for CReg expression using a two step staining protocol. 
5D5, MD1 and Mel4 rat anti-mouse Crry, CD55 and CD59 respectively were used and detected 
by donkey anti-Rat IgG-RPE (red line). Control (unstained) cell populations are shown in blue,
with isotype control treated populations in green. 10' 
representative of 5 separate experiments.
cells were analysed. Data shown are
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Figure 3.4: Analysis of CReg expression in K6 populations.
K6 populations were stained for CReg. The median shift in fluorescence was calculated 
following comparison to control cells treated with secondary Ab only. Five different K6 
populations were analysed and changes in fluorescence plotted. Figures adjacent to bars 
represent the mean shift in MFI value.
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3.2.2.2. Western blotting
An alternative method for detection of the above proteins is Western Blotting. 
This method allows detection of proteins in denatured i.e. non-native states as 
well as allowing estimation of protein molecular weights by reference to 
markers of known weight. Initial attempts to obtain working lysates proved 
unsuccessful due to protease digestion of proteins. Considerable optimisation 
of cell number, lysis protocol and inclusion of protease inhibitors was required 
as detailed in Chapter 2. K6 lysates were loaded onto 10% polyacrylamide 
gels and separated by electrophoresis. Resulting gels were blotted onto 
nitrocellulose and probed with rat mAbs as described above. A peroxidise 
conjugated donkey anti-rat IgG secondary Ab was used to detect bound Ab 
and visualised via chemiluminescence. K6 lysates were freshly prepared 
immediately prior to blotting with differing lysis conditions used to generate 3 
lysates from the same population. All three lysates were loaded to control for 
problems with protein degradation in these samples. Additionally, mouse 
erythrocyte lysates were included as a positive control for CReg presence.
Figure 3.5 shows presence of CD140a in each of 3 K6 lysates tested (blot A, 
lanes 1-3). The observed bands for each lysate resolved at 160-170kDa 
which corresponds to the expected size of the protein. As expected, CD140a 
was not found in the mouse erythrocyte lysate (lane 4) with no band visible. 
Data shown in blot B represents identical lysates stained with secondary Ab 
only. This controlled for non-specific binding of Ab with no bands visible on 
any blot stained with secondary Ab alone.
Figure 3.6 shows that K6 lysates did not contain detectable levels of CD55, as 
evidenced by the lack of visible bands in lanes 1-3. CD55 was detected in 
mouse erythrocyte lysates with a strong band visible at ~60kDa. Similarly, 
CD59 was not present in fibrosarcoma lysates (Figure 3.7). No bands were 
visible in lanes 1-3 whereas a band corresponding to ~15kDa was detected in 
the erythrocyte lysate (lane 4). Figure 3.8 shows the presence of Crry in K6 
and erythrocyte lysates with each band corresponding to a molecular weight
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Figure 3.5: Western blot analysis of CD140a in K6 cell lysates
K6 lysates were loaded onto a 10% gel and resolved. The gel was Western blotted onto 
nitrocellulose and probed with Apa5 rat anti-mouse CD140a. Bound mAb was detected using 
donkey anti-rat IgG-HRPO. Lanes 1-3 were loaded with K6 lysates prepared in different 
conditions as described in Chapter 2. Lane 4 was loaded with a mouse erythrocyte lysate. 
Panel B was not treated with primary antibody and controlled for Ab specificity.
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Figure 3.6: Western blot analysis of CD55 in K6 cell lysates
K6 lysates were loaded onto a 10% gel and resolved. The gel was Western blotted onto
nitrocellulose and probed with MD1 rat anti-mouse CD55. Bound mAb was detected using 
donkey anti-rat IgG-HRPO. Lanes 1-3 were loaded with K6 lysates prepared in different 
conditions. Lane 4 was loaded with a mouse erythrocyte lysate. Panel B was not treated with
primary antibody and controlled for Ab specificity.
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Figure 3.7: Western blot analysis of CD59 in K6 cell lysates
K6 lysates were loaded onto a 10% gel and resolved. The gel was Western blotted onto 
nitrocellulose and probed with Mel-4 rat anti-mouse CD59. Bound mAb was detected using 
donkey anti-rat IgG-HRPO. Lanes 1-3 were loaded with K6 lysates prepared in different 
conditions. Lane 4 was loaded with a mouse erythrocyte lysate. Panel B was not treated with 
primary antibody and controlled for Ab specificity.
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Figure 3.8: Western blot analysis of Crry in K6 cell lysates
K6 lysates were loaded onto a 10% gel and resolved. The gel was Western blotted onto 
nitrocellulose and probed with 5D5 rat anti-mouse Crry. Bound mAb was detected using 
donkey anti-rat IgG-HRPO. Lanes 1-3 were loaded with K6 lysates prepared in different 
conditions. Lane 4 was loaded with a mouse erythrocyte lysate. Panel B was not treated with 
primary antibody and controlled for Ab specificity.
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of ~60kba. Crry was missing in lane 1, suggesting protein degradation in this 
lysate. The presence of Crry in lysates 2 and 3 was sufficient to prove that 
Crry is present in the analysed cell population. In each of Figures 3.5-3.8, the 
control blot showed no chemiluminescent signal confirming the specificity of 
the primary Abs.
3.2.3. Estimation of C3 secretion by K6 cells
As described above, cells of fibroblast origin are known to secrete certain C 
components in vivo, an effect that may lead to enhanced tumour progression. 
Production and/or secretion of the central C component C3 has been reported 
by tumour cells and may be an important feature in terms of fibrosarcoma 
proliferation. An Enzyme-Linked ImmunoSorbent Assay (ELISA) was 
therefore used to assess and quantify C3 secretion by K6 ceils into tissue 
culture media.
A rat anti-mouse C3/C3b/iC3b mAb was used to detect C3 secreted by 
confluent K6 populations into culture supernatant (s/n). Cells were cultured to 
~40% confluence, fresh media added and incubated for 16 hours. S/n was 
removed from each population (approx 5x106 cells), spun to remove cellular 
debris and assayed in triplicate for C3/C3b/iC3b presence using a plate- 
bound rat monoclonal Ab specific for these proteins. Bound protein was 
detected using a rabbit polyclonal anti mouse C3 Ab and a peroxidase 
conjugated donkey anti-rabbit IgG Ab. A range of known C3 concentrations 
was assayed on the same plate comprising a titration of mouse C3 
concentrations, purified from WT sera. These known concentrations were 
used to create a standard curve against which s/n readings could be 
compared. These data are shown in Figure 3.9 and allow estimation of C3 
concentrations in the range 20-360ng/ml. However, absorbance values 
indicated in Figure 3.9 for a pool of three independently maintained K6 lines 
porrespond to concentrations below the threshold (20ng/ml) for detection in 
this assay. Consequently s/n from each of the populations were pooled and 
concentrated 10-fold prior to re-assay, again no C3 was detected (data not 
shown).
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Figure 3.9: ELISA detection of C3 secretion by K6 cells.
A 96 well plate was coated with a monoclonal Rat anti-mouse C3 antibody and incubated with a serial 
dilution of known C3 concentrations. Plates were washed before incubation with polyclonal Rb anti-mouse 
C3. Bound antibody was detected using HRPO-conjugated anti-rabbit IgG and visualised using an OPD 
preparation. Dilutions of C3 were assayed in triplicate. Values shown adjacent to the graph represent 
absorbance values following incubation with tissue culture s/n from a K6 population. Data shown are 
representative of 2 separate experiments.
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3.2.4. RT-PCR detection ofCD55, CD59 and C3 mRNA
Previous data shown above demonstrate a lack of CD55 and CD59 
expressed on cells, while no C3/C3b/iC3b could be detected in tissue culture 
s/n following Incubation with cells. Whilst these data suggest a lack of protein 
expression or secretion, an alternative method, RT-PCR, can provide a 
measurement of mRNA transcription in vitro. CD55, CD59 and C3 proteins 
may be transcribed at very low levels or be stored intra-cellularly resulting in 
the observed result above. However, RT-PCR is a highly sensitive technique 
and may identify mRNA transcription in the absence of protein expression. 
mRNA was obtained and reverse transcribed to cDNA prior to amplification 
and analysed using Platinum SYBR Green qPCR SuperMix (Invitrogen). 
Primers specific for CD55, CD59 and C3 (method described fully in Chapter 
2) were used to assess mRNA content associated with these genes. Figure 
3.10 shows negligible amplification of CD55, CD59 or C3 mRNA from K6 
cells. Hepatocyte cells were included as a control and showed significant 
amplification for each protein. These data showed that negligible mRNA for 
CD55, CD59 or C3 was present in K6 cells in vitro and support previous 
findings described in this Chapter.
3.2.5. in vivo growth of K6 fibrosarcomas
Established tumour cell populations can provide valuable models of in vivo 
tumour growth profiles with growth dependent on numerous factors including 
nature/type of cells, site of injection and number of cells inoculated. In order to 
identify an appropriate dose of K6 cells, initial experiments were performed 
using varying cell numbers. Figure 3.11 shows tumour growth in male WT 
animals as measured following inoculation of 104, 10s and 106 cells 
respectively. Tumours grew in each group with 100% tumour take in the two 
groups inoculated with higher doses of K6. Tumours appeared to grow at 
comparable rates independent of the initial number of K6 cells administered. 
However, while 100% tumour incidence was observed when 105 or 106 cells 
were inoculated, only half of the mice developed tumours following inoculation
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Figure 3.10: RT-PCR analysis of CD55, CD59 and C3 mRNA in K6 cells
mRNA was extracted from K6 cell populations or fresh liver sample. RNA was converted to 
cDNA via reverse transcription. Primer sequences specific for mouse CD55, CD59, C3 
and p-actin were used to amplify sequences in presence of Sybr-Green fluorescent dye. 
Fluorescence levels per cycle were recorded and used to calculate C(t) values for each 
protein per cell line. Reference gene data (p-actin) was deducted and values expressed 
relevant to a population deficient in relevant gene.
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Figure 3.11: in vivo tumour incidence following K6 cell inoculation into WT mice.
Inoculation of K6 cells into male WT mice. Mice were injected on day 1 with varying 
doses of tumour cells suspended in 100pL PBS. Number of cells inoculated is 
displayed next to each curve. Injections were made on the flank and mice monitored 
regularly with tumour sizes measured. Each line is representative of one individual 
mouse. Mice were sacrificed when tumour reached 200mm3. Each group consists of 
pooled data (n=8) from 2 separate experiments (n=4).
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of 104 cells. The observation that 100% incidence was recorded following 
inoculation with 105 and 106 ceils suggests that a threshold for incidence may 
exist whereby tumour cell numbers are high enough to form a progressively 
growing tumour in the vast majority of mice injected. Inoculation of 10s K6 
cells was selected for further experiments detailed in Chapter 4.
3.2.6. Discussion
The aim of the work described in this Chapter was to characterise a 
fibrosarcoma cell line and assess suitability of this line to investigate the roles 
of specific C components on tumour growth in mice. Additionally, data 
obtained through these experiments were used to guide further experiments 
involving the K6 cell line and described in subsequent Chapters. The 
experiments performed confirmed that the ceils were fibrosarcomas (CD140a 
-  positive) and that they grew progressively in immunocompetent animals. An 
inoculum of 10s K6 cells ensured tumour take in WT mice. Additionally, 
knowledge of certain cell characteristics was considered important for this 
project. As such, expression of the membrane CRegs Crry, CD55 and CD59 
along with secretion of key C component C3 was assessed.
Flow cytometric staining of K6 revealed unexpected results regarding CReg 
expression. The presence of Crry but not CD55 or CD59 was confirmed for 
these cells. This observation is somewhat surprising given the propensity of 
many tumour types to over-express CReg (reviewed by Fishelson, 2003), and 
previous reports of CD55 and CD59 expression on rodent fibroblasts (Powell 
et al 1997, Hinchliffe et al. 1998). However, Crry alone is a potent regulator 
and is the most Important CReg on mouse erythrocytes with deficiency 
causing spontaneous haemolysis (Miwa et al. 2002b). Deficiency of CD55 and 
CD59 in the same study had lesser effects with erythrocytes deficient in either 
of these regulators shown to have a normal lifespan. Whilst K6 cells were 
shown to be negative for CD55 and CD59 expression in vitro, it remains 
possible that CReg are up-regulated in vivo in response to C-attack with 
numerous cytokines associated with up-regulation of CReg in humans 
(TakOuchi et al. 2001, Spiller et al. 2000), while CD55 expression may be
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induced Inmouse endothelial cells by incubation with TNFa (Ahmad et al, 
2003). ^
Western blotting was also used to examine presence of CReg in these cells. 
This technique provides an estimate of protein molecular weight by 
comparison to known standards loaded alongside fibrosarcoma and control 
lysates and confirms data obtained by flow cytometry. This can be an 
important tool for identifying differential glycosylation patterns associated with 
certain tumour types (Nakagawa et al. 2001). In these cases, protein bands 
observed resolved at identical sizes to those derived from erythrocyte lysates 
indicating similar glycosylation in tumour and red blood cells. An additional 
advantage of assaying total cell lysates is the ability to detect intra-cellular 
protein stores i.e. non-surface expressed proteins which would not be 
detected by flow cytometry as described above. Considerable difficulties were 
encountered in attaining working lysates. Proteins within resulting lysates 
were rapidly degraded and protein content lost. Optimised conditions and a 
‘cocktail’ of protease inhibitors were required, with all steps performed on ice. 
Resulting lysates were effective if used immediately, but no protein could be 
detected following storage at -80°C. One lysate tested negative for Crry 
(Figure 3.8), demonstrating the vulnerability of these lysates to degradation. 
Western Blotting experiments performed in this Chapter confirmed the 
presence of Crry and CD140a, and the absence of CD55 and CD59 in K6 
total cell lysates. These findings substantiate previous findings via flow 
cytometry.
An important characteristic to consider is the secretion of C3 observed in 
some tumour cells (Kitano and Kitamura 1993). Additionally, co-secretion of 
C3 with a C3 cleaving enzyme has been observed in human melanoma cells 
with secretion shown to correlate with high metastatic potential (Jean et al. 
1997). G3 secreted by transformed cells may contribute to the host anti­
tumour Immune response in vivo via deposition as C3b and contribution to the 
amplification loop of the alternative pathway. Whilst this may contribute to 
anti-tumour immune responses, either through C-mediated lysis or 
opsonisation, C3b may alternatively be stimulating cells and promoting tumour
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progression as discussed in Section 1.12. The exact mechanisms influencing 
such effects remain unclear though numerous cellular signalling and 
proliferative effects have been associated with C3b / MAC deposition 
including increased resistance to C (Reiter, Ciobotariu and Fishelson 1992), 
intra-cellular protein phosphorylation (Donin et al. 2003) and enhanced 
proliferation (Longo et al. 2005). These observations, and the propensity of 
non-transformed fibroblast cells to secrete C3 (Katz et al. 1989) suggested 
that C3 synthesis/secretion is a possible characteristic of fibrosarcoma cells 
derived using this model. However, ELISA data examining tissue culture s/n 
found no detectable trace of C3, C3b or iC3b in s/n following overnight 
incubation with confluent K6 populations. Purified C3 of known concentration 
was used to provide a standard curve, with tissue culture s/n measured 
against the curve. A previous study reported secretion of C3 by malignant 
metanoma ceils with 350ng detectable by ELISA following incubation of s/n 
with 106 cells over a 24 hour period (Jean et al. 1997). However, absorbance 
values acquired from s/n were lower than the 20ng/ml threshold of sensitivity 
for the assay, even when s/n was concentrated 10-fold prior to testing. These 
data indicate that negligible or no C3 is secreted by these cells in vitro.
RT-PCR data provided a measure of mRNA transcription and is an extremely 
sensitive method able to detect small amounts of mRNA present in a sample. 
However, the assay was unable to identify CD55, CD59 or C3 mRNA in K6 
ceils. The experiment was controlled using hepatocytes derived from a WT 
mouse, with significant amplification observed associated with each protein. 
This confirmed the specificity of the primers used and the efficacy of this 
technique for this purpose. The findings support previous data from flow 
cytometric, Western blotting and ELISA analysis of these cells and suggest 
that CD55, CD59 and C3 are neither synthesised nor secreted in vitro.
Experiments described in subsequent Chapters aim to investigate the 
respective roles of individual C components and regulators in tumour survival 
and proliferation. In order to ensure suitability of K6 as a model for this 
purpose, and to obtain reliable data, analysis of in vivo growth was deemed 
necessary. The in vivo growth of an appropriate tumour line must be of high
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incidence and provide a consistent model with minimal variability between 
experiments. As shown in Figure 3.11, the number of K6 cells inoculated had 
a potent effect on tumour growth with a low (104) K6 dose exhibiting poor 
survival in vivo. Data derived from higher doses (10s and 106) were similar 
and exhibited 100% tumour take in WT mice. Growth of cells was recorded 
following inoculation and found to exhibit normal tumour growth patterns. 
However, following a dose of 104 K6 cells, poor tumour incidence was 
observed with only 50% of mice inoculated developing a tumour (n=8). This 
compares unfavourably with incidences observed following inoculation with 
10® or 10® cells, each of which caused 100% tumour incidence. The growth 
curves for the higher doses were found to be comparable and showed no 
difference in growth or survival. This indicates a threshold above which 
tumour cells are able to escape immune surveillance and below which, 
immune responses are sufficient to clear tumour dose and prevent growth. 
Although the findings suggest a threshold, tumour dose was not shown to 
affect growth rate following tumour occurrence, in this way, initial tumour dose 
appears to affect incidence rather than progression of K6 tumours. A high rate 
of tumour incidence is important for further work in elucidating differences in 
tumour growth between groups, as such a K6 dose of 105 cells was chosen 
for further experiments using this model. This inoculum was selected so as to 
grow tumours in a high proportion of mice injected, whilst not inoculating such 
a high burden as to ‘over-burden’ the host immune system which may 
potentially mask differences in tumour growth between different groups.
The K6 cell fibrosarcoma line appears well adapted for in vitro growth and 
provides an effective model allowing investigation of the effects of C proteins 
on tumour growth in vivo. Interestingly, these cells were shown not to express 
the important CReg CD55 and CD59 and also shown not to secrete the 
central C component C3 in vitro.
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4. The effect of complement deficiencies on in vivo growth of the 
fibrosarcoma line K6
4.1. Introduction
The aims of the experiments described in this Chapter were to investigate the 
relative contributions of various C proteins to tumour growth in vivo. An 
established fibrosarcoma line, characterised in Chapter 3, was inoculated into 
groups of mice lacking C1q, C3, C5 or lacking both the CRegs CD55 and 
CD59. Each experiment was controlled using age-matched WT mice and 
tumour growth, C3b/iC3b and C9 deposition and CD4+ infiltrate was analysed 
and compared between groups. As discussed in Chapter 1, protection from C 
is an important characteristic of all tumour cells. There is also evidence to 
support a role for C activation and deposition in tumour survival and 
proliferation. Knock-out mice deficient in C1q, C3 and lacking CRegs CD55 
and CD59 were available in house providing in vivo models for investigation of 
the relative roles played by these proteins in tumour survival and growth. In 
addition, a monoclonal antibody (mAb) specific for mouse C5 protein was 
used to neutralise this protein in serum in vivo allowing effects associated with 
C5 cleavage and downstream activation products to be investigated. BB5.1 is 
a murine lgG1 mAb raised through immunisation of C5'7' mice (Frei, Lambris 
and Stockinger 1987) and has been shown to block C5a formation and inhibit 
MAC deposition (Wang et al. 1995). Comparisons between test and WT 
groups were carried out in order to reveal differences in tumour growth and 
incidence, C activation and T-cell infiltration to be assessed providing 
important clues as to the contributions of C1q, C3, C5 and CReg to tumour 
progression in vivo.
The C1q protein is the initiator molecule of the classical activation pathway 
upon Ab binding. C3 is a crucial molecule central to all three activation 
pathways and responsible for a wide range of immunological effects. 
Cleavage of the C5 protein represents activation of the terminal pathway and 
may lead to MAC deposition and ultimately cell lysis while CD55 and CD59 do 
not contribute to C activation and are instead protective molecules expressed
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by hqsft cells to inhibit C and iimit autologous attack. These proteins are 
discussed in Chapter 1 and their respective roles in the C pathways are 
represented in Figure 1.1.
4.2. Results
4.2.1. Male mice possess higher haemolytic activity than female mice
The C system provides a rapid and effective means of lysing target cells 
through activation of one or more C pathways. Non-nucleated cells are 
particularly prone to C-mediated lysis and are regularly used to assess serum 
C potency (Porcel et al. 1993). Considerable differences have been observed 
in the abilities of mouse serum to lyse sensitised erythrocytes. This variation 
may be attributed to differing haemolytic activity of serum according to mouse 
strain (Terry, Borsos and Rapp 1964), or gender (Holt et al. 2001), used in the 
assay. For this reason, initial investigation of haemolytic capabilities of serum 
from male and female C57/BL6 mice was performed. Serum from 3 male and 
3 female C57/BL6 mice was collected and incubated with rabbit erythrocytes 
coated with a mouse anti-rabbit erythrocyte Ab and able to activate the 
classical pathway in vitro. Erythrocytes incubated with H2O (100% lysis) and 
those not incubated with serum (0% lysis) provided controls against which 
percent lysis mediated by a range of serum dilutions was calculated. 
Haemoglobin released by cells was recorded and expressed as percent lysis 
in Figure 4.1. As shown, serum from male mice was able to lyse cells far more 
readily than that obtained from female mice. A commonly used method for 
comparing C haemolytic activity involved calculation of the serum 
concentration required to cause 50% lysis in a given assay, known as CH50. 
However, whilst serum from male mice caused lysis of 50% erythrocytes at a 
concentration of ~60% serum, serum from female mice failed to lyse 50% 
erythrocytes and caused lysis of only 20% erythrocytes even with neat serum. 
Whilst a quantitative difference is therefore difficult to assess, a clear 
difference exists whereby serum from male mice is significantly more lytic 
than that from female mice. The observed disparity means that any
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Figure 4.1: Haemolytic capabilities of male and female WT mice
Rabbit erythrocytes were sensitised using a mouse anti-rabbit erythrocyte pAb 
and inbubated with serum from 3 male and female WT mice. Haemoglobin 
release following classical pathway activation was measured and expressed 
relative to a 100% control lysed with H20.
differences hqtjfd in tumour growth may arise as a result of differential C 
activity in mab and female mice and make accurate conclusions concerning 
the impact of C on tumour growth difficult. For this reason, male mice would 
be expected to provide a better opportunity to elucidate differences in tumour 
progression dependent on C effects. Both males and females possess an 
effective C system in vivo, however, male mice were used in the majority of 
experiments described in this thesis, in the following experiments, WT mice 
and those deficient in specific proteins of interest were injected 
simultaneously with fibrosarcoma cells. Differences in tumour incidence, 
growth and survival as a result of C deficiencies were monitored.
4.2.2. The effect o f C1q deficiency on K6 fibrosarcoma growth
Mice deficient in C1q were used to investigate the effects of activation of the 
classical C pathway on tumour growth in vivo. These mice were previously 
generated by targeted deletion of the C1q gene (Botto 1998). C1q‘A mice are 
unable to activate C in response to antibody binding to tumour cells and as 
such, all C-mediated effects must be elicited via the alternative or MBL 
pathways. By abrogating one potent pathway of C attack, it would seem likely 
that tumours would be subjected to a sub-optimal C response and therefore 
be less susceptible to CDC. In addition to direct C effects (e.g. killing, 
anaphylatoxin release), various other mechanisms are associated with C1q 
binding. These are discussed in detail in Chapter one and include 
opsonisation, cellular cytotoxicity and clearance of apoptotic cells. 
Mechanisms associated with C1q binding would be expected to be inhibited in 
C1qv* and may impact on tumour progression in various ways. However the 
complexity and variety of such mechanisms suggest that a multitude of factors 
could contribute to any observed effects. Figure 4.2 shows growth rates as 
observed in 8 wild type and C1q_/' mice following sub-cutaneous injection of 
1x105 K6 cells. All mice developed a tumour with the majority arising between 
4-8 days after inoculation. In each case, the tumour proliferated with similar 
growth kinetics (i.e. comparable slopes to the curves) and no clear differences 
between the groups were observed. However, tumours appeared to arise
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Figure 4.2: Growth of K6 fibrosarcoma line in WT and C1qv* male mice 
Eight WT and C1q-/- mice were inoculated with 105 K6 cells. Mice were injected on day 1 with 
100pL tumour cells on the flank and monitored regularly with tumour sizes measured. Each 
line is representative of one individual mouse. Mice were sacrificed when tumour reached 
200mm9. Data shown (n=8) are representative of 3 separate experiments.
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slightly earlier in the WT group with 2 tumours in particular growing 
particularly aggressively. Although every care was taken to use genetically 
identical littermates and identical tumour cell doses, differences within a group 
i.e. between identically treated littermate control mice is inevitable. Although 
tumour growth showed consistency within groups, it is difficult to analyse 
differences between groups in terms of tumour growth rate. Instead, 
alternative parameters such as tumour incidence or survival, are more 
appropriate to analyse differences and assess statistical significance.
The impact of C1q deficiency on tumour growth was further analysed using 
pooled data from 3 (n=8) separate and identical experiments (n=24). In each 
case, differences between the groups were analysed using the log-rank test. 
Figure 4.3 shows tumour incidence in WT and Clq"7* mice. The incidence 
graph plots percent of mice bearing a visible tumour while the survival graph 
shows number of mice tumour free, or bearing a tumour smaller than the 
threshold for sacrifice. These graphs demonstrate any difference in time taken 
to form a tumour of 200mm3 following cell inoculation. Neither graph reveals a 
discemable visual difference between K6 incidence or survival of WT and 
C1qv“ mice. This observation is reflected by the non-statistically significant p 
values (0.178 and 0.715) obtained from these data via the log-rank statistical 
test. Based on these data, K6 appears to grow in WT and C1q‘/_male mice 
with similar incidence, survival and growth rates.
4.2.3. The effect of C3 deficiency on K6 fibrosarcoma growth in mice
Mice deficient in the central C component C3 have been generated previously 
by targeted disruption of the C3 gene (Pekna et al. 1998). These mice were 
used to investigate the large scale effect of C activation on tumour 
progression in vivo. WT mice possess a fully functional C system and 
activation and deposition of C components has been demonstrated (Niculescu 
et al. 1992, Magyarlaki et al. 1996). Conversely, only the initial steps prior to 
C3 cleavage are possible in the C3 /_ mice. Therefore no alternative pathway 
activation is possible. C1q or MBL can bind targets, allowing cleavage of C4
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Figure 4.3: K6 incidence and survival in WT and C1qv' male mice
Pooled data from WT male (n=24) and C1qv' male (n=24) .Mice were inoculated with 105 K6 
cells, sub-cutaneously into the left flank. K6 incidence occurs when a visible tumour is 
observed, while survival events are marked when tumour reached pre-determined volume 
(200mm3). Differences between the two groups were analysed using the log-rank test. The 
effects were found not to be statistically significant (p>0.05)
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and C? but no further steps in any C pathway, nor any of the downstream 
effects associated with C are possible.
Figure 4.4 shows growth of K6 tumours following inoculation into 8 WT and 
C34* male mice. These data are pooled from three separately controlled 
experiments (n=8). As with the previous experiment (Figure 4.2), no visual 
differences can be seen between the groups. Reduced regulation of tumour 
growth (by C) would allow tumours to arise earlier and/or show a faster 
proliferation rate visualised through a steeper curve. As previously, these 
data are more appropriately assessed by the use of incidence and survival 
curves and statistically analysed using the log-rank test. Figure 4.5 shows no 
differences in time taken for tumours to arise between the two groups, there 
was also no difference observed in survival. The p values of 0.442 and 0.736 
respectively reflect this and suggest that C deposition and associated effects 
are not important either for the control or development of K6 tumours.
4.2.4. The effect of C5 neutralisation on K6 fibrosarcoma growth in mice
A blocking mAb against mouse C5 is available and was harvested and 
purified in house. Hybridoma cells were cultured as described in Chapter 2, 
supernatant was collected and antibody purified using Protein G affinity 
chromatography. Figure 4.6 shows reduced and non-reduced samples of 
antibody stained with Coomassie blue. The antibody sample is pure and non­
aggregated with the native protein forming a single band at ~150kDa. The 
reduced portion shows a heavy chain band at ~50kDa and the light chain at 
~25kDa. These weights are consistent with known Ab structures. An IgG Ab 
consists of two heavy and two light chains linked by disulphide bonds and 
forming a native protein of ~150kDa (Edelman, 1969). Mice administrated with 
an appropriate dose of this Ab are rendered ‘C5-neutralised’ and provide a 
useful model for observing the impact of C5 on tumour growth.
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Figure 4.4: Growth of K6 fibrosarcoma line in WT and C3-/- male mice
Eight WT and C3-/- mice were inoculated with 10s K6 cells. Mice were injected on day 
1 with 100pL tumour cells on the flank and monitored regularly with tumour sizes 
measured. Each line is representative of one individual mouse. Mice were sacrificed 
when tumour reached 200mm3. Data shown (n=8) are representative of 3 separate 
experiments.
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Figure 4.5: K6 incidence and survival in WT and C3-/- male mice
Pooled data from WT male (n=24) and C3-/- male (n=24) .Mice were inoculated with 
10s K6 cells, sub-cutaneously into the left flank. K6 incidence occurs when a visible 
tumour is observed, while survival events are marked when tumour reached pre­
determined volume (200mm3). Differences between the two groups was analysed 
using the log-rank test The effects were found not to be statistically significant 
(p>0.05)
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Figure 4.6: Coomassie stained reduced and non-reduced antibody samples
7.5% gel electrophoresis (SDS-PAGE) stained with Coomassie blue. BB5.1 and isotype control 
antibody were loaded at 2.5pg (left) and 5pg (right) in native (non-reduced) and reduced ((3- 
mercaptoethanol treated) form. NEB broad range pre-stained protein markers of known size were 
loaded simultaneously (middle lane) to allow mass estimation.
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4.2.4.1. Neutralisation of C5 by BB5.1 administration
In order to neutralise C5 over the course of tumour growth, dose of BB5.1 was 
first titrated to ensure circulating C5 was neutralised then further doses of 
BB5.1 were administered to remove newly synthesised C5. Since C5 is 
required for activation of the terminal pathway and the lytic effector MAC, 
assessment of haemolytic capability was deemed an appropriate way to 
determine whether C5 was available or had been de-activated. Figure 4.7 
shows in vitro blocking of C5 and subsequent abrogation of haemolytic 
capability. Serum was incubated with varying amounts of BB5.1 and shown to 
possess lower haemolytic activity dependent on dose of mAb administered. 
Concentration of BB5.1 was plotted against percent inhibition following 
incubation. The dose required to neutralise C5 activity over the course of an 
experiment depends on numerous factors including C5 plasma concentration, 
weight of the animals, rate of removal from the bloodstream and rate of 
resynthesis. Based on the in vitro experiment illustrated in Figure 4.7, a dose 
of 2mg BB5.1 anti-mouse C5 was chosen to test C inhibition in vivo. BB5.1 
was injected intra-peritoneally, blood was sampled at regular intervals and 
serum harvested. A classical pathway haemolysis assay was used to 
determine the lytic capabilities of serum at different timepoints post mAb dose. 
Figure 4.8 shows that haemolytic capability is lost until day 6 in male mice 
and day 11 in female mice. Haemolytic activity slowly returned as de novo 
synthesis replaced C5 and remaining BB5.1 antibody was either bound or 
removed from circulation in these animals. The differences observed between 
sexes are likely to be due to male mice being larger than female counterparts 
at adulthood -  thus males possess a greater total blood volume and therefore 
total C5 amounts in serum vary between sexes. However, the amount of C5 
present per ml blood may also be gender dependent. A dose of 1mg BB5.1 
per mouse, administered at 4 day intervals was chosen to ensure complete 
neutralisation of C5 throughout the period of tumour growth, this dose was 
consistent with that used by other groups (Liu et al. 2005). In order that C5 
was neutralised prior to tumour inoculation, the initial BB5.1 dose was 
administered 1 day prior to K6 inoculation.
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Figure 4.7: In vitro inhibition of complement by C5 depletion
Rabbit erythrocytes were sensitised by incubation with a mouse anti-rabbit erythrocyte 
pAb and treated with normal mouse serum pre-incubated with various titres of BB5.1 
to deplete C5. Haemoglobin release was measured and expressed relative to 100% 
control erythrocytes lysed using H20.
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Figure 4.8: in vivo inhibition of complement in male and female WT mice
Three male and female WT mice were treated with a 2mg BB5.1 dose. Serum haemolytic 
capabilities were assessed via classical pathway activation on rabbit erythrocytes sensitised using 
a mouse anti-rabbit erythrocyte pAb. Lysis was measured relative to 100% control erythrocytes 
lysed in H20. Bold lines represent individual male wild type mice, dashed lines represent female 
mice.
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4.2.4.2. K6 tumour growth in C5 neutralised male mice
In order to investigate the contribution of C5 to tumour growth in this model, 
mice were administered with a neutralising Ab and controlled with age- 
matched untreated mice. Due to differences observed in Figure 4.1, male and 
female groups were analysed separately and compared only with same 
gender groups. Figure 4.9 shows tumour growth in male and female mice 
treated with BB5.1 and the control group without Ab (n=6). Initial observation 
suggests that tumours grew more slowly in male mice following BB5.1 
administration. The C5-neutralised male mice experienced a slower rate of K6 
tumour growth, i.e. a less steep growth curve, as compared to non-treated 
control mice. Additionally, these mice appeared to survive for longer. As with 
previous experiments, tumour growth curves do not provide a good parameter 
for assessing statistical significance. This effect was not mirrored in the 
female group, perhaps due to the lower haemolytic activity and therefore less 
pronounced effects following C activation. Interestingly, one male and one 
female mouse (from groups of 6) treated with BB5.1 failed to develop a 
tumour compared to 100% tumour take in the non-treated mice. Figure 4.10 
illustrates increased survival in mice treated with BB5.1 and revealed a strong 
protective effect found to be statistically significant (p=0.005) upon analysis 
using the log-rank test. Therefore, neutralising C5 in male mice protects 
against K6 tumour growth and suggests a role for C5 in promoting tumour 
progression in untreated hosts.
Figure 4.10 also shows survival data from the female groups and supports the 
earlier observation from Figure 4.9 that significant protection is not observed 
in these mice. Although one mouse did not develop a tumour, the initial trend 
in females was for Ab-treated mice to be sacrificed at earlier timepoints as 
tumours reached their maximum size more rapidly. This indicates a faster 
growth of tumours in these mice. However, the area between the survival 
curves is considerably less than that observed in male groups and a p-value 
of 0.938 confirms there is no statistically significant difference. Figure 4.10 
also demonstrates incidence curves derived from the same data. K6
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Figure 4.9: Growth of K6 fibrosarcoma line in WT and C5-depleted mice
K6 fibrosarcoma cells were inoculated into C5-depleted (2 mg dose I.P. on day -1, day 6, day 
13 and day 21) and non-treated male and female mice. Each line represents one individual 
mouse, six mice per group. Mice were sacrificed when tumour size exceeds 150mm3.
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Figure 4.10: K6 incidence and survival in WT and C5-depleted mice
K6 fibrosarcoma growth in C5-depleted (2 mg dose I.P. on day -1, day 6, day 13 and 
day 21) and non-treated male and female mice. Bold lines represent WT mice, dashed 
represent C5-depleted. K6 incidence occurs when a visible tumour is observed, while 
survival events are marked when tumour reached pre-determined volume (200mm3).
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occurrence is plotted for male and female mice, both in WT and OS- 
neutralised groups. These data lend support to the earlier findings and 
suggest a possible protective trend following 05 neutralisation, however, the 
differences between groups are less evident and this is reflected in the higher 
and non-statistically significant p-values of 0.103 and 0.095 respectively.
In order to ensure the validity of these results, three experimental parameters 
required addressing. Firstly, larger group sizes were necessary to ensure 
experimental significance. Secondly, an appropriate isotype control Ab 
(mouse lgG1) was required to control for non-specific binding of BB5.1 to 
cellular or serum proteins and Ab aggregation effects which may affect tumour 
growth non-specific to effects of C5 neutralisation. Use of a control mouse 
lgG1 Ab at the same concentration would prove that the specific and direct 
effects of C5 neutralisation were responsible for the protective effect. Thirdly, 
post-experimental testing of the antibody sample found high titres of 
endotoxin contamination (>30EU/ml). Lipopolysaccharide (LPS) detected 
within the Ab samples can have large scale effects on numerous immune 
functions, most notably activation of phagocytic cells (reviewed by Heine et al. 
2001) and may significantly distort the immune response to injected tumour 
cells used in this model. Although an isotype control antibody prepared via 
these same methods would likely contain comparable levels of endotoxin 
contamination and therefore control for the specificity of the anti-C5 effect, the 
immunostimulatory and inflammatory properties of LPS would create a non- 
physiological environment for tumour growth, casting doubt upon the validity 
of the findings.
In order to remove endotoxin from the antibody preparations, a polymixin B 
preparation (‘Detoxigel’ supplied in columns by Pierce Biotechnology) was 
used as described in Chapter 2. Despite attempts to remove endotoxin 
contamination from antibody preparations, levels of endotoxin remained high 
(>25EU/ml). In order to generate clean preparations for reliable data, new 
BB5.1 and a mouse lgG1 anti-human C4 antibody (chosen as a control and 
demonstrated not to cross-react with murine C4) were purified. This involved 
using endotoxin free reagents and rigorous steps to minimise contamination
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and is described in detail in Chapter 2. Upon testing, endotoxin concentrations 
of 0.38 EU/ml and 0.40 EU/ml respectively were found. These readings were 
provided by the endotoxin screening service (Department of Medical 
Microbiology, Heath Park, Cardiff University). Standard endotoxin limits for 
commonly used animal models in preclinical research suggest that for a 
typical mouse, endotoxin dose should be below 1.5EU/ml as defined by the 
United States Food and Drug Administration (USFDA) (Malyala and Singh 
2008).
The isotype control antibody was obtained from Dr Claire Harris, Cardiff 
University and is specific for human C4. To ensure, that this antibody does not 
cross-react with mouse C4, a haemolytic test was performed. Figure 4.11 
shows that BB5.1 and not the isotype control Ab was able to inhibit C- 
mediated haemolysis and that the control Ab has no effect on haemolytic 
capability of mouse serum. Whilst this data shows that the mAb does not 
affect the haemolytic capacity of mouse serum, it does not prove that the anti­
human C4 mAb is not binding to mouse C4. In order to test this, a Western 
blot was performed and is shown in Figure 4.12. A band for the C4 protein is 
detected in lanes loaded with human serum, but not with mouse serum. Other 
bands shown are also present in the control blot, treated with secondary Ab 
only and represent IgM and IgG heavy chains non specifically bound by the 
rabbit anti-rat IgG secondary. Together these data show that the mouse anti­
human C4 mAb does not cross react with mouse C4 and provides a suitable 
isotype control for the mouse anti-mouse C5 mAb.
Figure 4.13 shows tumour cell growth in male mice treated with endotoxin-low 
BB5.1 or anti-C4. In this experiment, a larger group size was used (n=12) 
although numbers were limited due to large antibody doses required and the 
available supply of Ab. Data shown in Figure 4.13 do not allow any 
differences between groups to be clearly discerned. However there was a 
trend for mice to be sacrificed later in the C5-neutralised group. Additionally, 
three of these mice remained tumour free compared to one in WT group. 
Figure 4.14 shows incidence and survival curves derived from these data. The 
survival curves clearly demonstrate a protective effect of C5 neutralisation
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Figure 4.11: in vitro inhibition of complement by BB5.1
Rabbit erythrocytes were sensitised using 0.5% mouse anti-rabbit erythrocyte pAb and 
treated with normal mouse serum pre-incubated with various titres of BB5.1 or an isotype 
control Ab. Haemoglobin release was measured and expressed relative to 100% control 
erythrocytes lysed using H20. Serial dilutions assayed in triplicate.
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Figure 4.12: Western blot analysis of anti-C4 mAb binding to mouse I human serum
Lanes 1 and 2 were loaded with reduced normal human serum (160ng and 80ng C4 
respectively based on normal serum level 0.6mg/ml). Lanes 3 and 4 contain reduced serum 
(160ng and 80ng C4 respectively) from a WT mouse. Panel A is stained with monoclonal 
mouse anti-human C4 at 10jag/ml, followed by 1:2000 HRPO-conjugated rabbit anti-mouse 
IgG. Panel B is stained with rabbit anti-mouse IgG only.
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Figure 4.13: Growth of K6 fibrosarcoma line in WT and C5 neutralised male mice
WT and C5-neutralised mice were inoculated with 105 K6 cells. Mice were injected on day 1 
with 100|jL tumour cells on the flank and monitored regularly with tumour sizes measured. 
Each line is representative of one individual mouse. Mice were sacrificed when tumour 
reached 200mm3. Each group consists of 12 mice. Each line is representative of one 
individual mouse.
129
100
so-
SS
■g 60-
3<0
sP 40-
20-
0 10 20 30 40
BB5.1
aC4
P=0.045
Days post inoculation
eoc•22
oc
£
100-.
80-
60-
40-
20-
BB5.1
aC4
P=0.357
10 20 30
Days post inoculation
40
Figure 4.14: K6 survival and incidence in WT and C5-depleted male mice
K6 fibrosarcoma growth in C5-depleted (BB5.1) and isotype control treated male mice. 
Bold lines represent WT mice, dashed represent C5-depleted. Survival data is shown 
above, incidence data below. K6 incidence occurs when a visible tumour is observed, 
while survival events are marked when tumour reached pre-determined volume (200mm3). 
Differences between WT and C5-depleted curves were analysed using the log rank 
statistical test.
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compared to the control group with the effect found to be statistically 
significant (p=0.046). This supports the previous findings of retarded tumour 
growth in these animals. However, tumour incidence data also in Figure 4.14 
do not show a significant difference between C5-neutralised and control 
groups. Collectively, these data show that C5 neutralisation retards, but does 
not completely suppress, growth of K6 tumours in male mice. It is therefore 
possible that C5 cleavage, causing C5a release and activation of the terminal 
pathway in WT host animals is important and contributes to driving tumour 
proliferation.
4.2.5. The effect of CD55 and CD59 deficiency on K6 fibrosarcoma 
growth
CD55 and CD59 are potent CReg involved in protection of numerous tumour 
cells types from CDC (Li et al. 2001, Yu et al. 1999). However, more recent 
reports have highlighted important immunological roles for these proteins un­
related to CDC. Both proteins have been shown to possess down-modulatory 
functions on T-cells reviewed by (Longhi et al. 2006). Additionally, since host 
cells close to tumour cells lack these CReg, large scale C activation and 
inflammation may occur in the tumour environment. Mice of this genotype 
have previously been shown to be more susceptible to induced 
glomerulonephritis, attributable to CD55 deficiency and associated with 
increased C3b deposition and inflammation compared to WT controls (Bao et 
al. 2007). Exacerbation of the autoimmune disease myasthenia gravis is also 
reported in these mice, with both CReg contributing to protection in WT mice 
(Kaminski et al. 2006). Investigation of tumour growth in mice lacking these 
CReg may provide an insight into the innate and adaptive immune 
mechanisms affecting tumour growth in this model.
CD55‘/\CD59"/' mice possess all the components for a normal C response. 
However since all host tissues lack two key CReg, impaired C regulation 
would be expected, and may lead to increased consumption of C components 
and a lower lytic capacity. Data described in Chapter 3 showed that K6 cells
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do not express CD55 or CD59 in vitro, however, these cell lines possess the 
genes encoding both proteins and may up-regulate their expression in 
response to C deposition or cytokine stimuli (Spiller et al. 2000). Figure 4.15 
shows that mice deficient in CD55 and CD59 possess equivalent haemolytic 
activity to WT mice. This suggests that circulating C components are not 
consumed in CD55/'.CD59'/' animals and that activation of C pathways in 
these or WT hosts will cause similar initial effects. However, following 
activation, impaired inhibition on CD55'/'.CD59'/' host tissues may result in 
enhanced deposition and inflammation around activating surfaces i.e. tumour 
cells. Figure 4.16 shows tumour cell growth in 8 male wild types and 8 male 
CD55‘/\CD59'/" mice. No statistically significant difference between the groups 
is evident from the growth curves. However Figure 4.17 shows incidence and 
survival curves from pooled data and identified a positive trend correlating 
absence of CD55 and CD59 in hosts with earlier incidence of K6 tumours and 
similarly earlier termination of these animals. However, the effects were not 
statistically significant (p=0.162, p=0.105) although higher group sizes may be 
needed to further examine this trend and to reach a more definitive 
conclusion.
4.2.6. C3b/iC3b deposition on K6 tumour tissue
Deposition of C3 activation fragments on K6 tumour sections taken from WT, 
C1q‘7', C3'7' and CD55"/\CD59'/' mice can be analysed using
immunohistochemical techniques. The mAb used recognises native C3, the 
active deposited fragment C3b and the associated inactivation product iC3b 
(Mastellos et al. 2004). Deposition of C3b provides a valuable marker of C 
activation and targeting to tumour cell surfaces. Figure 4.18 shows a 
representative slide from a K6 tumour section grown in each of WT, C1q_/', 
C3‘a and CD55'/\CD59‘/' genotypes. Each picture is representative of 8 
sample image slices taken from 6 separate tumours inoculated into each 
mouse strain. C3b/iC3b deposition was observed on each tumour section 
analysed except those inoculated into C3‘/_ animals. This indicates that K6 
tumours are stimulating one or more pathways of C activation. In the case of
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Figure 4.15: Haemolytic capabilities of male WT and CD55'/'.CD59'/' mice 
Rabbit erythrocytes were sensitised with mouse anti-rabbit erythrocyte pAb and 
incubated with serum from 3 male WT and CD55'1'.OD59'1' mice. Haemoglobin 
release was measured and expressed relative to a 100% control lysed with H20.
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Figure 4.16: Growth of K6 fibrosarcoma in WT and CDSS -^CDS '^ male mice
Eight WT and CD55'I'.CD59'1' mice were inoculated with 10s K6 cells. Mice were injected on 
day 1 with 100pL tumour cells on the flank and monitored regularly with tumour sizes 
measured. Each line is representative of one individual mouse. Mice were sacrificed when 
tumour reached 200mm3. Data shown (n=8) are representative of 3 separate experiments.
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Figure 4.17: K6 survival and incidence in WT and CD55'/'.CD59'/' male mice
Pooled data from WT male (n=24) and CD55'1'.CD59'1' male (n=24) .Mice were 
inoculated with 105 K6 cells, sub-cutaneously into the left flank. K6 incidence occurs 
when a visible tumour is observed, while survival events are marked when tumour 
reached pre-determined volume (200mm3). Differences between the two groups was 
analysed using the log-rank test. The effects were found not to be statistically 
significant (p>0.05).
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Figure 4.18: C3b/iC3b deposition on K6 tumour sections
C3 cleavage and deposition on K6 tumours grown in WT and KO hosts was assessed by a two step 
staining protocol as detailed in Chapter 2. Staining was optimised on sections of diseased tissue (not 
shown) using a rat monoclonal anti-mouse C3/C3b/iC3b antibody. Alexa-fluor 594 conjugated 
donkey anti-rat secondary antibody was used to detect fluorescence. Images shown are 
representative sections from each tumour (n=6). Tissue from each genotype of tumour was also 
stained using an isotype control antibody, negative staining was found.
136
C1q deficiency, host C3 must be derived from alternative or MBL pathways. 
However, it is possible that K6 synthesises and secretes C3, leading to 
tumour derived C3b deposition on its own surfaces. However the lack of C3b 
deposited on K6 in C3"/_ mice suggests this is not the case and that deposition 
on other tumour tissues is derived from the host animal. In order to quantify 
levels of C3 fragment deposition on K6 cells, sections were analysed using 
Image Pro Analyser software. Use of this software allows a fluorescence 
threshold to be set, above which signal is marked as positive, The % area 
stained positive can then be calculated per random camera frame. Data 
shown in Figure 4.19 show comparable and consistent levels of C3b/iC3b 
deposition detected on K6 tissue in WT, C1q'/_ and CD55‘/\CD59‘/' hosts. All 
tissues examined showed signs of C activation except those grown in C3'/_ 
animals where no positive signal for C3b/iC3b was observed, this was found 
to be statistically significant compared to staining in WT group (p<0.001).
Data showing C3b/iC3b deposition on K6 tissues in C5-neutralised and 
isotype control treated mice are shown in Figure 4.20. Quantitation of 
C3b/iC3b deposition again revealed no differences between the groups 
indicating similar levels of C activation and subsequent deposition of C3 
fragments in these groups (Figure 4.21).
4.2.7. C9 deposition on K6 tumour tissue
Deposition of C9 also represents an informative marker of C activation, and 
the presence of C9 on membranes indicates activation of the terminal 
pathway thus providing evidence of C5a release and MAC deposition. Both 
these effects are significant and may have important effects on tumour cells, 
and various other cells in the tumour microenvironment e.g. immune effector 
cells. Effects associated with C5a release and MAC deposition are described 
in sections 1.2.1 and 1.12 respectively. Figure 4.22 shows a representative 
slide from a K6 tumour section grown in each of WT, C1q_/', C3_/' and CD55‘/_ 
.CD59"/_ genotypes. Each picture is representative of 8 sample image slices 
taken from 6 separate tumours inoculated into each mouse strain. Evidence
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Figure 4.19: Immunohistochemical analysis of C3b/iC3b deposition
Percentage area stained positive for C3b/iC3b deposition was assessed using Image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group used. 
Data were analysed using a 2 tailed, unpaired t-test. * indicates p<0.05.
C5 depleted Isotype control
Figure 4.20: C3b/iC3b deposition on K6 tumour sections following C5 depletion
C3 cleavage and deposition on K6 tumours grown in WT and C5-depleted hosts was 
assessed by a two step staining protocol as detailed in Chapter 2. Staining was optimised 
on sections of diseased tissue (not shown) using a rat monoclonal anti-mouse 
C3/C3b/iC3b antibody. Alexa-fluor 594 conjugated donkey anti-rat secondary antibody 
was used to detect. Images shown are representative sections from each tumour (n=6). 
Tissue from each genotype of tumour was also stained using an isotype control antibody, 
negative staining was found.
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Figure 4.21: Immunohistochemical analysis of C3b deposition following C5 depletion
Percentage area stained positive for C3b/iC3b deposition was assessed using Image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group used. Data 
were analysed using a 2 tailed, unpaired t-test.
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Figure 4.22: C9 deposition on K6 tumour sections
C9 deposition on K6 tumours grown in WT and KO hosts was assessed by a two step staining 
protocol as detailed in Chapter 2. Staining was optimised on sections of diseased tissue (not 
shown) using a rabbit anti-rat C9 antibody. Alexa-fluor 594 conjugated donkey anti-rat 
secondary antibody was used to detect fluorescence. Images shown are representative 
sections from each tumour (n=6).
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for C9 deposition was observed on each tumour section analysed, with the 
exception of those grown in C3_/' hosts. This result is expected given the 
accepted mechanisms for initiation of the terminal pathway (see Figure 1.1) 
and indicates that C9 deposited on other K6 tumours is generated via 03- 
dependent mechanisms. These data were analysed as described for 
C3b/iC3b deposition in order to obtain quantifiable data and compare levels of 
C9 deposition between groups. Figure 4.23 shows no statistically significant 
difference in fluorescence per tumour frame between WT and C1q'/_ (p=0.817) 
or WT and CD55'/".CD59'/‘ groups (p=0.789) with mean % deposition values 
shown to be equivalent between groups. By contrast, a statistically significant 
difference was observed between K6 tumours grown in WT and C3'/_ hosts 
(p<0.001). This finding provides conclusive evidence for the C3-dependent 
generation of C9 deposition and suggests that the various effects associated 
with MAC deposition may be relevant in this model.
Data shown in Figure 4.24 are representative of C9 staining on K6 tumours 
grown in C5-neutralised mice, and those treated with an isotype control Ab. 
Representative images shown reveal C9 deposition in WT (isotype control) 
group, but no deposition in C5-neutralised hosts. This finding is confirmed 
following quantitation analysis (Figure 4.25) which shows a statistically 
significant difference in C9 deposition between WT and C5-neutralised groups 
(p<0.001). Cleavage of C5 represents the initiation step for activation of the 
terminal pathway, and the lack of C9 deposition in C5-neutralised hosts 
provides strong evidence against activation of the terminal pathway in these 
mice. Consequently, negligible MAC deposition is observed, demonstrating 
that C5 neutralisation was effective and that no C5a is released following 
activation of C by tumour cells.
142
r
*
1
0 .7 5 1
£
O
w 0.50  o
CLm
"O
m
O  0.25
0.00
■■ A
AA
■ > Aaa
■
a* a
AA i i
----------- ---------------
‘ aS*1”
a*
* aa
, Aa*
----A* A tA iA-------
&
X
a
x *
s f
Mean ± SEM
WT 0.202 ± 0.020
iicr
O
0.196 ± 0 .019
C3'/_ 0.004 ± 0.001
CDSS'-.CDSS'- 0.209 ± 0.022
Figure 4.23: Immunohistochemical analysis of C9 deposition
Percentage area stained positive for C9 deposition was assessed using Image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group used. 
Data were analysed using a 2 tailed, unpaired t-test. * indicates p<0.05.
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C5 depleted Isotype control
Figure 4.24: C9 deposition on K6 tumour sections following C5 depletion
C9 deposition on K6 tumours grown in WT (isotype control treated) and C5-depleted 
hosts was assessed by a two step staining protocol as detailed in Chapter 2. Staining 
was optimised on sections of diseased tissue (not shown) using a rabbit polyclonal anti­
rat C9 antibody. Alexa-fluor 594 conjugated goat anti-rabbit secondary antibody was 
used to detect fluorescence. Images shown are representative sections from each 
tumour (n=6).
144
co
0 .751
m 0.50- o 
Q. 
m 
u
m
O
$
A
A
A
*-AA
0 .2 5 i i { i A
0.00 —
P<0.001
* Jv
s i
Mean ± SEM
C5-depleted 0.005 ±0.001
control 0.197 ±0 .0 1 6
Figure 4.25: Immunohistochemical analysis of C9 deposition following C5 depletion
Percentage area stained positive for C3b/iC3b deposition was assessed using image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group used. Data 
were analysed using a 2 tailed, unpaired t-test (p<0.001). * indicates p<0.05.
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4.2.8. CD4* cells infiltrate K6 tumour tissue
It has previously been reported that CD4+ T-cell responses are enhanced in 
mice lacking CD55 (Liu et al. 2005) and CD59 (Longhi et al. 2005). For this 
reason, differences in CD4+ infiltrating cells may be evident in mice of different 
genotypes. Infiltration of CD4+ cells, the majority of which are T-cells (Awen 
Gallimore, personal communication), into K6 tumours was assessed by 
immunohistochemistry. CD4+ cells were observed in all tumour tissues 
analysed and were visible as a defined ring of fluorescence (Figure 4.26). In 
order to assess differences between groups, numbers of infiltrating cells were 
counted (8 frames per tumour, n=6). The CD4+ infiltrate appears slightly lower 
in C1q'A and C3_/" hosts than in WT hosts. However, statistical analysis 
revealed that differences were not significant as evidenced by p-values of 
0.120 and 0.086 respectively (Figure 4.27).
Similar data gathered from C5-neutralised and isotype control treated host 
mice revealed no difference between these groups with similar levels of 
infiltration as shown in Figures 4.28 and 4.29.
4.3. Discussion
The aims of the work described in this Chapter were to identify differences in 
tumour growth as a result of deficiencies in specific C proteins. Deficiencies in 
C1q, C3 and double deficiency in CD55 and CD59 did not cause significant 
observable differences in K6 growth or survival of inoculated mice. Despite 
the lack of classical pathway activation in C1q‘7' mice, and abrogation of all 
three activation pathways in C3'7' mice, no pro-tumour effects were observed 
through impaired immune responses. If C was contributing significantly to 
immune-mediated control of K6 growth, either directly or through related 
effects, differences in tumour development would be expected. Therefore, 
these data suggest that C plays little if any role in controlling growth of the 
established fibrosarcoma line K6 in vivo. Additionally, the hypothesis that C
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Figure 4.26: CD4+ Cell infiltrate in K6 tumour sections
CD4+ cells in K6 tumours were assessed by a two step staining protocol as detailed in Chapter 
2. Staining was optimised on sections of spleen (not shown) using a rat monoclonal anti-mouse 
CD4 antibody. Alexa-fluor 594 conjugated donkey anti-rat secondary antibody was used to 
detect. Images shown are representative sections from each tumour (n=6). Tissue from each 
genotype of tumour was also stained using an isotype control antibody, negative staining was 
found. CD4+ cells were counted by eye.
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Figure 4.27: Immunohistochemical analysis of CD4+ infiltrate
Numbers of CD4+ cells per section were counted, 8 frames were assessed per 
tumour with 6 tumours per group used. Data were analysed using a 2 tailed, 
unpaired t-test.
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C5 depleted Isotype control
Figure 4.28: CD4+ Cell infiltrate in K6 tumour sections
CD4+ cells in K6 tumours from WT and C5-depleted mice were assessed by a two step 
staining protocol as detailed in Chapter 2. Staining was optimised on sections of spleen (not 
shown) using a rat monoclonal anti-mouse CD4 antibody. Alexa-fluor 594 conjugated donkey 
anti-rat secondary antibody was used to detect. Images shown are representative sections 
from each tumour (n=4). Tissue from each genotype of tumour was also stained using an 
isotype control antibody, negative staining was found.
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Figure 4.29: Immunohistochemical analysis of CD4+ infiltrate
Numbers of CD4+ cells per section were counted, 8 frames were assessed per 
tumour with 4 tumours used per WT and C5-depleted group. Data were 
analysed using a 2 tailed, unpaired t-test.
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may aid tumour proliferation was also not supported by these data as no 
differences were observed in the absence of C1q or C3. If either protein was 
able to significantly drive K6 proliferation, faster growth rates, and lower 
survival would be expected in these groups.
However, K6 is a highly aggressive fibrosarcoma, arising shortly after 
inoculation and proliferating rapidly. As a result subtle differences between 
groups may be masked due to the rapid proliferation rates, and potential 
disparities in tumour growth between mouse strains may be hidden. As this 
tumour cell line takes just days, typically between 10-15 days, to progress 
from a barely visible tumour, to the mouse being sacrificed, large group sizes 
would be needed to dissect out differences between tumour growth patterns 
in differing genotypes. In order to investigate whether lower tumour 
challenges slowed tumour growth, the number of K6 cells inoculated into WT 
mice was varied. Differences in tumour challenge administered did affect 
number of mice developing a tumour, with lower K6 titres corresponding with 
lower tumour incidence. However, no differences in proliferation rates were 
observed as a result of administering 104, 105 or 106 K6 cells into WT mice 
(data not shown). Alternatively, a less aggressive cell line could be used to 
allow more time for potential differences to be visualised. This approach is 
detailed in Chapter 6.
Despite the aggressive nature of K6, initial data did suggest a protective effect 
mediated by administration of a blocking mAb against mouse C5. As 
described above, there were complications associated with this experiment. 
The presence of endotoxin in the antibody preparation and lack of control 
immunoglobulin in a preliminary experiment could both contribute to the 
observed effects. Endotoxin is known to stimulate large scale immune 
reactions and cytokine release (Cooke et al. 2002) which could well contribute 
to the immune response generated in these mice, unrelated to the 
neutralisationof C5. Endotoxins are known to strongly stimulate macrophages 
and neutrophils (Kirkland et al. 1993) and this heightened immune sensitivity 
is likely to alter the immune response to tumour inoculation in these animals.
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However, further controlled experiments corroborated the previous finding and 
neutralisation of C5 in vivo was shown to hinder tumour growth (p=0.045). 
Cleavage of C5 releases a potent anaphylatoxin C5a with powerful roles in 
the inflammatory response. Inflammation has long been considered a 
powerful driving mechanism facilitating tumour growth (Coussens and Werb, 
2002), and the lack of this inflammatory signal may be slowing tumour growth 
in C5-neutralised animals. However, recent data by Markiewski et al (2008) 
has shown that C5a can contribute to suppression of the immune response 
through a specific immunosuppressive mechanism. In this study, enhanced 
tumour growth was linked to recruitment of Myeloid Derived Suppressor Cells 
(MDSCs) known to express high levels of C5aR (Guo and Ward 2005). These 
suppressive cells can be stimulated to produce high levels of reactive oxygen 
species (ROS) (Corzo et al. 2009). The interaction of C5a and C5aR was 
demonstrated to be an important event with ROS also shown to inhibit CD8+ 
T-cell responses (Kusmartsev et al. 2004). The same study found that CD8+ 
T-cell responses, thought to contribute significantly to anti-tumour immunity, 
were enhanced after blocking of C5aR (Swann and Smyth 2007). Thus, the 
authors hypothesise a key role for C5a in suppressing immune responses 
through modulation of CD8+ T-cell activity.
The role of C5a as a pro-tumour effector molecule is not supported by other 
data from C3-/- animals. In this case, no C5 cleavage is expected as neither 
the classical nor alternative pathway C5 convertase can be assembled 
meaning that downstream effects are not possible. A similar protective effect 
to C5 neutralisation would initially be expected through similar dampening of 
the inflammatory response and abrogation of associated pro-tumour effects. 
One recent report describes generation of C5a in a C3 independent manner 
(Huber-Lang et al. 2006) yet the in vivo relevance of this pathway is unclear. 
Evidence against this hypothesis is also provided in (Figures 4.22 and 4.23) 
with the absence of deposited C9 in C3'7' mice. This observation indicated that 
no MAC is deposited in these mice and that MAC deposition in WT hosts 
requires C3b deposition. The lack of C5 convertase assembly and terminal 
pathway activation in C3"/_ mice also suggests that C5a release in these mice 
will be reduced or absent in the tumour microenvironment. The lack of a
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protective effect in C3”/_ mice may be a result of numerous mechanisms 
related to C activation and deposition. As discussed in Chapter 1, C3 has 
huge potential to interact with a wide range of immune cell types, any of which 
could be contributing to immune control of tumours in this model through 
significantly impaired opsonisation mechanisms. In this model, the near 
complete abrogation of C is these animals will have numerous effects in terms 
of inflammation and both innate and adaptive immunity. The hypothesis that C 
plays a dual role in tumour formation and proliferation remains valid with 
subtle differences unlikely to be observed using such an aggressive cell line. 
The effects of a ‘double-edged sword’ role played by C could be cancelled out 
in terms of its anti- and pro-tumour effects culminating in equivalent growth 
rates and survival. In depth evaluation of evaluating cell types into K6 tumours 
grown in different host genotypes may elucidate contributory mechanisms and 
allow further investigation into tumour growth in these mice.
The use of a neutralising mAb has a major advantage over the use of knock­
out animals as mice used are on identical genetic backgrounds and littermate 
controls may be used. In this way, the only difference between groups is the 
parameter in question. Experiments described in this Chapter investigated the 
effect of C5 protein on tumour take. Although every care was taken to back- 
cross onto the C57/BL6 background (at least 10 generations), C1q'7', C3'7' and 
CDSd'^.CDSQ'1' mice utilised in this study will have subtle genetic differences 
which may manifest as minor histocompatibility issues and lead to altered 
tumour growth. No differences were observed in K6 growth between WT and 
C1q_/‘, C3_/" and CD55'*'.CD59'/' hosts.
A non-significant trend was observed suggesting predisposition of CD55*7' 
CD59’7' mice to slightly faster tumour growth. However, differences were 
difficult to identify and found not to be statistically significant. Further studies 
would be required to validate this observation while reasons underlying the 
trend remain unclear and complex. Inflammation is known to drive tumour 
progression and these animals, with impaired ability to control C attack, would 
seem likely to have enhanced chronic inflammation. However, as discussed in 
Chapter 1, both these proteins play important roles outside C regulation and
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are implicated in T-cell responses. Deficiencies in either CD55 and CD59 
have been shown to enhance T-cell responses, reviewed by (Longhi et al. 
2006) and are thought to exhibit ‘exaggerated’ T-cell activities. However, data 
described indicate that K6 tumours grew as well in mice deficient in CD55 and 
CD59 as WT mice thus any enhanced T-cell responses were ineffective 
against K6 growth. An alternative effect could be mediated through lack of 
CD59. Expression of CD59 has been shown previously to enhance the NK- 
cell response (Omidvar et al. 2006). It is possible that defective NK responses 
in these mice allow tumour cells to escape immune killing more readily and 
contribute to the decreased survival observed in these mice.
Another important consideration is that injection of WT tumour cells into a 
knock-out mouse could stimulate an immune response to the corresponding 
protein encoded by the knocked-out gene. For example CD55 or CD59 
expressed on K6 cells may raise an immune response in CD55'/'.CD59'/' mice 
not tolerised to these proteins. However, no evidence to support additional 
immune responses to these cells is provided by these studies with K6 cells 
growing comparably in WT and CD55‘/‘.CD59'/' hosts. Additionally, there is 
evidence to support C1q (Al-Adnani and McGee 1976) and C3 (Garred et al. 
1990) secretion by fibroblasts, also with potential to raise antibody responses 
and trigger enhanced cytotoxicity. These proteins may be recognised as 
foreign and therefore elicit an immune response through Ab production or 
CD8+ T-cell responses. Data in Chapter 3 showed that neither CD55 nor 
CD59 is expressed on K6 cells in vitro while C3 was not detected by ELISA or 
RT-PCR techniques. As shown in Figure 4.23, no C3 was detected in/on K6 
cells grown in C3'/_ hosts. This observation suggests that K6 fibrosarcomas do 
not store C3 intra-cellularly, and do not exhibit tumour derived C3b/iC3b 
deposited on cell surfaces. These data also suggest that C3b/iC3b observed 
on other tumour sections is derived from activation of the host C system. 
Whilst non-transformed fibroblasts, and several tumour cell types have been 
shown to secrete C3 in vivo (Katz, Revel and Strunk 1989, Jean et al. 1997), 
induction of tumours by 3-MCA produces highly heterogeneous tumour cell 
populations with diverse phenotypes (Pimm, Embleton and Baldwin 1980). K6 
is an established homogeneous line and although no evidence of C3
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secretion is observed, that is not to say this is a common feature of all 
fibrosarcoma cells.
Similar levels of C3b/iC3b were found deposited in all host animals except, as 
expected, those deficient in C3. Given the similar haemolytic capabilities of 
WT and CD55‘/'.CD59/_ mice described in this Chapter, similar levels of 
activation and deposition of activation fragments would be expected in these 
groups. However, the observation that K6 cells exhibited comparable levels of 
C3b/iC3b deposition in Clq"7" mice is interesting and suggest that the classical 
pathway is not responsible for the majority of activation and point to an 
important role for MBL or alternative pathway activation by K6 cells. Since C5 
cleavage occurs downstream of C3 in all activation pathways (see Figure 1.1), 
no difference was expected in activation and deposition between OS- 
neutralised and control groups. This was confirmed by immunohistochemical 
analysis.
Scant data are available which describe levels of C deposition on normal i.e. 
non-transformed fibroblast cells in vitro. However, a study on normal human 
skin showed that fibroblasts could be identified in excised tissue biopsies, and 
that C3 deposition was only observed following in vitro incubation with high 
concentrations of sera (Schuler et al. 1982). Addition of C4-deficient sera 
resulted in samples which stained negative for C3 activation products. 
Fibroblasts excised from normal and C3-deficient patients both showed no 
deposition of C3 products after being transferred to cover slips and examined 
in vitro (Fishelson et al. 1999). A further study in mice has also showed that C 
activation and C3 deposition was observed on virus-infected cells but not on 
non-virus infected cells (Miyazawa et al. 1987). Cells examined in this study 
were not fibroblasts, but are of the same mesodermal origin, in this case 
smooth muscle cells.
Immunohistochemical analysis of C9 deposition on K6 tumours grown in WT, 
C1q'7' and CD55'/'.CD59'/' mice revealed no differences, as previously 
demonstrated for C3b/iC3b deposition. These findings are consistent given 
the requirement for C3b deposition for formation of both classical and
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alternative C5 convertases. Thus, equivalent levels of C3b deposition would 
be expected to generate equivalent levels of MAC deposition. Also consistent 
with previous findings was the absence of deposited C9 on tumours grown in 
C3'7' mice. These data suggest that no C3b deposition, C3a / C5a release or 
MAC deposition is occurring in these hosts. Therefore, the previous 
demonstration that K6 tumours grew comparably in WT and C3'7' hosts is 
particularly important and suggests that the effects associated with these 
important consequences of C activation are neither contributing to tumour 
immunosurveillance nor to promotion of tumour growth in this model.
No differences were observed following analysis of CD4+ infiltrating cells into 
K6 tumours. Whilst this marker provides a preliminary assessment of adaptive 
immune responses to tumour inoculation, further work would be needed to 
address T-cell phenotype and activity of these cells. However, the observation 
that T-cell numbers were not noticeably higher in CD55_/'.CD59'7' animals is 
important given the recent roles associated with these proteins expressed on 
T-cells. The short timespan for these experiments may prevent a significant 
difference from developing, while stronger responses may be elicited without 
excessive recruitment of cells.
Data presented in this Chapter provide a primary investigation of how C may 
affect tumour growth in vivo. As previously discussed, use of an established 
and aggressive tumour line allows only a brief timescale for differences to 
become evident. However, some significant effects were observed indicating 
a protective effect of C5 neutralisation in hosts allowing enhanced control of 
tumour growth. This finding contradicts dogma whereby a compromised C 
response would be expected to result in reduced control over tumour growth. 
A better understanding of the role of C over a longer timescale and in the 
developing tumour may provide an improved model for assessing the relative 
roles of C deficiencies. The use of a chemical carcinogen allows such 
investigation and is detailed in the following Chapter.
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5. The effect of complement deficiency on 3-methylcholanthrene (3- 
MCA) induced tumours
5.1. Introduction
As discussed in Chapter 1, C regulators are strongly implicated in protection 
of tumours from C-mediated lysis. Additionally, emerging evidence supports a 
role for C activation and deposition in tumour development. Investigation of 
the respective roles of certain C proteins (i.e. components/regulators) can be 
achieved by administration of the chemical carcinogen 3-MCA in mice. 
Fibroblasts are recruited to the site of injection and are subjected to the 
mutagenic properties of the carcinogen. Multiple mutations arise and de novo 
tumour development over a period of months can be assessed. Numerous 
studies have successfully used this model to dissect effects of various 
immune functions leading to enhanced tumour proliferation or rejection. Such 
studies include the respective roles of Interferon-y (Qin et al. 2002), cytotoxic 
T-cells (DeLustro and Haskill 1978) and NK-cells (Crowe, Smyth and Godfrey 
2002) in 3-MCA tumourigenesis. The role of C has not been investigated in 
this model.
The experiments presented in this Chapter were designed to assess whether 
deficiency of various C components or regulators in host mice, affected in vivo 
tumour development. Induction of tumours via chemical carcinogenesis varies 
considerably between different animal housing units with environmental 
factors, mouse strain and dose of carcinogen being important. Generally, 
tumours arise and develop over a period of 2-6 months with a plethora of 
factors affecting their development. Mice deficient in C1q, C3 and lacking both 
CD55 and CD59 were used to examine the respective roles played by these 
proteins in tumour formation and proliferation. The hypothesis that a 
compromised C system would lead to reduced control of tumour growth 
illustrated by higher incidence and faster proliferation was tested. It was 
further hypothesised that tumours induced in mice deficient in two potent 
CReg would exhibit reduced protection against C-attack thereby resulting in
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lower incidence and slower proliferation. Mice of differing genotypes (Clq'7’, 
C3_/‘ and CD55','.CD59',') were administered MCA alongside WT control 
animals. Tumour incidence and progression were monitored over several 
months with mice assessed weekly.
In addition to tumour incidence and survival of mice, further understanding of 
C-related effects was sought via post-excision analysis of tumour tissue. 
Fibrosarcomas were analysed for regulator expression and C deposition. 
Examination of tumour tissues was performed using flow cytometry on live 
cells and via immunohistochemical techniques on frozen tissue sections. 
Tumours induced in KO mice were compared to those induced in age- 
matched wild type mice. These mice provided a standard against which 
tumours lacking C-related proteins were compared. Additionally, since WT 
mice were injected alongside every KO group, these mice acted as a control 
against variations in tumour growth due to changes in environmental 
conditions. As reviewed by (Blankenstein and Qin 2003), considerable 
variation is observed between studies performed in different housing 
conditions and between strains of mice. As such, all mice were on identical 
C57 BI6 backgrounds, backcrossed for at least 10 generations and controlled 
against WT animals for each batch of MCA injections.
5.2. Results
5.2.1. Susceptibility of male and female WT mice to 3-MCA-induced 
tumours
Tumours induced in this chemical carcinogenesis model arise at varying times 
depending on 3-MCA dose, strain of mouse and environmental housing 
factors. Typically, WT C57BI/6 mice develop tumours between 90-150 days 
post injection of 400pg 3-MCA (Gareth Betts, personal communication, 
November 2005). Once these tumours reached 1cm diameter, mice were 
sacrificed and tumours excised.
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In order to evaluate differences attributable to deficiency in C proteins, 
experiments must be controlled with WT mice. An important variable to 
consider is gender of mice used in these experiments and it was first deemed 
necessary to investigate whether differences exist in 3-MCA tumour induction 
between male and female mice. As described in Chapter 2, mice were 
administered 400pg 3-MCA sub-cutaneously in the hind leg. Initially, male and 
female WT mice were injected simultaneously with tumour growth monitored 
over several months. Figure 5.1 shows survival data gathered from 16 male 
and female WT mice. No statistically significant differences in tumour 
induction were observed between male and female WT mice (p=0.23). 
However, a trend for higher tumour incidence was observed in male mice. In 
males, 0 from 16 mice remained tumour free compared to 5 from 16 female 
mice at the end of the experiment. This suggests that male mice are more 
susceptible to tumour development, a trend that would likely become 
significant given larger group sizes. Consequently, it was deemed 
inappropriate to compare male and female mice in the same group in follow- 
on experiments. Due to the enhanced C activity previously observed in male 
mice (Figure 4.1), any C-related differences between groups would be 
expected to be enhanced in males and give clearer understanding of the 
effects of C in tumour formation and progression. As such, male mice only 
were used in subsequent experiments to investigate deficiencies in C 
proteins.
5.2.2. The effect of C1q deficiency on MCA tumour induction in male 
mice
In order to investigate the role of classical pathway activation, and the 
multifunctional protein C1q in tumour induction, male mice deficient in this 
protein, were injected with 3-MCA along with a control group comprising age- 
matched male WT mice. C1q'7' animals are unable to activate the Ab- 
dependent arm of C which, as discussed in Chapter 1, has been shown to be 
a major source of C deposition in several tumour types including renal cell 
carcinoma (Magyarlaki et al. 1996), breast cancer (Niculescu et al. 1992) and
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Figure 5.1: 3-MCA induced tumour induction in WT male and female mice.
WT male (n=16) and female (n=16) mice were injected with 400|jg MCA, sub- 
cutaneously into the left hind leg and monitored weekly. Differences between the two 
groups were analysed using an implementation of the log-rank test. (p>0.05)
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papillary thyroid carcinomas (Lucas et al. 1996). As such, impaired immune 
control may be expected in these animals. However, the MBL and alternative 
pathways are able to function as normal allowing C activation, C3b and MAC 
deposition. Related effects including opsonisation and anaphylatoxin release 
(excluding C4a) are also possible through these activation pathways. The 
amplification capacity of C remains intact, though requires initial deposition of 
C3b to instigate the amplification.
Data shown in Figure 5.2 (n=24) are compiled from three separate 
experiments (n=8) performed at different times. As previously, mice were 
sacrificed when tumours reached 1cm diameter with incidences being noted 
and pooled. An implementation of the log rank statistical test revealed a 
statistically significant protective effect in male C1q"/_ mice from tumour 
occurrence (p=0.002) compared to WT controls. Notably around 40% C1q'/_ 
mice remained tumour-free at the end of the experiment and tumours arose 
later in C1q_/‘ mice than WT counterparts. These data support a role for C1q in 
promoting tumour growth in WT animals.
5.2.3. The effect of C3 deficiency on MCA tumour induction in male mice
A key experiment in determining the relationship between C and tumour 
induction involved mice deficient in the central C component C3. These mice 
are immuno-compromised through impaired B-cell responses and are 
essentially deficient in C and all of the downstream effects associated with 
activation. Although the initiation of classical or MBL pathways is possible, 
lack of C3 will arrest either pathway at an early stage. As such, C-mediated 
lysis is not expected in these mice, nor any of the wide-ranging effects 
precipitated by C3 cleavage. As mentioned previously, there are scant data to 
support C3-independent generation of C5b from C5 (Huber-Lang et al. 2006). 
However, Figure 4.23 shows evidence of C9 / MAC deposition on tumour cells 
inoculated into WT but not C3’7’ mice, suggesting that C3 is required for 
initiation of the terminal pathway of C in this model. Whilst the lack of any C-
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Figure 5.2: 3-MCA induced tumour induction in WT male and Clq''" mice.
WT (n=24) and C1q knock-out (n=24) male mice were injected with 400|jg MCA, 
sub-cutaneously into the left hind leg and monitored weekly. Differences between 
the two groups were analysed using an implementation of the log-rank test. 
(p<0.05).
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mediated lysis may impact on tumour development, the impairment of 
associated immune mechanisms including impaired B-cell and T-cell 
responses may also be of great significance. One such effect is opsonisation, 
whereby C activation serves to label cells and allow recognition of targets by 
various immune cell types involved with the anti-tumour response 
(summarised in Table 1.3). Opsonisation, release of anaphylatoxins (C3a, 
C5a) or MAC deposition may contribute to observed tumour development 
and/or progression in WT animals. However, such effects are absent in C3'7' 
mice.
Data shown in Figure 5.3 (n=24) are compiled from three separate 
experiments (n=8) performed at different times. Statistical analysis revealed 
that deficiency in C3 was protective in male mice against MCA-induced 
tumour growth. As in the case of C1q deficiency, C3'7' mice developed fewer 
tumours over the course of the experiment with tumours also arising later than 
in WT controls. The protective effect was found to be statistically significant 
(p=0.0017) and suggests that C3 is promoting tumour progression in WT male 
mice.
5.2.4. The effect of CD55 and CD59 deficiency on MCA induced tumour 
induction in male mice
Mice lacking the CRegs, CD55 and CD59, were shown in Chapter 4 to 
possess a fully functional C system with similar haemolytic capabilities to WT 
mice (Figure 4.15). However, tumours arising in these animals will lack two 
potent proteins for controlling or inhibiting C attack suggesting that C 
activation on tumour cells would be more likely to result in lysis. This impaired 
control over C deposition may therefore affect tumour induction in these mice.
Figure 5.4 shows that CDSS^.CDSQ'1' male mice were more resistant to MCA- 
induced tumour induction, as compared to age-matched wild type controls 
(n=24). As previously observed in C lq '7' and C3'7' groups, tumours were 
slower to arise in the CDSS' .^CDSQ'1' mice compared to age-matched WT
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Figure 5.3: 3-MCA induced tumour induction in WT male and 03^ mice.
WT (n=24) and C3 knock-out (n=24) male mice were injected with 400|jg MCA, 
sub-cutaneously into the left hind leg and monitored weekly. Differences 
between the two groups were analysed using an implementation of the log-rank 
test. (p<0.05).
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Figure 5.4. 3-MCA induced tumour induction in WT male and CD55'/'.CD59'/' mice, 
WT (n=24) and CD55'1'.CD59'1' (n=24) double knock-out male mice were injected with 
400pg MCA, sub-cutaneously into the left hind leg and monitored weekly. Differences 
between the two groups were analysed using an implementation of the log-rank test. 
(p<0.05).
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controls. Additionally, a greater proportion of these mice remained free of 
tumours at the end of the experiment. Statistical analysis of survival data 
revealed a highly significant difference between the groups (P<0.0001). The 
strong trend demonstrated is for a protective effect of CD55 and/or CD59 
deficiency against 3-MCA induced tumourigenesis. These data suggest that 
one or both of these regulators are involved with tumour progression in WT 
mice. Whilst this effect could be mediated through C deposition on cells not 
expressing these CReg (either through CDC or opsonisation), other non-C 
effects of CReg expression, discussed in detail later, may be contributing 
(Longhi et al. 2006).
5.3. Post excision characterisation of tumours by flow cytometry
Effective characterisation of tumour cells in an in vivo setting can be achieved 
by flow cytometric staining of tumours immediately post excision. Upon 
reaching a pre-determined size (1cm diameter), tumours were excised and 
either frozen for sectioning, or disaggregated and characterised by flow 
cytometry. CReg expression (CD55, CD59 and Crry) was assessed by this 
method, and controlled by inclusion of erythrocytes obtained from a WT 
mouse known to express each of these proteins (Miwa et al. 2002). 
Additionally, C3b/iC3b deposition was assessed by this method, providing a 
measure of C activation on the same tumour cell populations.
Cells were disaggregated immediately post-excision, washed three times, 
strained to obtain a single cell suspension and re-suspended in lysis buffer to 
remove red blood cells from the preparation. Cells were stained by a two-step 
staining protocol as detailed in Chapter 2. Cells obtained from dis-aggregated 
tumours exhibited highly heterogeneous scatter plots, as shown in Figure 5.5. 
In order to remove cellular debris and select fibrosarcoma population, cells 
were gated to include those within R1 as shown for fluorescence analysis. 
Figure 5.6 shows representative histograms from 5 tumours from each group 
of mice (WT, C1q-'', C3_/' and CD55 /‘.CD59-y-) stained for CD55, CD59, Crry 
expression and C3b deposition. As expected, no CD55 or CD59 expression
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Figure 5.5: Flow cytometric analysis of dis-aggregated fibrosarcoma populations
Flow cytometry data representative of dis-aggregated cells from freshly excised tumour. 
Heterogeneous tumours were excised, washed, strained and red blood cells lysed. 
Following antibody staining protocols, cells were analysed using flow cytometry.
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Figure 5.6. Post-excision staining of disaggregated fibrosarcoma cells by flow cytometry.
Cells were washed, strained and re-suspended in red blood cell lysis buffer. Rat anti-mouse CD55 (MD1), rat anti­
mouse CD59 (Mel4), rat anti-mouse Crry (5D5) and rat anti-mouse C3 (11H9) were used, followed by detection using 
RPE-labelled donkey anti-rat IgG. In each case, figure shown is representative of >3 separate experiments. Lines 
shown in red represent secondary antibody only binding to the same cell population.
was found on cells derived from mice deficient in these CReg, while no C3b 
was deposited on C3-/- tumour cells. Crry was expressed consistently within 
each group, while the absence of CD55 was also common to all populations 
analysed. However, there was some variation in CD59 expression and 
C3b/iC3b deposition between tumour genotypes. Figure 5.7 shows effective 
detection of CD55, CD59 and Crry by Mel4, MD1 and 5D5 Abs respectively 
on mouse erythrocytes confirming that the lack of CD55 observed on 
fibrosarcoma populations was due to lack of expression and not defective 
staining.
A potential difference was observed in levels of C3b/iC3b deposited on the 
tumour cells. Changes in median fluorescence intensity (MFI) compared to 
control populations are summarised in Figure 5.8 and show WT tumours to 
exhibit a higher mean level of deposition than was detected in other groups. 
However, this difference was influenced by one ‘flyer’ exhibiting particularly 
high levels of deposition. This tumour population with high levels of C3b/iC3b 
deposited may represent an anomalous data point yet no statistically 
significant difference existed between WT, C1q'7' and CD55'/'.CD59'/' groups. 
Tumours excised from C1q'/_ mice exhibited lower levels of deposition than 
those from WT hosts suggesting a role for classical pathway activation in C 
deposition on these cells. However, this observation was found not to be 
statistically significant when compared to normal (i.e. WT) levels (p=0.178). 
Tumours excised from CD55‘/'.CD59‘/' mice also showed decreased C3b/iC3b 
deposition compared to WT controls. However, this effect was not as strong 
as that observed in C1q';' tissues and was again found not to be statistically 
significant (p=0.195). The lack of CD55 on these tumours would be expected 
to lead to enhanced C3b deposition on these cells, however CD55 expression 
was not detected on any populations analysed in this Chapter and was not 
required for progression of these tumours in vivo. Comparison of C3 fragment 
deposition on WT and C37* cells was found to be statistically significant
(p=0.022).
Figure 5.9 shows summarised data whereby changes in median MFI 
observed following staining for CD59 are plotted for each group (n=5). The
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Figure 5.7: CReg staining on mouse erythrocytes
Staining of mouse erythrocyte cells by flow cytometry. Cells were washed and 
incubated with rat anti-mouse CD55 (MD1), rat anti-mouse CD59 (Mel4), rat anti­
mouse Crry (5D5) followed by detection using RPE-labelled donkey anti-rat IgG. 
In each case, figure shown is representative of >3 separate experiments. Mouse 
erythrocytes were used as a positive control for presence of CReg. Lines shown 
in red represent secondary antibody only binding to the same cell population.
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Figure 5.8: Flow cytometric analysis of C3b/iC3b deposition
Changes in median fluorescent intensity following C3 staining were recorded 
and plotted. Data were analysed using a 2 tailed, unpaired t-test. * indicates 
p<0.05.
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Figure 5.9: Flow cytometric analysis of CD59 expression
Changes in median fluorescent intensity following CD59 staining were recorded and 
plotted (n=5). Data were analysed using a 2 tailed, unpaired t-test.
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majority of tumours were found to express low levels of CD59 with the median 
expression higher in C1q'/_ and C3_/' tumours. When compared to WT, 
differences between C1q'/_ (p=0.145) and C3'/_ (0.080) groups were not 
statistically significant. However, the observation that tumour cells express 
CD59 is relevant and provides a mechanism for inhibition of lysis by 
regulation of the terminal pathway. The observed difference in CD59 
expression between WT and CD55"/'.CD59'/' tumour populations was 
statistically significant (p=0.013).
5.4. Immunohistochemical staining of MCA-derived tumours
5.4.1. Morphology
Excised tumours showed expected morphology for fibrosarcomas induced via 
3-MCA induction, as previously published (Blankenstein and Qin, 2002).
Figure 5.10 shows tumours to exhibit high density of cells, with haematoxylin 
and DAPI nuclear stains particularly prominent.
5.4.2. C3 staining
Once excised, tumours were frozen, sectioned and stained using 
histochemical techniques as described in Chapter 2. A rat mAb against 
mouse C3 was used to visualise deposition of C3. This antibody is specific for 
C3, C3b and iC3b (Mastellos et al. 2004), and provides a valuable indicator of 
C3b or the associated inactivation product iC3b deposited on membranes.
Significant C3b/iC3b deposition was observed in all tumour sections analysed 
(Figure 5.11), excepting those derived from animals deficient in C3 where no 
fluorescent signal was observed. It is not possible to determine from these 
data the source(s) of the C3 products. These may be tumour derived, a 
product of tumour cells activating host C or a combination of both 
mechanisms. Control tissues treated with isotype control mAbs and 
secondary Abs all exhibited no fluorescence. Thus, staining with the anti-C3 
primary Ab was specific.
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Figure 5.10: Nuclear staining of 3-MCA induced tumours
3-MCA induced tumours were excised and stained with haematoxylin (left panel) or 4',6- 
diamidino-2-phenylindole (DAPI) (right panel) in order to localise fibrosarcoma nuclei. 
Data shown are representative slides of fibrosarcomas excised from WT animals.
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Figure 5.11: C3b/iC3b deposition on 3-MCA induced tumour sections
C3 cleavage and deposition on MCA induced tumours was assessed by a two step 
staining protocol as detailed in Chapter 2. Staining was optimised on sections of 
diseased tissue (not shown) using a rat monoclonal anti-mouse C3/C3b/iC3b antibody. 
Alexa-fluor 594 conjugated donkey anti-rat secondary antibody was used to detect. 
Images shown are representative sections from each tumour (n=6). Tissue from each 
genotype of tumour was also stained using an isotype control antibody, negative 
staining was found.
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In order to quantify C3b/iC3b deposition on tumour sections, and identify any 
differences between tumour genotypes, sections were analysed using Image 
Pro Analyser software. Use of this software allows a fluorescence threshold to 
be set, above which any signal is marked positive. The percent area stained 
positive can then be calculated per random camera frame. Eight frames per 
tumour were analysed, with 6 tumours assessed per genotype. These data 
are summarised in Figure 5.12 and show comparable levels of deposition in 
each group, with the exception of C3'/_ animals where no positive signal was 
observed. Statistical analysis revealed no differences in deposition between 
WT and C1q_/' (p=0.320) or CD55‘/\CD59'/'(p=0.990) tumour sections. As 
expected, a strong statistically significant difference was observed between 
WT and C3'/_ sections (p<0.001). This provides a useful negative control and 
confirms the specificity of the Ab and staining procedure used.
5.4.3. C9 staining
Deposition of C9 was assessed to determine the presence of MAC on tumour 
tissue sections. An affinity purified Ab against rat C9 was used and 
fluorescence quantified as described above. As shown in Figure 5.13, 
significant C9 deposition was observed in tumour sections excised from WT, 
C1q_/" and CD55/\CD59'/' mice. No C9 deposition was observed on sections 
from C3'/_ mice suggesting that C3 is required for initiation of the terminal 
pathway. Collated data following quantitation of fluorescence levels are shown 
in Figure 5.14 and reveal comparable levels of C9 between WT and C1q_/' 
(p=0.897), and CD55‘/\CD59'/' (p=0.923) groups. As expected, a strong 
significant difference was observed between WT and C3'A groups (p<0.001). 
Negligible fluorescence was observed on C3'7' tumour cells indicating C3- 
dependent terminal pathway activation in WT and suggests that tumour cells 
in this model do not secrete and deposit C9 on their own surfaces.
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Figure 5.12: Immunohistochemical analysis of C3b/iC3b deposition
Percentage area stained positive for C3 deposition was assessed using image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group 
used. Data were analysed using a 2 tailed, unpaired t-test. * represents p<0.05.
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Figure 5.13: C9 deposition on 3-MCA induced tumour sections
C3 cleavage and deposition on MCA induced tumours was assessed by a two step 
staining protocol as detailed in Chapter 2. Staining was optimised on sections of 
diseased tissue (not shown) using a rabbit anti-rat C9 antibody. Alexa-fluor 594 
conjugated goat anti-rabbit secondary antibody was used to detect. Images shown 
are representative sections from each tumour (n=6).
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Figure 5.14: Immunohistochemical analysis of C9 deposition
Percentage area stained positive for C9 deposition was assessed using Image Pro 
Analyser software, 8 frames were assessed per tumour with 6 tumours per group 
used. Data were analysed using a 2 tailed, unpaired t-test. * represents p<0.05.
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5.4.4. CD4 staining
It has previously been reported that CD4+ T cell responses are enhanced in 
mice lacking CD59 (Longhi et al. 2005). Thus it is possible that tumours are 
better controlled in mice lacking this Creg as a consequence of more robust 
anti-tumour CD4+ T cell activity. Infiltration of CD4+ cells, the majority of 
which are T cells (Awen Gallimore, personal communication), into MCA- 
induced tumours was assessed by immunohistochemistry. This protein is a 
widely used marker for T-lymphocytes and was observed in all tumour tissues 
analysed as a defined ring of fluorescence (Figure 5.15). In order to assess 
differences between groups, numbers of infiltrating CD4+ cells were counted 
(8 frames per tumour, n=6, Figure 5.16). No observable differences were 
found between groups, with a mean of ~5 CD4+ cells found per tumour 
section. These data indicate no difference in T-cell accumulation in tumour 
development in C1q_/‘, C3_/" or CD55_/'.CD59_/' or WT hosts.
5.5. Discussion
The 3-MCA tumour induction model provides powerful reproducible data on 
the relative susceptibilities of WT and C component/CReg deficient mice to 3- 
MCA induced fibrosarcomas. Wild type mice were found to be more 
susceptible to tumour development than C lq ’7', C3'7' and CD55'/'.CD59'/' mice. 
In each case, the protective effect of C component/CReg deficiency was 
found to be statistically significant.
Induction of 3-MCA tumours in WT mice was observed with high incidence 
and found to be consistent with previous studies with the majority of tumours 
arising 15-25 weeks post 3-MCA administration (Figure 5.1). Differences in 
tumour induction observed in male and female WT mice were not statistically 
significant (p=0.23). However, while all 16 male mice developed a tumour by 
week 31, 5 from 16 female mice remained tumour free throughout the 
experiment. Sarcomas have previously been shown to elicit a greater immune
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Figure 5.15: CD4+ Cell infiltrate in 3-MCA induced tumour sections
CD4+ cells in MCA induced tumours were assessed by a two step staining protocol 
as detailed in Chapter 2. Staining was optimised on sections of spleen (not shown) 
using a rat monoclonal anti-mouse CD4 antibody. Alexa-fluor 594 conjugated 
donkey anti-rat secondary antibody was used to detect. Images shown are 
representative sections from each tumour (n=6). Tissue from each genotype of 
tumour was also stained using an isotype control antibody, negative staining was 
found.
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Figure 5.16: Immunohistochemical analysis of CD4+ infiltrate
Numbers of CD4+ cells per section were counted, 8 frames were assessed per 
tumour with 6 tumours per group used. Data were analysed using a 2 tailed, 
unpaired t-test.
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response in female mice than males (Pollack 1971), though many other 
factors can contribute to 3-MCA tumour induction e.g. age, sex, strain and 
environmental conditions. As shown in Chapter 4 (Figure 4.1), male mice 
possess significantly higher C activity than females. The stronger C response 
in male mice may contribute to the higher tumour incidence observed 
although numerous other factors, most notably those linked to 3-MCA 
metabolism, are likely to be involved with differing enzyme levels thought to 
be important (Salerno, Ramm and Whitmire 1973). Various enzymes are 
required to metabolise 3-MCA into genotoxic forms and allow carcinogenesis 
with cytochrome P450 enzymes being of particular importance (Moorthy et al. 
2002). Gender differences in expression of these enzymes have been 
reported, largely dependent on growth hormones (Sharma et al. 1998). In 
stark contrast to observations in rats and humans, female mice are 
consistently found to express higher levels of cytochrome enzymes (Salerno 
et al. 1973, Pampori and Shapiro 1999, Jarukamjorn et al. 2006). However, 
gender differences are much more subtle in these models with 40-100% 
increases typical compared to 300-500% observed in rats. Given these 
gender differences, the higher tumour incidence indicated in Figure 5.1 and 
the stronger C system in male mice, further experiments in WT, C1q_/', C3'/_ 
and CD55*/'.CD59‘/' mice were performed using male animals only.
Mice lacking C1q are unable to activate the classical pathway of C, shown 
previously to be a major source of C targeted to tumour cell surfaces ( Lucas 
et al. 1996, Niculescu et al. 2002). Activation and deposition of C in these 
animals must therefore occur via the alternative or MBL pathway. The 
hypothesis that the C-system may attack arising tumour cells through the 
classical pathway leading to tumour elimination or control was tested. 
However, data obtained in C1q_/' mice showed fewer tumours arising, and at a 
later date implying that C may instead be promoting tumour development. 
These data support other emerging data in the field, that events occurring in 
the C-sufficient mice could be enhancing tumour cell survival and driving 
proliferation. It seems likely that C1q deficiency demonstrates a protective 
effect through inability to initially deposit C3, curtailing the amplification
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capacity and denying these tumour cells the proliferative stimuli detailed in 
Chapter 1. However, C1q has numerous roles outside of C activation, which 
may contribute to the observed pro-tumour effect. A potential mechanism for 
this is a role for C1q and other classical pathway components in clearance of 
apoptotic cells (Taylor et al. 2000), which if impaired could result in multiple 
apoptotic bodies -  a known feature of C1q'7' mice (Botto et al. 1998). This in 
turn could lead to enhanced alternative pathway activation (Matsui et al. 1994) 
and the proliferative effects associated with C deposition. A wealth of 
evidence exists to support a role for C1q in binding apoptotic blebs and aiding 
phagocytotic clearance of these cells. C1q is known to bind directly to blebs 
and induce C activation (Nauta et al. 2002). However in the absence of C1q, 
the alternative pathway of C can also be activated (Matsui et al. 1994, Tsuji, 
Kaji and Nagasawa 1994). Opsonisation of apoptotic cells in this way has 
been shown to label them for phagocytosis by macrophages (Mevorach et al. 
1998, Ogden et al. 2001) and clearance from tissues. Impaired clearance of 
apoptotic cells in C1q'7‘ animals may lead to accumulation of dying cells within 
the tumours of these mice. These apoptotic cells may then be stimulating the 
alternative pathway and leading to increased C3 deposition. This effect could 
be responsible for making up any shortfall caused by a lack of classical 
pathway activation. This would mean that C3 fragments deposited on C1q'7' 
tissues are not a marker for C activation by progressively growing tumour 
cells and that C is not deposited on actively proliferating cells. Flow cytometric 
data showed marginally higher levels of C3b/iC3b deposition on WT tumour 
cells. However, the mean shift in fluorescence was skewed in the WT group 
by one population on which C3b/iC3b staining was much stronger. 
Nevertheless, the differences between WT, C1q‘7' and CD55'/'.CD59'/' groups 
were shown not to be significant. A statistically significant difference was only 
observed between WT and C3'7* groups. Further analyses by 
immunohistochemistry support this observation and found comparable levels 
of both C3b/iC3b and C9 deposition on WT, C1q'7* and CD55'7'.CD59‘7‘ tumour 
sections. As found by flow cytometry, a statistically significant difference was 
found between WT and C3'7' groups. Whilst the data in Figure 5.2 suggest a 
pro-tumour role for C1q, it is unclear whether this is mediated through C
activation given the comparable levels of C3b/iC3b and C9 deposition 
observed via flow cytometry and immunohistochemistry.
Differences in tumour induction in C3'7' mice were also shown to be 
statistically significant compared to WT controls. The observed difference was 
again a protective effect against tumour development and progression 
conferred by a deficiency in C. These data support the findings in C1q_/' mice 
and point to a role for C in driving tumour growth in WT mice. Tumours arising 
in these mice may activate C via CP or MBL pathway but have no capacity for 
C3b deposition and therefore all downstream effects of C activation are 
abrogated. In these animals there can only be release of C4a anaphylatoxin 
and not the more biologically active C3a and C5a fragments. The strength of 
the protective effect (p=0.0017) is also important and suggests that C3 may 
play a major role in promoting tumour progression in WT mice. C3'/_ mice 
essentially possess a non-functional C system and as such are severely 
immuno-compromised with no lytic capacity and markedly impaired 
opsonisation. As discussed in Chapter 1, C3b and associated breakdown 
products have numerous important immune effects outside of C activation 
including B-cell responses (Rickert 2005), T-cell activation (Knopf et al. 2008), 
dendritic cell differentiation (Reis et al. 2008) and NK cell activation (Wang et 
al. 2008). The observation that it was considerably more difficult to induce 
tumours in these mice point to a pro-tumour role for C3 even with the 
impairment of several immune mechanisms known to contribute to 
immunosurveillance. As with C1q_/' mice, these mice exhibit impaired 
clearance of apoptotic cells through inability to deposit C3 activation products 
(Taylor et al. 2000, Morelli et al. 2003). However, in contrast to C1q_/‘ mice, a 
build of apoptotic blebs would not activate the C alternative pathway in C3'7' 
hosts. The deposition of neither C3b/iC3b nor C9 was detected on tissue from 
C3'/_ mice either by flow cytometry or immunohistochemical staining. The 
absence of deposited C3 products on these tissues indicates that C3'7' tumour 
cells are not subjected to any of the stimulatory effects mediated by 
deposition of these proteins, which may be responsible for the reduced 
tumour induction in these mice. A role for C3 activation and deposition has 
been demonstrated in increased cellular proliferation by normal and
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transformed cells (Kuraya et al. 1990). Further, such deposition is known to 
induce proliferation of a mouse carcinoma line (di Renzo et al. 1999) later 
shown to be mediated through protein kinase activation (Longo et al. 2005). 
Numerous effects associated with MAC deposition have been described (see 
section 1.12) and are also absent in tumours generated in C3'/_ mice.
Impaired tumour incidence and progression were also observed in CD55'7' 
CD597' male mice compared to WT controls. This observation cannot be 
explained by a pro-tumoural role for C. CDSS^.CDSO'7' mice have a fully 
functional C system, allowing activation of all three pathways. This is 
evidenced by the comparable haemolytic capabilities observed in these and 
WT mice (Figure 4.15). Induction of tumours in these mice gives rise to 
tumour cell populations unable to synthesise and express CD55 or CD59. The 
lack of these proteins may lead to increased C-susceptibility through impaired 
regulation of both activation pathways (CD55) and the terminal pathway 
(CD59). Therefore the decreased tumour incidence, and slower growth rates 
observed in these animals may be attributable to enhanced clearance of 
tumour cells via CDC. However, no tumours examined in this model in vivo or 
in vitro were shown to express CD55 suggesting that expression of this 
regulator on tumour cells does not normally influence progression. Expression 
of CD59 was detected on excised tumours from WT, C1q'7' and C3'/_ mice, 
though at relatively low levels. This protein is a potent inhibitor of MAC 
formation and may play a role in protecting 3-MCA induced tumours against C 
attack thus contributing to the higher incidence and faster growth rate of 
tumours induced in WT compared to CD55‘/\CD59'/' mice. This protein has 
previously been associated with enhanced tumour growth and is considered a 
promising therapeutic target (Macor et al. 2007, Donev et al. 2008). The 
observation that comparable amounts of C3b/iC3b and C9 were deposited on 
tumours arising in CDdS'^.CDdS'1' and WT mice (found by flow cytometry and 
immunohistochemical techniques) is expected given the similar lytic 
capabilities of these mice and suggests that tumour populations in these mice 
activate C to similar extents.
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CD59 expression was detected on tumour cells derived from WT, C1q_/' and 
C3'7' mice with no statistically significant difference observed despite a trend 
for elevated levels in tumours from C3'7' animals. The presence of CD59 and 
absence of CD55 in these tissues suggests that CD59 expressed on tumour 
cells may contribute to tumour progression. The role of CD59 is primarily to 
regulate the terminal pathway by preventing the incorporation of C9 molecules 
into the cell membrane. As such, elevated levels of C9 deposition would be 
expected in mice lacking CD59 compared to WT and C1q'/_ mice which have 
been shown to deposit significant amounts of C3b/iC3b and express CD59. 
However, data shown in Figure 5.14 do not support this and indicate 
comparable levels of C9 deposition between groups with no elevated 
deposition observed on CD55'/‘.CD59/' tumour tissue. Further investigation 
into the individual effects of CD55 and CD59 deficiency would be achieved 
using mice deficient in CD59 only.
A crucial consideration in this study is that differences in tumour growth may 
be independent of CD55 or CD59 expression by the tumour cells themselves. 
Expression of these regulators has recently been shown to have important 
effects on APCs and/or T cells in both CD55/_ and CD59'7' mice. Mice lacking 
CD55 have heightened T cell responses, measured by proliferation and IFNy 
production, compared to controls with normal CD55 expression (Liu et al. 
2005, Heeger et al. 2005). This effect, which was accompanied by a decrease 
in IL-10 production, was attributed to lack of CD55 on T-cells in one study (Liu 
et al, 2005). However, the parallel study found CD55 expression on both T- 
cells and dendritic cells to play a role, with enhanced C activation on the 
APCs necessary and C3, C5 and fD demonstrated to contribute to enhanced 
responses (Heeger et al 2005). Additionally, CD4+ T-cells have been shown 
to proliferate more extensively in response to antigen in CD59‘/_ mice 
compared to WT controls (Longhi et al. 2005). This effect, unlike effects 
mediated by CD55, was shown to be independent of C activation. Thus, 
reduced tumour incidence observed in CD55'/'.CD59'/' mice could reflect 
stronger anti-tumour T-cell responses in these mice compared to WT controls.
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Initial analysis of CD4+ cellular infiltrate in tumour sections revealed no 
differences between WT and CD55‘7'.CD59'7‘ tissues with infiltrating cells 
readily observed in both. Whilst this may imply no role for CD4+ T cells in 
promoting tumour rejection, effects may be due to different T-cell activities, 
rather than recruitment or proliferation of these cells. It is also possible that at 
this stage in tumour development, progressing tumours have evaded the 
immune responses rendering the T-cells ineffective. Analysis of anti-tumour T- 
cell responses in tumour-free WT and CD55'7\CD59'7‘ mice may therefore 
prove more informative in elucidating their influence on tumour progression.
Data described in this Chapter reveal clear differences between 3-MCA 
induced tumour growth in WT mice and those deficient in the C components 
C1q and C3. A fully functional C system appeared to have an important pro­
tumour role in this model and was able to drive tumour progression in WT 
mice. Mice with impaired C responses developed tumours at a slower rate 
with a number of mice remaining tumour free at the end of the experiment. 
Additionally, mice deficient for CD55 and CD59 were also found to be 
resistant to tumour induction. Whilst tumours lacking CReg would be expected 
to be more prone to clearance, the impact of these CReg on T-cell activity 
may also be important. Complement activation and deposition was observed 
in 3-MCA induced tumours, though it is not clear whether C3 fragments are 
derived from host C activation, or synthesis by tumour cells. In order to 
address this question, novel cell lines were generated from tumours excised 
from the C-deficient and WT mice. Generation and use of these lines is 
detailed in the following Chapter.
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6. Generation and characterisation of new fibrosarcoma lines from MCA- 
induced tumours
6.1. Introduction
The aims of the experiments described in this chapter were to generate, 
select and characterise fibrosarcoma cell lines of known C genotypes. 
Tumours were induced by 3-MCA carcinogenesis in WT, C1q'/_, C3'7' and 
CD55'/\CD59'/" mice, excised and cultured in vitro. These heterogeneous 
fibrosarcoma populations possess the same genotype as the mouse in which 
they were raised and can be examined in vitro to identify behavioural or 
phenotypic differences associated with each deficiency listed above. The 
following characteristics are of particular relevance to this study and were 
assessed in this Chapter: fibrosarcoma phenotype, in vitro proliferation rate, 
CReg expression, C3 secretion, in vitro sensitivity to complement and in vivo 
growth in WT and C3'/_ hosts.
Due to the multi-cellular origin of 3-MCA induced tumour populations (Reddy 
and Fialkow 1979), clonal cell lines were also generated and expanded from 
the original populations. These novel lines maintain the genotype of the 
parent line and are derived from one cell thus providing a more stable and 
uniform model for interpretation of the above characteristics. An additional 
advantage to this technique is that clones (of differing genotypes) exhibiting 
comparable in vitro characteristics can be selected allowing intra-experimental 
control for subsequent in vivo experiments.
Differences observed between heterogeneous populations or clones of 
different genotypes may provide interesting insights into the respective roles 
of individual C components in tumour cell phenotype. Additionally, re­
inoculation of lines sufficient and deficient in C3 allows investigation of the 
source of this protein observed by immunohistochemistry on the tumour cell 
surfaces. A typical experiment as outlined in Table 6.1 would indicate whether 
activated C3 is derived from the host animal or secreted by the tumour cells 
as has been reported and described in Section 1.13.
189
Tumour Line Recipient Animal Complement Source
C3 - C3'- No C3
C3 + C3'- Local (tumour C3 only)
C3 -
++COO Systemic C3
C3 + C3+/+ Local & Systemic C3
Table 6.1: Control over host/tumour derived C3 secretion
Mice sufficient and deficient in C3 are injected with fibrosarcoma cells with and without the ability 
to synthesise C3. In this way, the effects of systemic and tumour-derived C3 on fibrosarcoma 
incidence or growth can be assessed.
6.2. Cloning of fibrosarcoma lines
Induction of fibrosarcomas by 3-MCA gives rise to highly heterogeneous 
tumour populations of multi-cellular origin. As such, clonal lines offer a more 
homogeneous and consistent phenotype. For this reason, a number of clones 
(n=8) were isolated from each genotype of tumour cells collected. WT, C1q'/_, 
C3_/‘ and CD55'1'.CD59'1' tumours were excised, disaggregated, washed and 
cultured as described in Chapter 2. Many cells did not survive, and a number 
of non-fibrosarcoma cells were also present in the initial culture populations. 
These cells were quickly outgrown and fibrosarcoma cells rapidly became the 
dominant cell type in culture samples. Once a healthy fibrosarcoma 
population was observed, clonal lines were isolated as described in Chapter 
2. Briefly, cells were plated at <1 cell per well and wells containing only one 
clone were selected, lifted with an EDTA solution, and grown out. This 
procedure was repeated 3 times as described in section 2.3.3. Figure 6.1 
shows an example of flow cytometry data with cells from each tumour 
genotype stained with a fibroblast marker (anti-CD 140a). This Ab binds to 
Platelet Derived Growth Factor Receptor-alpha (PDGFRa) on cell surfaces 
and was used to confirm a fibroblast phenotype. Populations were stained 
prior to and following the cloning procedure. Initial heterogeneous populations 
(column A) showed a broad range of CD140a expression, while clones 
displayed a more homogeneous histogram with vastly reduced variation
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Figure 6.1: CD140a expression on parent and clonal fibrosarcoma lines
Cultured cells from excised tumours were stained by flow cytometry for expression of 
CD140a pre and post cloning. Apa5 (rat anti-mouse CD140a) was visualised using 
donkey anti-rat IgG-RPE. Column A depicts one representative cell population from 
each genotype after culturing. Column B depicts final population after 3 cloning steps.
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(column B). Expression of CD140a was variable and appeared relatively low- 
level. This observation may be attributable to low CD 140a expression on 
these cells, or a poor affinity Ab. However, it has been previously shown that 
tumours derived through 3-MCA carcinogenesis often down-regulate 
fibroblast-specific markers (Kopp, Croci and Trueb 1995, Schreier et al. 
1988). This effect may also be affecting CD140a detected on these cells. 
CD140a was detected in all fibrosarcoma populations (both pre- and post­
cloning) and provided a useful indicator of hetero/homogeneity of populations. 
At least 8 clonal lines of each genotype were selected and cultured.
6.3. in vitro comparison of clonal proliferation rates
The use of 3-MCA induced carcinogenesis results in a multitude of random 
mutagenic events. This and the heterogeneity of resulting populations suggest 
that differences are likely to be observed between clones of the same 
genotype. In order to identify and select clones with equivalent proliferative 
rates, an in vitro assay was optimised utilising a colorimetric method based on 
metabolism. The method is detailed in Chapter 2 and involves incubation of a 
known number of cells with a non-toxic coloured metabolite (10% Alamar 
Blue™) on a daily basis. The rate of metabolite consumption is proportional to 
the number of cells per well and a quantifiable colour change is observed 
upon metabolism of the compound. The colour change was observed as a 
result of a reduction-oxidation (REDOX) indicator dye included to detect 
reduction of the Alamar Blue compound. Observed colour change over a 2 
hour period was quantified via fluorescence measurement and population 
expansion plotted over a 10 day period. Cells were plated at 1.5x104 per well 
in triplicate and assayed on 10 consecutive days.
Figure 6.2 shows proliferation of 8 separate WT clones as measured over a 
10 day period. As expected, there was some variation between the clones 
though all followed a sigmoidal curve pattern, characterised by a lag, log and 
stationary phase where all the metabolite was consumed. After 10 days, data 
became erratic as cell death occurred through lack of space and nutrients. 
Two clones grew noticeably slower than the majority, while another grew at a
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Figure 6.2: In vitro proliferation of 8 WT clones
Cells were plated at 1.5x104 per well in triplicate and incubated daily with 10% Alamar 
Blue solution for two hours. Fluorescence was recorded and plotted over 10 day period. 
Data are representative of 2 separate experiments. * represents cell line excluded from 
further experiments.
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particularly fast rate. Similar observations were made in C lq '7', C3‘/_ and 
CD55'/\CD59‘/' clones as shown in Figures 6.3, 6.4 and 6.5 respectively. 
Several lines were identified as differing from the dominant normal growth 
pattern within the same group. Those clones with abnormal growth curves 
were not used for further experiments - these are denoted by * on Figures 6.2-
6.5. Data shown is representative of two separate experiments. Subsequently, 
three clones were identified from each of WT, C1q'/_, C3'7' and CD55'/'.CD59'/' 
groups which showed comparable and reproducible growth curves. The 12 
selected clones were re-tested for proliferative rates with all shown to grow at 
comparable rates in vitro. These data are shown in Figure 6.6 and confirm 
suitability of these clones for further experiments.
6.4 Characterisation of clones 
6.4.1 CReg characterisation by flow cytometry
As described in Chapter 1, tumour cells are often found to express high levels 
of one, or several CReg proteins. These proteins are known to be important 
in protecting cells from C and enhanced tumour killing has been achieved by 
down-regulation (Zell et al. 2007) or blockade (Di Gaetano et al. 2003) of 
these proteins. As such, expression of CReg is an important parameter likely 
to have implications in C susceptibility and in vivo growth of these cell lines. 
Differences between groups in the CReg molecules and levels expressed 
were important considerations for further experiments and must have 
implications when analysing the behaviour of these cells in response to C. 
Data described and discussed in Chapter 5 highlighted a major difference in 
CReg expression between heterogeneous populations of WT, C lq '7*, C3'/_ and 
CD55‘/\CD59‘/' tumour cells. The expression or lack of Crry and CD55 was 
consistent between groups, however, only tumours excised from C3'7' animals 
were found to express CD59. In contrast, expression of CD59, and thus the 
ability to regulate the terminal pathway of C was not observed in tumours 
excised from WT, Clq*7’ or CD55'/'.CD59 /‘ mice.
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Figure 6.3: /n vitro proliferation of 8 C1q^ ' clones
Cells were plated at 1.5x104 per well in triplicate and incubated daily with 10% 
Alamar Blue solution for two hours. Fluorescence was recorded and plotted over 10 
day period. Data are representative of 2 separate experiments. * represents cell line 
excluded from further experiments.
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Figure 6.4: in vitro proliferation of 8 CZ"1' clones 
Cells were plated at 1.5x104 per well in triplicate and incubated daily with 10% 
Alamar Blue solution for two hours. Fluorescence was recorded and plotted over 
10 day period. Data are representative of 2 separate experiments. * represents 
cell lines excluded from further experiments.
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Figure 6.5: In vitro proliferation of 8 CD55''’.CD59'/* clones 
Cells were plated at 1.5x104 per well in triplicate and incubated daily with 10% Alamar 
Blue solution for two hours. Fluorescence was recorded and plotted over 10 day period. 
Data are representative of 2 separate experiments. * represents cell lines excluded from 
further experiments.
197
Flu
or
es
ce
nc
e 
Fl
uo
re
se
nc
e
4000 .  C 1 q4000. WT
o 3000-3000-
®  2000-2000 -
1000-
100 2 4 6 8 0 2 4 6 8 10
Days Days
4 000-i CD55~,m.CD59
3000-
o  3000-
2000-
£  2000-
1000- 1000-
100 2 4 6 8 0 2 64 8 10
Day* Days
Figure 6.6: In vitro proliferation of 3 WT, C1q ‘^, CZ'1' and CD55'/'.CD59'/' clones 
3 clones per group were selected and plated at 1.5x104 per well in triplicate. Populations were 
incubated daily with 10% Alamar Blue solution for two hours. Fluorescence was recorded and 
plotted over 10 day period. Control wells contained no cells.
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Novel clonal cell lines were selected and expanded from each tumour 
genotype as described above. These populations were characterised for 
CReg expression (CD55, CD59, Crry) via flow cytometry as fully described in 
Chapter 2. Cells were stained with appropriate antibodies against CD55, 
CD59 and Crry with fluorescence noted and compared to control populations. 
As with previous experiments, mouse erythrocytes were included as a positive 
control. These cells are known to express high levels of each of these CReg 
(Miwa et al. 2002) and were useful to confirm the functionality of the 
antibodies used. These data are summarised in Figure 6.7 and confirmed the 
presence of CD55, CD59 and Crry on erythrocytes. This is evidenced by a 
clear shift in median fluorescence values following staining with MD1 (anti- 
CD55), Mel-4 (anti-CD59) and 5D5 (anti-Crry) monoclonal antibodies. Each 
was detected by staining with RPE-conjugated donkey anti-rat IgG secondary 
Ab and MFI values noted and compared to control (unstained) populations.
Figure 6.8 shows summarised flow cytometry data from the 12 clones. In each 
case, the shift in median fluorescence intensity (MFI) between stained and 
control cells was plotted allowing quantification of protein expression for each 
line. Figure 6.9 displays the mean and standard deviation of shifts observed 
for each genotype and each CReg. CD55 was not detected on any of the cell 
lines as was repeatedly found and described in Chapters 4 and 5. Crry was 
detected at high levels on all cells analysed with seemingly equivalent levels 
observed for each genotype. This was evidenced by a consistent mean shift 
(64-72 MFI units) for each genotype and no discernable difference between 
data in different groups. However, a clear difference was found in terms of 
CD59 expression with none detected in WT, C1q_/' or, as expected, in CD55'/_ 
.CD59'7" cell lines. Conversely, each of the three clonal lines deficient in C3 
expressed significant amounts of CD59. The observed change in median was 
seen only in C3_/' clones and there was found to be a statistically significant 
difference between this group and each of the others (p=0.005).
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Figure 6.7: CReg expression on mouse erythrocytes
Mouse erythrocytes were stained using CD55, CD59 and Crry specific Abs. A 
secondary donkey anti-rat-RPE Ab was used to visualise bound Ab and is plotted 
in red. Control cells stained with secondary Ab only are also shown as the blue 
DODulation.
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Figure 6.8: CReg expression on 3 WT, Clq''', C31' and CD55'I'.CD59'1' clones
Clonal lines were stained using CD55, CD59 and Crry specific Abs. A secondary 
donkey anti-rat-RPE Ab was used to visualise bound Ab. Control cells stained 
with secondary Ab only were used to calculate shift in median fluorescence. Data 
were analysed using the unpaired students t-test. * represents p<0.05
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Crry CD55 CD59
WT 64 ± 16 1 ± 3 1 ± 3
c v 64 ± 8 2 ± 4 3 ± 2
C 3' 72 ± 1 5 2 ± 2 35 ± 1 0
CD55-'\CD59-'- 69 ± 9 2 + 3 1 ± 4
Figure 6.9: Mean CReg expression on 3 WT, C3"/‘ and CDSS .^CDSS* clones
Shifts in median fluorescence intensities were recorded for 3 clones per group. Data 
shown include mean ± SEM.
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6.4.2 ELISA characterisation of C3/C3b/iC3b present in s/n
A hypothesis integral to this thesis is that tumour cells may utilise C to aid 
their proliferation or metastasis. Cancer-derived cell lines have previously 
reported to synthesise and secrete their own C3 into the tumour micro­
environment (Jean et al. 1997, Kitano and Kitamura 1993) while fibroblasts 
are also known to produce the C3 protein (Katz, Revel and Strunk 1989). 
Therefore a potentially important characteristic to assess is the secretion of 
C3 by these fibrosarcoma lines. An ELISA method was used to detect C3 
released into tissue culture s/n, additionally presence of the activation product 
of C3 cleavage (C3b) and the inactivated form of this protein (iC3b) was also 
tested using the mAb described in previous Chapters. Cells were cultured to 
-40% confluence, fresh media added and incubated for 48 hours, s/n was 
removed from each population (approx 5x106 cells), spun to remove cellular 
debris and concentrated 10-fold via centrifugation through a 0.22pm 
centrifugal concentrator, s/ns were assayed in triplicate for C3/C3b/iC3b 
presence using a plate-bound rat monoclonal Ab specific for these proteins. 
Bound protein was detected using a rabbit polyclonal anti mouse C3 Ab and a 
peroxidase conjugated donkey anti-rabbit IgG Ab. A range of known C3 
concentrations was assayed on the same plate comprising a titration of 
purified mouse C3 concentrations. These known concentrations were used to 
create a standard curve against which s/n readings could be compared, whilst 
fresh cell culture medium was included as a negative control. Additionally, 
purified mouse C3 (100ng/ml) was added to culture media as a positive 
control to ensure that positive signal could be detected and was not inhibited 
by culture media. A positive signal was recorded from the C3 ‘spiked’ sample, 
and corresponded to a concentration of ~92ng/ml when compared to the 
standard curve.
Figure 6.10 shows a standard curve of C3 concentrations and allowed 
accurate detection of C3 concentrations in the range 15-1200ng/ml. However, 
absorbance readings obtained following analysis of tissue culture s/n from 3 
clonal cell populations (from WT, C lq ’7', C3'/_ and CD55'/'.CD59'/') were below 
the threshold of detection in this assay. Figure 6.11 shows levels of C3 as
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Figure 6.10: C3/C3b/iC3b detection by ELISA
96 well plates were coated with a monoclonal rat anti-mouse C3 Ab and incubated 
with a serial dilution of known concentrations of purified mouse C3. Plates were 
washed before incubation with polyclonal rabbit anti-mouse C3 Ab. Bound antibody 
was detected using HRPO-conjugated anti-rabbit IgG and visualised using an OPD 
preparation. Dilutions of C3 were assayed in triplicate.
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Figure 6.11: Assessment of C3/C3b/iC3b by ELISA in cell culture supernatants
96 well plates were coated with a monoclonal rat anti-mouse C3 Ab and incubated 
with tissue culture supernatant from 3 clonal lines from each genotype. Supernatant 
was concentrated 10-fold prior to assay. Plates were washed before incubation with 
polyclonal rabbit anti-mouse C3 Ab. Bound antibody was detected using HRPO- 
conjugated anti-rabbit IgG and visualised using an OPD preparation. Supernatant 
from each clone was assayed in duplicate. Horizontal bars represent means of the 3 
clones per genotype while horizontal dashed bar represents minimal detectable level 
of C3 15ng/ml. Data are representative of 2 separate experiments.
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assessed by ELISA with the dashed line representing the C3 detection 
threshold (15ng/ml). All mean values corresponding to clonal cell lines were 
below this detection threshold. One clone of CD55'/'.CD59"/' genotype 
exhibited a reading marginally above the threshold but exhibited high variation 
between triplicate values and was not reproducible. Figure 6.12 indicated 
mean ± SEM values for each genotype. A previous study reporting C3 
secretion in vitro by a human melanoma population found 350ng C3/106 
cells/24 hours. This value is significantly higher than the observed values for 
fibrosarcoma lines measured in this assay despite increased cell numbers, 
incubation time and s/n concentration. These data suggest no C3/C3b or iC3b 
is present in tissue culture media incubated with clonal fibrosarcoma lines. A 
mean control value of 0.058 was recorded for fresh media alone indicating the 
Ab used did not cross-react with bovine C3 in tissue culture media.
Heterogeneous (parent) cell populations were also assayed for C3 secretion 
as described above. Use of heterogeneous (multi-cellular origin) populations 
increases the probability of the population containing C3-secreting cells. 
However, levels of C3/C3b/iC3b detected in these populations depends on 
the proportion of C3-producing cells in addition to amounts secreted per cell. 
Figure 6.13 shows a standard curve of known C3 concentrations with a 
minimum C3 concentration detection level of 20ng/ml. The absorbance values 
also shown in Figure 6.13 correspond to C3 concentrations below this level 
and substantiate the previous finding further suggesting that negligible or no 
C3, C3b or iC3b is present in tissue culture s/n incubated with the tumour 
cells over a 48 hour period.
6.4.3 RT-PCR characterisation of C3, CD55 and CD59 mRNA levels
Convincing data exist to support the over-expression of protective proteins on 
tumour cells in vivo e.g. CD55 (Varsano et al. 1998) and CD59 (Kuraya et al. 
1992). CD55 was not detected on fibrosarcoma surfaces either in clonal or 
parent lines. CD59 was detected only on C3'A lines, while ELISAs described 
above did not detect secreted C3 (or associated cleavage products) by clonal 
or parental lines. However, analysis of mRNA can provide a quantitative and
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Figure 6.12: Assessment of C3/C3b/iC3b by ELISA in cell culture supernatants
Mean absorbance levels were calculated from 3 clones per group following ELISA. Data 
shown represents mean ± SEM. Dashed line represents threshold for detection.
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Figure 6.13: Assessment of C3/C3b/iC3b by ELISA in parent cell culture
supernatants
96 well plates were coated with a monoclonal rat anti-mouse C3 Ab and incubated with 
purified C3 concentrations (panel A) or tissue culture supernatant from 3 
heterogeneous lines from each genotype (panel B). Supernatant was concentrated 10- 
fold prior to assay. Plates were washed before incubation with polyclonal rabbit anti­
mouse C3 Ab. Bound antibody was detected using HRPO-conjugated anti-rabbit IgG 
and visualised using an OPD preparation. Supernatant from each cell population was 
assayed in duplicate. Horizontal bars represent means of the 3 clones per genotype 
while horizontal dashed bar represents minimal detectable level of C3 20ng/ml.
208
highly sensitive measure of gene transcription regardless of protein 
expression. Detection of CReg or C3 mRNA could point to intra-cellular stores 
of these proteins which would be undetectable by the above methods. 
Assessment of mRNA levels for these proteins was undertaken via 
quantitative real-time PCR (RT-PCR) as fully described in Chapter 2. Briefly, 
mRNA was isolated from cell cultures and converted to cDNA via reverse 
transcription. Primers specific for CD55, CD59 and C3 were used to identify 
and amplify specific sequences. Included in the PCR procedure is a 
fluorescent dye (SYBR® Green) which is measured in real time following each 
amplification cycle allowing quantification of DNA concentrations. A 
preparation of fresh mouse liver was included as a positive control. 
Hepatocytes are known to synthesise C3 and express CD55 and CD59 
(Funabashi et al. 1994, Song et al. 1996). Each population tested was also 
assayed for amplification of a housekeeping gene (P-actin), known to be 
uniformly expressed in cells and used to normalise detected levels between 
samples. For each population and gene, a Ct (cycle threshold) value is 
produced and represents the number of cycles required for fluorescence to 
reach a pre-determined threshold. Included in the experiment are negative 
controls for C3 mRNA (C3''' lines) and CD55 and CD59 (CD55‘/\CD59'/' 
lines). These lines were used as a baseline and Ct values referenced against 
this value and used to calculate relative gene expression in each population.
Data shown in Figure 6.14 closely correspond with the flow cytometry and 
ELISA data described previously. Graph A shows no significant CD55 mRNA 
present in any clones, graph B shows CD59 mRNA present in C3'7' lines 
(p=0.008) only while no C3 mRNA was detected in any clones assayed (C). 
C3, CD55 and CD59 mRNA was detected at high levels in hepatocyte cells. 
Almost identical findings were observed following analysis of data from parent 
populations (n=3). These data are shown in Figure 6.15 and mirror the 
previous findings. Again, no CD55 or C3 mRNA was detected in any 
fibrosarcoma populations analysed.
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Figure 6.14: RT-PCR analysis of CD55, CD59 and C3 mRNA in clonal populations
mRNA was extracted from clonal cell populations or fresh liver sample. RNA was converted to 
cDNA via reverse transcription. Primer sequences specific for mouse CD55, CD59, C3 and p- 
actin were used to amplify sequences in presence of Sybr-Green fluorescent dye. Fluorescence 
levels per cycle were recorded and used to calculate C(t) values for each protein per cell line. 
Reference gene data (p-actin) was deducted and values expressed relevant to a population 
deficient in relevant gene. Data were analysed using a non-paired students t-test. * indicates a 
p-value <0.05
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Figure 6.15: RT-PCR analysis of CD55, CD59 and C3 mRNA in heterogeneous populations
mRNA was extracted from heterogeneous cell populations or fresh liver sample. RNA was 
converted to cDNA via reverse transcription. Primer sequences specific for mouse CD55, CD59, C3 
and p-actin were used to amplify sequences in presence of Sybr-Green fluorescent dye. 
Fluorescence levels per cycle were recorded and used to calculate C(t) values for each protein per 
cell line. Reference gene data (p-actin) was deducted and values expressed relevant to a 
population deficient in relevant gene. Data were analysed using a non-paired students t-test. * 
indicates p<0.05.
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6.5 in vitro sensitivity to complement
In order to assess the relative sensitivities of clones to C, a ‘killing’ assay was 
used based on classical pathway activation. Variation between populations in 
susceptibility to C-mediated lysis may highlight important differences between 
groups and provide useful indicators by which in vivo growth can be predicted 
or assessed. Cells were sensitised, incubated with various titres of C and 
treated with 4pg/ml propidium iodide (P.I.) solution. P.I. binds tightly to DNA 
strands and emits a strong fluorescent signal, detectable by flow cytometry. 
Only dead/dying cells with compromised cell membranes allow the passage of 
P.I. into the cell and alive/healthy cells do not exhibit fluorescence. The 
sensitising Ab used was a rabbit anti-mouse erythrocyte Ab and as depicted 
in Figure 6.16 binds to these tumour cell lines at high levels as detected by 
RPE-conjugated donkey anti-rabbit IgG Ab. However, despite using extremely 
high titres of a polyclonal sensitising Ab and neat mouse serum, negligible 
killing of clones could be detected. As shown in Figure 6.17, the maximal 
lysed population makes up just 2% of the entire cell count suggesting that 
these cells are resistant to C-mediated cytotoxicity or that the assay is 
ineffective. In order to verify the lytic capability of serum used in the assay, 
serum was also assayed for activity against sensitised mouse erythrocytes as 
shown in Figure 6.18. Erythrocytes were readily lysed by low doses of C as 
evidenced by haemoglobin release. This indicates that the serum is 
functionally active and that the Ab chosen is capable of activating the classical 
pathway.
Cell populations were observed to aggregate during the repeated wash/re­
suspend steps involved with the assay described above. Cells were observed 
to aggregate and required vigorous and lengthy shaking to re-obtain a single 
cell suspension. Fibrosarcoma cells are naturally adherent, while this 
observation may also be attributed to an effect known as agglutination 
whereby cells ‘clump’ together following Ab fixation. Consequently, an 
alternative assay was developed to determine C-susceptibility in which cells 
remained adherent to a surface throughout the protocol. Cells were grown to 
50-60% confluency on 6-well plates and loaded with calcein acetoxymethyl
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Figure 6.16: Binding of sensitising Ab to fibrosarcoma populations
Clonal populations of known genotypes were incubated with polyclonal rabbit anti­
mouse erythrocyte Ab. Bound Ab was detected using RPE-conjugated donkey anti- 
rabbit IgG. Red lines represent clonal populations incubated with secondary Ab 
only. One representative clone is shown from each group comprising three separate 
clonal lines.
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Figure 6.17: Propidium iodide staining of cells following CP activation
Cells were sensitised with 6.67% polyclonal rabbit anti-mouse erythrocyte antibody, 
before incubation with normal mouse serum at varying dilutions. Lysed cells were 
stained using propidium iodide and analysed using flow cytometry. Panel A, B and C 
depict cells treated with 10%, 50% and 100% rat serum. Region 1 (R1) contains cells 
staining positive for propidium iodine and represents ‘dead’ population.
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Figure 6.18: Haemolysis of mouse erythrocytes following CP activation
Erythrocyte cells were sensitised using 2% polyclonal rabbit anti-mouse Ab. Cells 
were washed and incubated with a range of mouse serum dilutions and 
haemolysis calculated by reference to 0% and 100% lysis values.
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ester (Calcein-AM). This compound is readily transported across plasma 
membranes where it is cleaved by cytosolic esterases to free calcein -  a 
fluorescent dye which is not membrane permeable. Cells were sensitised, 
washed and attacked in situ with titres of fresh mouse sera. Dye release was 
measured by recording fluorescence using 490nm excitation and 530nm 
emission filters, thus providing a quantitative assessment of cell death.
Figure 6.19 shows representative data from 1 clone from each genotype: WT, 
Clq"7', C3‘/_ and CD55'/'.CD59'/'. The graph depicts fluorescence following C- 
mediated lysis at a range of sera dilutions and provides a measure of calcein 
release proportional to the number of dead cells. Additionally, intact cells 
remaining impermeable and retaining calcein were treated with 0.5% 
detergent. This step released remaining calcein, fluorescence was again 
recorded to provide a measure of cells surviving C-attack. Fluorescent signal 
released by C-mediated lysis (bottom line) and signal released by detergent 
(top line) are plotted. Wells in which populations were previously exposed to 
high C titres exhibited lower fluorescence following detergent-mediated lysis. 
Combining these data allowed calculation of % lysis for each cell population 
whereby calcein released by C can be determined as a proportion of the total 
calcein release (C-mediated and detergent-mediated lysis combined). Data 
collected from clonal cell populations are presented in Figure 6.20. Graph A 
depicts % lysis data following treatment of populations with 0-100% mouse 
serum. Each curve represents one genotype with each following a similar 
pattern. The curves tended towards a maximal killing value (KmaX) value of 25- 
30% lysis with WT and C3'7' lines appearing to lyse less readily than C1q'/_ or 
CD55'/_. CD597'. However, the observed differences were slight while each 
population exhibited a high background lysis with ~18% lysis observed in 
each population following incubation with 1% BSA/ CFD i.e. in the absence of 
C. Figure 6.20B shows the same data following subtraction of background 
lysis from each fluorescence reading. Each curve corresponding to the 
populations tended towards a plateau i.e. threshold of lysis at a comparable 
value although the C3'/_ curve was peaked slightly lower and the WT curve 
reached a slightly higher value than that corresponding to C3'7' populations, 
higher standard errors were also observed in this group. Data shown in this
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Figure 6.19: Lysis of fibrosarcoma populations via calcein release assay
Cells were pre-loaded with calcein-AM and sensitised with 6.67% polyclonal rabbit anti-mouse 
erythrocyte Ab. Cells were washed and incubated with a range of mouse serum dilutions. 
Fluorescence of media was measured. Remaining cells were lysed by detergent and fluorescence 
re-measured. Complement mediated calcein release is represented by squares while detergent 
mediated release is represented by triangles. Fluorescence measured at 530nm.
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Figure 6.20: Complement mediated lysis of fibrosarcoma populations
% lysis values were calculated as a proportion of total calcein release. Data shown are mean 
values derived from duplicate assay of three clones per group. Data shown are 
representative of 2 separate experiments. Panel A represents raw lysis data, panel B 
represents data following subtraction of background lysis values.
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Figure suggest that, while lysis is increased according to serum dilution, C 
remains ineffective at lysing ceils in this system as evidenced by the low 
maximal percentage lysis values shown in Table 6.2.
WT C1q
COO CD551'.C o w ­
K m a x 22 ±9 19 ± 2 14 ±2 ' l l  ± 'I
Table 6.2: Calcein release assay
Maximal killing observed in 3 clonal populations per group. K^ ax refers to maximal killing 
possible. Mean ± SEM are shown.
The term Kmax refers to the threshold of killing i.e. the plateau reached by 
each trace, determined using GraphPad Prism software. These observations 
support data shown in Figure 6.17 suggesting that transformed fibrosarcoma 
cells are resistant to C mediated lysis.
6.6 C3b/iC3b deposition assay
Data described in the previous section outline difficulties in achieving lysis 
through C attack on fibrosarcoma lines generated through 3-MCA tumour 
induction. However, C activation and opsonisation is crucial to many immune 
and cellular responses as described in Section 1.2. As such, measurement of 
C3 activation products on cell surface can provide an additional parameter to 
assess the relationship between C and tumour cells of differing genotypes. A 
flow cytometric assay was optimised employing the sensitisation and C- 
activation steps as described above. Following incubation with a range of 
serum titres, cells were stained for the presence of activated C3 fragments 
deposited on surfaces by incubation with rat anti-mouse C3 mAb. Fixed anti- 
03 mAb was visualised using a donkey anti-rat secondary Ab conjugated to 
an Alexa-Fluor-594 fluorescent probe. Conventional thinking is that cells 
better protected against C, or with proficient mechanisms for cleaving or 
shedding 03 would be expected to have lower levels of C3 (and associated 
fragments) deposited on its surface. This could predict better survival in vivo.
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However, an alternative hypothesis is emerging whereby C3 activation and 
deposition may benefit cells through cellular activation mechanisms described 
in Section 1.12. In this assay, cells were treated with a maximum dose of 50% 
serum. This, as shown in previous section, will cause negligible cell death. 
Accurate analysis of data in this assay requires avoidance of cell death in the 
experimental populations as these events exhibit irregular forward and side 
scatter patterns and are not collected by the flow cytometer. It is also possible 
that dying cells may activate the classical (Taylor et al. 2000), MBL (Nauta et 
al. 2003) or alternative pathway (Xu et al. 2008). This activation by dead/dying 
cells could deposit further C3b/iC3b detectable in the assay and distort data 
collected. However, the short timespan of this experiment means that this 
effect is likely to be negligible.
Initial data shown in Figure 6.21 show MFI values following incubation of three 
clones from each of WT, C lq '7', C3'A and CDSS'^-CDS^* groups with Ab 
specific for C3b/iC3b. Deposition of C3 fragments followed a similar pattern 
on each cell line whereby no C3b/iC3b was detected in the absence of C. 
Deposition levels were observed to increase corresponding with increased 
serum concentration. In each case, deposition tended towards a maximal 
level between 2000-3000 MFI units. In most cases the three clones of each 
genotype behaved consistently though two clones in CDSS'^.CDSQ'7' group 
activated C to a lesser extent than others. However, it is unclear from these 
data whether differences in C3b/iC3b deposition are caused by differential 
binding of the sensitising Ab rather than C sensitivity. The levels at which the 
Ab binds could be causing or masking potential differences between clones 
by activating C to different extents in different groups. As such, cells were 
assayed for binding of pAb via incubation with 5% sensitising Ab followed by 
detection using a donkey anti-rabbit secondary Ab conjugated to an Alexa- 
Fluor-594 fluorescent probe. Figure 6.22 illustrates amounts of fixing Ab 
bound per cell line with a clear difference observed between WT and the other 
groups. WT clones were shown to exhibit a significantly smaller shift in MFI 
than C1q'/_ (p=0.005), C3‘'‘ (p=0.003) and CD55-'-.CD59''' (p=0.05). Different 
levels of bound sensitising Ab is likely to skew measurement of C3 deposition
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Figure 6.21: C3b deposition on clonal fibrosarcoma populations
Three clonal cell lines of each genotype were sensitised using 5% polyclonal rabbit anti-mouse 
erythrocyte Ab. Cells were washed before incubation with a range of mouse serum dilutions. C3b 
deposition was assessed via flow cytometry. Cells were stained with rat anti-mouse C3, and bound 
Ab visualised using RPE-conjugated donkey anti-rat IgG. Median fluorescence intensities are 
shown.
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Figure 6.22: Binding of sensitising Ab to fibrosarcoma populations
Clonal populations of WT, Clq'7', C3 and CDSS^ .CDSST7' genotypes were incubated with 
polyclonal rabbit anti-mouse erythrocyte Ab. Bound Ab was detected using RPE-conjugated 
donkey anti-rabbit IgG. Control cells stained with secondary Ab only were used to calculate 
median shift in fluorescence. Three clones are shown. Data was analysed compared to WT 
using the students unpaired t-test.
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in subsequent experiments and prevents accurate comparison of C3 
deposition between groups.
In order to sensitise all clones to the same extent, a range of Ab dilutions was 
used to bind each clonal line and a sample of the population stained for 
presence of sensitising Ab as previously described. Figure 6.23 shows highly 
consistent sigmoidal curves and indicates that populations of genotypes bind 
pAb in different ways. However, virtually no variation was observed between 
clones of the same genotype. Particularly noticeable was the maximal amount 
of pAb bound in each group with maximum MFI shifts showing a clear trend: 
WT (-550) < CD55^I^ .CD59 ,^^  (~ 650) < C lq''’ (-750) < C3‘/- (~ 1000).
A change in MFI value equating to approximately 500 was selected to achieve 
significant but not maximal sensitisation on each clone. Selecting serum 
dilutions eliciting similar amounts of Ab binding allowed normalisation of the 
experiment and significantly reduced the effect of Ab binding as a variable. 
The dilution of sensitising Ab corresponding to this level of Ab fixation was 
selected in each clonal population, as detailed in Figure 6.24. The remaining 
cells were then incubated with a range of serum dilutions, before staining for 
C3b/iC3b as described. Differing clonal lines of the same genotype were 
found to require only marginally different Ab dilutions to achieve equivalent 
binding (WT and CD55'1'.CDSd'*' groups only showed any difference). 
Discrepancies between groups were noticeably larger with differing genotypes 
requiring differing Ab dilutions. Figure 6.25 depicts C3 deposition levels 
increasing according to serum concentration on clones each fixed with similar 
amounts of sensitising Ab. As previously, clones tended towards a plateau of 
maximal C3 deposition with a maximal shift of approximately 2000 MFI units 
observed for each clone, in order to accurately compare levels of C3b/iC3b 
deposition on each cell population, an estimation of Effective Concentration 
50% (EC50) was made by determining concentration of serum required to 
cause an MFI shift of 1000 (50% of maximum). As shown in Figure 6.26 there 
were clear differences observed between groups while EC50 values were 
found to be consistent within each group. This intra-group consistency 
contributes to the statistically significant differences observed between WT
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Figure 6.23: Sensitising Ab binding to clonal fibrosarcoma populations
Three clonal cell lines of each genotype were sensitised using a range of dilutions of rabbit anti­
mouse erythrocyte Ab dilutions. Cells were washed before incubation with a RPE-conjugated 
donkey anti-rabbit IgG. Control cells stained with secondary Ab only were used to calculate mean 
shifts in MFI. Cells were assayed in duplicate with data from three clones shown per graph.
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Cell Line Dilution A MFI
WTc 1/15 444
WTh 1/15 481
WTj 1/10 499
Clq_/'e 1/20 469
Clq’^ i 1/20 532
Clq*j 1/20 525
C3_/'d 1/25 529
C3v'e 1/25 516
C3v g 1/30 500
CD55'/'.CD59‘/'d 1/20 446
CD55*.CD59,/j 1/20 515
CD55/‘.CD59/ k 1/20 488
Figure 6.24: Selected dilution of sensitising Ab per clonal line
Clones were incubated with a range of dilutions of rabbit anti-mouse erythrocyte, 
washed and stained using an RPE-conjugated donkey anti-rat secondary antibody. 
Appropriate dilutions of sensitising antibody were chosen for each clone yielding an 
approximate shift in MFI of 500 as compared to secondary only control.
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Figure 6.25: C3b deposition on populations with normalised sensitisation
Three clonal cell lines of each genotype were sensitised using rabbit anti-mouse erythrocyte 
pAb. Cells were washed before incubation with a range of mouse serum dilutions. C3b 
deposition was assessed via flow cytometry. Cells were stained with rat anti-mouse C3, and 
bound Ab visualised using RPE-conjugated donkey anti-rat IgG. Median fluorescence 
intensities are shown. Cells were assayed in duplicate with data from three clones shown per 
graph.
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Figure 6.26: EC50 analysis of C3b deposition on fibrosarcoma cells
Dilutions of sera required to elicit half maximal C3b deposition (EC50) were calculated 
for each of three clones per genotype. Data shown include mean ± SEM of three clones 
and were analysed using the unpaired students t-test.
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clones and C1q'/' (p=0.037), C3’'’ (p=0.001) and CD55-'\CD59'/' (p=0.001) 
with WT requiring a significantly higher dose than each other group to evoke 
the same level of C3 deposition. Deficiency in CD55.CD59 appears to render 
populations more susceptible to C3 deposition than WT counterpart, as would 
be expected due to impaired C regulatory mechanisms. However, reasons 
underpinning the increased susceptibility of C1q and C3 deficiencies are less 
obvious yet remain significant.
6.7 in vivo growth of selected fibrosarcoma clones
Key experiments planned for this chapter involved investigation of the 
incidence / rate of tumour growth in vivo exhibited by tumour cell lines with 
and without the ability to synthesise C1q, C3 or express the CRegs CD55 and 
CD59. However, due to time constraints, a full investigation utilising these cell 
lines was not possible. A preliminary analysis of a potential role for C3 
synthesis and secretion by tumour cells in vivo was performed. Data shown 
previously (Figures 6.11 and 6.14) suggests that WT cells do not secrete or 
synthesise C3 in vitro. However, cells derived from a WT animal possess the 
C3 gene, and may be stimulated to secrete C3 into the tumour micro­
environment in vivo. In contrast, C3'7‘ tumours do not have the gene encoding 
C3 and are unable to synthesise the protein. Three WT and three C3'7' lines 
were selected which exhibited similar growth kinetics in vitro (as shown in 
Figure 6.6). One observed difference between WT and C3‘/_ lines is the 
consistent expression of CD59 on C3'/_ clones (illustrated in Figure 6.8). This 
is expected to confer enhanced protection from MAC deposition and lysis to 
these cells compared to WT cells lacking CD59 while immunological roles for 
the CD59 protein may also be significant. Re-inoculation of these cells back 
into WT and C3V' host animals has the potential to elucidate differences in C 
susceptibility in vivo and allow determination of the source of any C3 
deposited on these tumours i.e. whether C3 detected via 
immunohistochemical staining is derived from host immune system or locally 
produced by tumour cells (see Table 6.1).
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Clonal fibrosarcoma lines were generated and selected as described above. 
The three clonal lines of WT and C3'7' genotype were re-inoculated into 
groups of 4 WT or C3‘7" as previously described in Chapter 4. However, the 
majority of mice did not develop a tumour. Several tumours were observed 
but arose later than expected and exhibited atypical growth characteristics. 
Figure 6.27 illustrates poor tumour incidence in WT animals of three WT and 
three C3'7' clonal lines. Additionally, the K6 fibrosarcoma line was included 
and also found to exhibit poor tumour take. These lines were injected 
simultaneously into C3'7' hosts with similarly poor tumour incidence observed. 
This suggests that the lack of growth is not caused by CDC or C3-mediated 
opsonisation. As previously described in Chapters 3 and 4, the K6 tumour line 
is known to have high incidence and grow aggressively in both WT and C3'7' 
mice. However, these experiments were performed approximately 18 months 
after the observations in Chapter 4 and yielded markedly different results with 
<40% tumour incidence observed, compared to ~90% in Chapter 4. Despite 
repeated attempts to achieve typical tumour incidence following K6 
inoculation, mice appeared resistant to tumour growth and incidence 
remained low. Figure 6.27 incorporates collated data from several separate 
experiments and illustrates the poor growth rates observed following 
inoculation of each clonal line. There is insufficient tumour incidence to form 
any meaningful conclusions from these data. It appears that external factors 
were preventing tumour incidence and distorting observations. Although K6 
tumour growth remained inconsistent and with uncharacteristically low 
incidence, 9 out of 24 (WT and C3'7' combined) mice did develop a tumour. 
This is a higher proportion than any other clonal line, the next highest 
incidence was observed in a WT clone (3 out of 24).
The inability to grow tumours at this time corresponded with the 
commencement of building works close to the animal housing facility. It is 
possible that raised stress levels and an altered immune response contributed 
to the irregular tumour growth observed. Whilst numerous factors are likely to 
impact on immune responses, noise levels have been linked to 
immunomodulation of T-lymphocytes (Monjan et al. 1977), and macrophages 
(Spehner et al. 1996). The finding that growth was not restored in C3'7' host
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WT host WTc WTh WTj C3d C3e C3g K6
Mice inoculated 16 12 12 8 8 8 16
Mice developing 
tumour
2 1 0 1 0 0 6
CZ'1' host WTc WTh WTj C3d C3e C3g K6
Mice inoculated 8 8 4 4 4 4 8
Mice developing 
tumour
1 0 0 0 0 0 3
Figure 6.27: Tumour incidences following inoculation of mice with fibrosarcoma cells
Cells were inoculated in 100 i^L PBS sub-cutaneously on the mouse flank. Male WT and C3'/_ 
mice were inoculated with 10s cells of various WT and C3'1' clonal fibrosarcoma populations. 
Number of mice developing a palpable tumour is indicated. Data is pooled from 3 separate 
experiments.
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animals suggests that the effect is unlikely to be mediated by C whereby only 
the very early stages of CP or MBL pathway activation are possible. In order 
to ensure that cells were free of mycoplasma and endotoxin contamination, all 
populations were screened and found to be mycoplasma negative and 
endotoxin-low. As an additional control, K6 cells were inoculated into Rag'7' 
mice simultaneously with WT mice. Rag'7' mice possess no mature B-cells or 
T-cells and thus exhibit severely impaired immune responses (Mombaerts et 
al. 1992). These data are shown in Figure 6.28 and illustrate rapid tumour 
growth and 100% incidence in Rag'7' mice while WT incidence remained low. 
This observation suggests that the cells are able to grow normally without 
immune pressures (B-cell/T-cell responses) and further suggests a link 
between immune responses and tumour clearance in this model.
Following a period where tumour growth was of low incidence and erratic, 
growth of K6 populations in WT mice was observed to be close to normal 
levels (6 mice developing tumours from 8 inoculated). Subsequently, 
heterogeneous (parent) fibrosarcoma populations were inoculated into WT 
and C3'7' male mice and tumour growth monitored. These lines were expected 
to provide a more robust model for examination of growth characteristics due 
to positive selection of cells most suitable for in vivo growth i.e. least 
immunogenic. Two WT and two C3'7' non-clonal populations were inoculated 
into both WT and C3'7' hosts. Tumour volumes were measured over a one 
month period following inoculation and are displayed in Figure 6.29. As can 
be seen, tumour incidence was higher than previously recorded (88% 
incidence in pooled data). Growth curves exhibited the conventional 
exponential characteristic and suggested that tumour growth had returned to 
previously observed and consistent kinetics. Few comparisons can be made 
from data of this type, however, a visual trend was identified whereby C3'7' 
cells formed a palpable tumour in WT mice (Panel B) more rapidly than the 
same cells inoculated into C3'7' host mice (Panel D) i.e. tumours arose at an 
earlier timepoint in WT mice. However, incidence data displayed in Figure 
6.30 do not support this observation and while a trend to this effect is 
observed, the p-value of 0.643 indicates that the effect is not statistically 
significant following analysis using the log-rank statistical test. Corresponding
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Figure 6.28: Inoculation of K6 cells into WT and Rag1' male mice 
Inoculation of 105 K6 cells into WT (panel A) and Rag‘/_ (panel B) mice. Mice were injected 
on day 1 with lOOpL tumour cells on the flank and monitored regularly with tumour sizes 
measured. Each line is representative of one individual mouse. Mice were sacrificed when 
tumour reached 200mm3. Each group consists of 4 mice.
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Figure 6.29: Inoculation of heterogeneous fibrosarcoma populations into WT and C3'/* mice 
Inoculation of 105 heterogeneous cells into male mice. Mice were injected on day 1 with 10O^ L 
tumour cells on the flank and monitored regularly with tumour sizes measured. Each line is 
representative of one individual mouse. Mice were sacrificed when tumour reached 200mm3.
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Figure 6.30: Tumour incidence in WT and CZ’1' mice
Tumour cells were inoculated into WT (bold lines) and C3'7' male (dashed lines) 
mice and tumour incidences noted. Inoculation of WT cells (graph A) and C3'7' cells 
(graph B) are shown. Data were analysed using the logrank statistical test.
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fdata showing incidence of WT tumours in WT and C3'7' mice revealed no 
difference between the groups (p=0.932). Survival data derived from the same 
tumour volume measurements is shown in Figure 6.31 and suggested a weak 
trend towards enhanced tumour growth in WT mice compared to C3'7'. 
However, this trend is not statistically significant following inoculation of either 
WT (p=0.215) or C3'/_ cells (p=0.159). Data were further analysed for 
differences in WT tumour incidence and survival in WT and C3'7' hosts. These 
data are shown in Figures 6.32 and 6.33 and found no difference in terms of 
incidence (p=0.832) or survival (p=0.502). Corresponding data following 
inoculation of C3‘7' is also included on the above Figures with similar findings 
observed for incidence (p=0.264) and survival (0.671).
Excised tumours were sectioned and stained for intracellular C3 stores or 
C3b/iC3b deposition by immunohistochemistry (Figure 6.34). Following 
quantitation of these data, comparable deposition was observed on both WT 
and C3‘7’ tumour cells inoculated into WT hosts (Figure 6.35). Conversely, no 
C3/C3b/iC3b presence was detected on the same WT and C3'7' cell lines 
inoculated into C3’7' hosts. This observation strongly suggests that C 
deposition observed on these cells is derived from the host and is not tumour 
derived as evidenced by the lack of deposition on WT cells in a C3'7' host. 
This is consistent with the in vitro lack of secreted C3 or intracellular C3 
mRNA described above. It is possible that tumour cells do secrete C3 or 
activation products but that an initial nidus of C3b deposition is required to 
kick-start this mechanism. However, a more likely conclusion from data 
described in this Chapter is that neither WT nor C3‘7' fibrosarcoma cells 
generated in this model synthesise or secrete C3 in vitro or in vivo.
Further immunohistochemical analysis was performed by staining for the 
presence of C9 in these tissues (Figures 6.36 and 6.37), providing a marker 
for terminal pathway activation and MAC deposition. These data closely 
resembled the previous findings for deposition of C3b/iC3b with significant 
levels of C9 present in WT hosts, but none observed in C3'7' hosts further 
supporting the findings above and also providing evidence against C9 
synthesis by the fibrosarcoma cells since C3'7' cells cannot generate C9 by C
235
fA
100
15
>
»
2 5
0
0
P=0.215
10
Days post inoculation
3 0
B
100
7 5 -r t
>
£
3
CO
2 5 -
0 10 20 3 0
Days post Inoculation
Figure 6.31: Percentage survival in WT and C3'/' mice
Tumour cells were inoculated into WT (bold lines) and C3',m (dashed lines) male mice 
and survival data noted. Inoculation of WT cells (graph A) and C3-/- (graph B) cells 
are shown. Data were analysed using the logrank statistical test.
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Figure 6.32: Tumour incidence in WT and C3*7' mice
Tumour cells were inoculated into WT (graph A) and C3'1' male (graph B) mice and 
tumour incidences noted. Inoculation of WT cells (bold lines) and C3_/' cells (dashed 
lines) are shown. Data were analysed using the logrank statistical test.
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Figure 6.33: Percentage survival in WT and C3"'' mice
Tumour cells were inoculated into WT (graph A) and C3'7' (graph B) male mice and 
survival data noted. Inoculation of WT cells (bold lines) and C3-/- cells (dashed lines) 
are shown. Data were analysed using the logrank statistical test.
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Figure 6.34: C3 deposition on heterogeneous fibrosarcoma populations
Heterogeneous WT cell populations were inoculated into WT (A) and C3_/' (C) male mice. 
Heterogeneous C3'/_ cell populations were inoculated into WT (B) and C3‘/_ (D) male mice. 
Excised tumours were sectioned and stained for C3/C3b/iC3b presence by incubation with 
a rat anti-mouse C3 mAb and detected using Alexa Fluor-594 conjugated donkey anti-rat 
IgG secondary Ab. Panels shown are representative of 8 sections per tumour, from 4 
separate tumours per group.
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Figure 6.35. Immunohistochemical analysis of C3b/iC3b deposition
Percentage area stained positive for C3b/iC3b deposition was assessed using Image Pro 
Analyser software, 8 frames were assessed per tumour with 4 tumours per group used. Data were 
analysed using a 2 tailed, unpaired t-test. * indicates p-value <0.05.
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Figure 6.36: C9 deposition on heterogeneous fibrosarcoma populations
Heterogeneous WT cell populations were inoculated into WT (A) and C3'/_ (C) male mice. 
Heterogeneous C3'A cell populations were inoculated into WT (B) and C3'/_ (D) male mice. 
Excised tumours were sectioned and stained for C9 presence via incubation with rabbit anti­
rat C9 and Alexa-fluor-594 conjugated goat anti-rabbit IgG. Panels shown are representative 
of 8 sections per tumour, from 4 separate tumours per group.
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Figure 6.37. Immunohistochemical analysis of C9 deposition
Percentage area stained positive for C9 deposition was assessed using Image Pro Analyser 
software, 8 frames were assessed per tumour with 4 tumours per group used. Data were 
analysed using a 2 tailed, unpaired t-test. * indicates p-value <0.05.
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activation, but fibrosarcoma cells have been shown to synthesise and secrete 
C9 (Garred et al. 1990).
6.8. Discussion
Clonal fibrosarcoma lines were generated In order to provide homogeneous 
populations with consistent and reproducible characteristics both in vitro and 
in vivo. The cloning procedure used gave rise to uniform populations in terms 
of CD140a expression. This molecule represents a useful marker for 
fibrosarcoma phenotype and was expressed in all cell lines analysed despite 
reported down-modulation of such antigens following 3-MCA tumour induction 
(Kopp et al. 1995, Schreier et al. 1988).
It was considered necessary to generate homogeneous populations in order 
to attain consistent in vitro characteristics such as proliferation rate and C- 
susceptibility and to allow comparison between lines. This allowed selection of 
lines which behave consistently and are therefore more likely to yield reliable 
results. Expression of CReg was also shown to be consistent between clones 
of the same genotype.
Therefore, clonal lines of each genotype (WT, C1q'7', C3'/_ and CD55'/'.CD59‘/‘ 
) were assayed for in vitro proliferation rates. The use of Alamar Blue as a 
measure for proliferation provided a reproducible comparator of growth 
kinetics on cell populations. From these data, lines exhibiting anomalous 
growth curves were discarded and 3 comparable clones selected from each 
group. Data displayed on the proliferation graphs were consistent with 
expected growth patterns showing a lag, log and stationary phase. Each cell 
line was tested in triplicate and data shown are representative of 2 separate 
experiments. The lack of variation observed within the same line further 
supports the use of the Alamar Blue proliferation assay for this purpose. 
Three clones displaying consistent and ‘average’ growth patterns were 
selected from each group, clones deficient in C1q-/-, C3-/- and CD55-/-.CD59- 
/- were then re-analysed and compared to clones from the WT group. All 12
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selected clones grew comparably and reproducibly in vitro when re-analysed 
in the same experiment at the same time (Figure 6.6).
All 12 clones were shown to express high levels of Crry, this is consistent with 
post-excision staining of MCA-induced tumours as shown in Chapter 5. This 
molecule is ubiquitously expressed by murine cells and has been shown to 
enhance tumour growth in a rat breast cancer model (Caragine et al. 2002). 
Additionally, enhanced anti-tumour responses have been observed following 
blockade of Crry (Ohta et al. 2004, Gelderman et al. 2004). Significant 
expression of Crry is expected on these tumour lines and provides an 
effective control mechanism against early stage C deposition and C-mediated 
lysis. Despite being generated in a host lacking a functional C system and 
expressing CD59, C3'7’ cells were shown to express comparable levels of Crry 
to those generated from other genotypes.
Lack of CD55 expression was also consistent across all 12 clones analysed 
with no protein detected on cell surfaces. Mouse erythrocytes were used to 
control for binding of MD1, a rat monoclonal anti-mouse CD55 Ab and were 
found to exhibit a significant shift in fluorescence. The lack of CD55 
expression observed is consistent with data described in Chapter 5 whereby 
no CD55 expression was observed by post-excision analysis of fibrosarcoma 
populations. This protein is also known as ‘Decay Accelerator Factor’ (DAF) 
and serves to enhance the rate of C3 convertase decay. The complete lack of 
CD55 expression on fibrosarcoma cells examined in this thesis is an 
interesting observation given the propensity of many tumour cell types to 
over-express CRegs. However, the observed presence of the murine specific 
CReg Crry may be significant with this protein functioning in a similar fashion 
to CD55. Thus, CD55 may be of more relevance in human tumour models 
than in mice.
A clear difference in CD59 expression was observed with C3_/' lines shown to 
express this terminal pathway CReg. Cells of WT, C1q_/' and CD55 /*.CD59'/' 
genotypes did not express any CD59. As described in Chapter 5, WT, C1q'A 
and C3_/' tumours do express low levels of CD59 in vivo. However, this
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expression was not conserved in the three clonal lines selected from WT and 
C1q'A tumours and indicates that CD59 expression is lost by these cell lines 
following culture in vitro. The observation that CD59 expression was not lost 
in G3'/_ lines, and was conserved in all three clones, may suggest a more 
important role for this protein on C3"7" tumours. This is unexpected since host 
mice were lacking in C3 and have no capacity to activate the alternative or 
terminal pathway with only the initial activation steps of the classical pathway 
possible. Tumour populations generated in C3'7' mice did not stimulate MAC 
deposition (whereas MAC was deposited on WT, C1q_/‘ and CD55‘/'.CD59'/' 
tissue), yet these C3'/_ tumours were the only populations shown to conserve 
CD59 expression following in vitro culture and cloning. A number of roles for 
the CD59 protein outside of C regulation have been reported. These include 
modulation of T-cell (Deckert et al. 1995), NK-cell (Omidvar et al. 2006) and 
neutrophil (van den Berg et al. 1995) responses. Such roles are described in 
detail in Chapter 1.7.2 and are generally attributed to CD59 expression on the 
immune cells rather than targets although further investigation is necessary to 
determine whether conserved CD59 expression by C3_/‘ fibrosarcoma cells is 
related to the lack of C3b and MAC deposition during generation of the parent 
populations in vivo.
These data were supported by investigation of mRNA levels for CD55 and 
CD59 in fibrosarcoma populations. Only hepatoctyes were found to contain 
CD55 message, while hepatocytes and C3_/‘ populations were shown to 
contain CD59 message in both clonal (p=0.007) and heterogeneous lines 
(p=0.040). These findings support flow cytometry data and appear to rule out 
the possibility of CReg being stored intra-cellularly (Rowan et al. 1998) 
(Hatanaka et al. 1998), released in soluble form (Jurianz et al. 2001), or 
secreted on tumour-released exosomes in vitro (Clayton et al. 2003). in vitro 
characteristics were conserved in the clonal lines and consistent with those of 
the parent populations in each case for each of the parameters assessed in 
this Chapter.
Fibroblastic cells have been reported to synthesise C3 in vitro (Katz et al. 
1989). The in vitro secretion of C3 by malignant melanoma cells has also
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been reported with 350ng detectable by ELISA following incubation of s/n with 
106 cells over a 24 hour period (Jean et al. 1997). However no C3 secretion, 
or presence of activation products was detected in culture medium incubated 
with any of the clonal or parent lines tested in this Chapter. A concentration of 
15ng/ml and 20ng/ml (in 100pL) purified C3 was detectable in assays shown 
in Figures 6.11 and 6.13. The observation that s/n contained no detectable 
C3/C3b/iC3b following 10-fold concentration suggests that the cells are not 
secreting C3 in vitro. These data alone are not sufficient to determine the 
capacity of these cells to secrete C3. Whilst the cells tested may not 
synthesise or secrete this protein into s/n, it is possible that C3 is maintained 
in intra-cellular stores ready for secretion following an in vivo stimulus. 
Alternatively, C3 may only be synthesised following Interleukin stimuli such as 
IL-1 (Katz and Strunk 1989), IL-6 (Katz et al. 1989) and IL-13(Katz et al. 1995) 
as previously reported in fibroblasts. The lack of C3 message as assessed by 
RT-PCR appears to rule out the possibility that C3 is stored intra-cellularly in 
vitro. This technique is regarded to be highly sensitive although negligible C3 
mRNA was detected in any of the clones tested. The significant amounts of 
C3 message found in liver cells confirms the ability of this technique to detect 
C3 message and that hepatocytes synthesise C3.
Susceptibility to C attack may be a key characteristic relating to the behaviour 
of these cell lines in an in vivo setting. Whilst data in Chapter 5 illustrate 
evidence of C activation and targeting to tumour cells, it is extremely difficult 
to assess contributions of C to killing in vivo. However, the in vitro sensitivity 
of these clones provides a useful indicator of likely scale of C attack in vivo. 
Whilst tumour cells generated in this model have effective basal resistance to 
C (through expression of Crry), investigation of C-susceptibility in different 
lines can provide clues as to possible induced mechanisms of C resistance. 
These cellular activation mechanisms are described fully in Section 1.12 and 
may be present in one or more of the genotypes generated in this model. 
Such mechanisms are not well understood, however, activation of a protein 
kinase pathway has been shown to lead to Ca2+ influx (Morgan and Campbell 
1985), protein activation (Kraus, Seger and Fishelson 2001) and increased 
protein (Reiter, Ciobotariu and Fishelson 1992) and lipid (Ohanian and
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Schlager 1981) synthesis following C deposition. These cellular activation 
events may contribute to increased proliferation or enhanced resistance to 
further C attack.
A potent obstacle to tumour immunotherapy is the poor C activating capacity 
of the majority of anti-tumour antibodies (Wang and Weiner 2008). In 
addition, nucleated cells are adept at removing bound Ab from their surfaces 
either by internalisation (Mariani et al. 1989), or shedding (Campbell, 1985). 
This represents an effective mechanism for removal of Ab from tumour cell 
surfaces and thus reduces the effects of Ab-dependent cellular cytotoxicity 
and C activation through CP. In order to elicit a substantial C attack on the 
cloned fibrosarcoma lines, a polyclonal rabbit anti-mouse erythrocyte Ab was 
used. This Ab binds a multitude of mouse antigens shared by erythrocytes 
and tumour cells as evidenced by the considerable shift in fluorescence 
observed on all tumour types in Figure 6.16. However, despite high titres of 
C-fixing Ab, negligible killing was observed by PI staining of DNA in lysed 
cells. Neat mouse serum was unable to cause significant cell death in tumour 
cells despite being shown to readily lyse sensitised erythrocytes. Nucleated 
cells are known to be significantly more resistant to CDC (Ohanian, 1981). 
However, the complete lack of lysis observed may be indicative of enhanced 
C-resistance of tumour cells over non-transformed cells. This could be tested 
by the use of non-tumour nucleated cells e.g. fibroblasts. One problem 
associated with this technique was the repeated settling and re-suspending of 
cells, leading to aggregation and consequently limiting tumour cell surface 
available for deposition. A rat monoclonal anti-mouse Epcam Ab against a 
common tumour antigen, and rat anti-mouse CD140a fibroblast marker were 
both examined as potential sensitising antibodies but evoked no C3 
deposition or lysis (data not shown).
Further studies using a calcein release assay allowed a more effective 
analysis of C-susceptibility in clonal cell lines. Cell death in this assay was 
again limited by the strong resistance to C-mediated killing. However, 10-15% 
of cells were lysed using this method. Cells were sensitised and treated with 
high doses of C in situ with dye release measured. Lysis of remaining cells
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was achieved by treatment with detergent and used to generate killing curves 
based on percentage lysis. Despite cells remaining adherent throughout the 
experiment, a relatively high background lysis was observed in the absence of 
C. Background lysis values were subtracted from other dilutions to give an 
accurate estimation of C-mediated killing. The observed result that C3'/_ cell 
lines appeared less susceptible to C-mediated lysis is likely due to the 
expression of CD59 conferring ability to regulate the terminal pathway and 
block assembly of the MAC. This is evidenced by the lower Kmax value 
observed for these populations. Values for C1q'y' and CDSS'^.CDS^7' 
populations were also lower than WT, but were not as effectively protected as 
C3‘/_ lines. This experiment is also influenced by differing levels of sensitising 
Ab bound by these cells.
As described in Chapter 1, the abilities of CReg proteins to inactivate C3b and 
dissociate C3 convertases are highly significant for protection against C. 
Levels of C3b deposition can therefore provide a useful indication of C attack 
with increased deposition likely to correlate with increased C activation and/or 
reduced resistance capabilities. Detection of deposited C3b/iC3b was noted 
on all clones in a dose dependent manner, with maximal C3 deposited 
following incubation with 50% serum in all cases. The high MFI values at such 
concentrations indicated significant amounts of C3b/iC3b deposited but, as 
previously shown, these cells were not killed meaning that the cells remain 
intact even with large amounts of C3 products deposited on their surfaces. 
This observation is important to the hypothesis that tumour cells may in fact 
be stimulated by C deposition and exhibit enhanced proliferation or 
progression following a sublytic attack. Numerous cellular events are 
associated with both C3b and MAC deposition and are described fully in 
section 1.12. Thus the deposition of C fragments throughout these 
experiments may actually strengthen tumour cells, rather than just failing to 
cause lysis.
It is important to note that the rat anti-mouse C3 Ab used in this assay reacts 
with C3, C3b and also iC3b (including the breakdown fragment C3dg). The 
native C3 protein cannot bind to cells and requires cleavage through initial
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activation of the AP, MBL pathway or, as in this assay, CP. Following initial 
C3b deposition, both the classical and alternative C3 convertases are 
involved with further deposition and amplification of the C response. iC3b is 
an ‘inactive’ product of factor I (fl) mediated cleavage and cannot contribute to 
continuation of the C pathway. Despite inactivity in terms of C-activation, iC3b 
remains an important molecule in terms of its role as an opsonin in vivo with 
the ability to contribute to immune recognition and clearance. Factor I is a 
serum protein and is a co-factor to numerous CReg (as described in Chapter
1). fl has been found to be secreted by fibroblasts (Vyse et al. 1996) and may 
be contributing to cleavage of C3 and protection from CDC in this model. 
Deposition of C3b and cleavage into inactive fragments is likely to be a key 
mechanism contributing to effects observed in Chapters 4 and 5 whereby C 
appeared to drive tumour proliferation. Persistent low-level C activation and 
C3b deposition may stimulate metabolic pathways which trigger proliferation 
and boost tumour growth. Rapid cleavage to inactive C3b breakdown 
products would protect cells from C-mediated lysis.
As evidenced by the data shown in Figure 6.22, clones of different genotypes 
were sensitised to different extents by the pAb. Relatively little variation was 
observed within each group with clones of the same genotype shown to bind 
similar levels of Ab. The difference was found to be statistically significant in 
each case. It is interesting to note that WT clones bind less Ab than each of 
the other groups since tumours were more readily induced in WT mice as 
described in Chapter 5. A possible explanation for this could be provided by 
enhanced classical pathway activation in WT tumours, stimulated via 
increased binding of Ab. However, flow cytometry and immunohistochemistry 
data failed to support this hypothesis although further investigation into the 
precise fragments deposited on different tumours is needed to fully quantify C 
activation and inactivation of deposited fragments by these tumours
Significant levels of C3b/iC3b were detected on each line assessed via flow 
cytometry. However, as described above, few cells are consequently lysed 
through this C activation. It seems likely that inactivation of C3 is a critical C 
regulatory protective mechanism of these cells as only CD59 is able to
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regulate the terminal pathway with the majority of cells shown not to express 
this protein but remain highly resistant to CDC. Analysis of C5a could be used 
to determine initiation of the terminal pathway in this assay. A fair assessment 
of susceptibility to C attack on cell surfaces requires ‘normalised’ levels of 
sensitising Ab. As such, cells were treated with a range of sensitising Ab 
dilutions. Populations exhibiting equivalent levels of bound pAb were selected 
and incubated with serum. Calculation of EC50 values for clones allowed 
accurate comparison of susceptibility to C3b/iC3b deposition in this model. 
The data demonstrate statistically significant differences between groups, not 
evident from non-normalised data. The finding that WT clones required higher 
titres of serum to elicit equivalent levels of C3b/iC3b deposition is unexpected 
and does not easily fit with previous data showing the same populations to be 
marginally more susceptible to C-mediated killing. C3'/_ and CDSS '^.CDSQ'7' 
clones were least susceptible to C3b deposition. The observed differences in 
C3b levels could be explained by differing proportions of C3b and iC3b, both 
bound by the Ab used in this assay. WT cells may have less total C3b/iC3b 
deposited than other clonal cell types though if a greater proportion was C3b 
(as opposed to inactive form), this could still contribute to enhanced killing. 
Further study of C3 fragments present on cell surfaces would be needed to 
investigate these hypotheses.
Although exhibiting effective resistance to C, and strong growth in vitro, these 
clones were unable to survive in vivo and were effectively cleared by both WT 
and C3'/_ host immune systems. Due to the favourable pro-tumour 
environment which existed in the original tumour, these clonal lines may be 
poorly adapted to grow in a naive mouse i.e. clones may be ‘lethally 
immunogenic’ and be cleared by immune responses. As discussed in Chapter 
1, inflammation, cytokines and angiogenesis are key to the tumour micro­
environment and contribute to tumour progression. These contributory factors 
help create a suitable environment to drive tumour survival and proliferation. 
In the absence of these factors, cultured and cloned lines may not survive. 
However, in order to rule out environmental factors, K6 was inoculated 
simultaneously into mice and found to exhibit different growth patterns to 
those observed in Chapter 4. Observed incidence was poor and inconsistent
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under the same experimental conditions, endotoxin and mycoplasma 
contamination was ruled out suggesting that physiological changes in host 
mice were causing unreliable data. K6 tumour take was drastically reduced 
from ~90% (January 2006- April 2008) to ~40% (June 2008-November 2008) 
with tumours also arising later and exhibiting abnormally slow growth rates. 
However, Rag'7' mice which possess a severely compromised immune system 
(lacking in T-lymphocytes and B-lymphocytes) were also inoculated and 
showed regular and consistent K6 growth patterns. These data indicate a 
physiological alteration in immune responses to these cells by WT and C3'7' 
mice leading to enhanced clearance of fibrosarcomas. The anomalous 
findings coincided with the commencement of building works within the animal 
housing facility and increased noise and disruption to animals. Increased 
incidence of unexplained deaths within non-experimental mouse populations 
was noted and decreased litter sizes within breeding colonies. Increased 
stress levels may be present within animal populations leading to heightened 
immune responses effected through the release of various stress hormones. 
Such effects have been shown for increased leukocyte trafficking (Dhabhar et 
al. 2000), NK-cell activity (Dhabhar et al. 2000) and cytotoxic T-cell activity 
(Schild et al. 1999) through actions of heat shock proteins. However, the role 
of stress in immune responses remains a controversial subject with numerous 
findings of lower immune responses (reviewed by (Stefanski 2001)). 
Repeated attempts to achieve reliable data during this period were 
unsuccessful while various titres of fibrosarcoma cells were inoculated without 
significant improvement. These data are not shown here but involved titration 
of tumour load between 104 and 106 cells inoculated per host. Increased 
tumour dose was not sufficient to restore tumour take.
Following the return of fibrosarcoma growth in experimental mice (K6 
observed to grow with ~80% incidence), lines generated as described in this 
Chapter were used to investigate differences in WT and C3'7' tumour growth in 
C3 sufficient and deficient mice. Time constraints prevented a full 
investigation of tumour growth fully utilising the WT, C1q'7', C3'7' and CD55'7' 
.CD59'7' cell lines generated in this Chapter. However, each of these 
experiments would provide important data and remain novel and important
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tools with which to work further in this area. The previous lack of tumour 
growth, and time limitations meant that only an initial investigation of one 
experimental parameter was possible. Consequently, it was decided to 
investigate the growth of WT and C3'7' tumour populations in WT (C-sufficient) 
and C3'7“ (C-deficient) hosts. Additionally, heterogeneous (parent) lines were 
chosen for this experiment due to the higher tumour incidence and more 
robust model provided by these cells over clonal lines. Use of the clonal lines 
described above would have been preferable, however, to ensure that 
interpretable data with high incidence rates were generated in this final 
experiment, parent lines were selected. Two WT and C3"7' lines were 
inoculated into WT and C3‘7' male mice with high incidence recorded. From 48 
mice inoculated, only 6 failed to develop a tumour. This incidence level is 
-88% and in line with K6 data described in Chapter 4. Data were presented 
and analysed in terms of incidence and survival using the logrank statistical 
test. However, each parameter analysed included 2 groups with relatively low 
group sizes (n=12). A trend was observed suggesting retarded tumour 
incidence following inoculation of C3'7' cells into C3'7‘ hosts, however low 
group sizes prevent this from achieving statistical significance and further 
investigation of these data is needed to elucidate any differences in 
fibrosarcoma growth rates. Such parameters are difficult to evaluate in the 
absence of a very strong trend and would likely require group sizes 
considerably larger than used in these studies. However, such experiments 
would be difficult to manage in terms of age-matched controls. Despite small 
group sizes used, these data are difficult to reconcile with previous data 
described in Chapters 4, 5 and above. It was shown that C3b/iC3b deposition 
observed in this model was derived solely from activation of host C, and that 
no C3, C3b or iC3b was detectable in tissue culture supernatant incubated 
with these cells in vitro. The lack of C3 secretion by tumours (as a deliberate 
attempt to drive tumour progression) suggests a difference would not 
necessarily be expected between in vivo progression of WT and C3'7' lines. 
However, experiments in Chapter 5 described pro-tumour effects attributed to 
host C3 activation, thus, a difference would be expected when inoculating 
either WT or C3'7' lines into Wt and C3‘7‘ hosts through lack of pro-tumour 
effects in absence of host C3. However, these data are in agreement with
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those in Chapter 4 and, as discussed, may be attributed to fast fibrosarcoma 
growth rates masking potential differences. Alternatively, C-driven tumour 
progression may be more relevant in growth of a developing tumour (i.e. 3- 
MCA induction, <200 days) than in an established tumour (i.e. cultured lines, 
< 28 days). Significant further work, involving use of all WT, C1q'7', C3'7' and 
CD55‘7'.CD59'7’ clonal lines generated, sizable experimental groups and 
characterisation of arising tumours is required to further understanding of the 
roles for C-components or CReg in this model, while the use of the anti-C5 
mAb may also help elucidate mechanisms contributing to or opposing tumour 
growth.
Post excision immunohistochemical staining of these tumours suggested that 
fibrosarcomas generated in this model do not secrete their own C3, or that 
levels are below the detection threshold. No C3/C3b/iC3b was detected in C3‘ 
7' hosts despite the same tumour populations exhibiting positive staining in WT 
hosts. This indicated that tumour cells activate host C rather than secrete 
tumour-derived C3 in this model. Taken alone, these data are insufficient to 
conclude that WT populations do not secrete C3 in vivo. The use of 
heterogeneous lines is advantageous for this reason, in that the populations 
comprise numerous fibrosarcoma sub-populations and thus the likelihood of 
C3-secreting cells is greatly improved. The use of just two WT lines in this 
experiment represents a clear limitation to the study, however, this finding 
substantiates previous findings in Chapter 4 (no C3b/iC3b detected on K6 
cells in C3'7" hosts). This, and the in vitro lack of C3 secretion and C3 mRNA 
described provide convincing evidence against C3 secretion in this model.
Data described in this Chapter illustrate in vitro characteristics of WT, C1q'7', 
C3'7' and CD55'7'.CD59'7‘ fibrosarcomas generated through 3-MCA tumour 
induction. Clones from each genotype were selected which exhibited 
comparable growth rates as determined by Alamar Blue metabolism over a 
10-day period. Few differences were observed between groups with no CD55 
expression or mRNA detected. Expression and RNA transcription of CD59 
was conserved from heterogeneous populations only in C3'7' clones. No C3 
secretion or mRNA was detected in any populations assessed. All clones
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analysed were resistant to C-mediated killing (via CP activation) in both a flow 
cytometric and plate-based fluorescence assay. Further analysis of C 
susceptibility was performed via measurement of C3b deposition. Differences 
in Ab binding were controlled using differing titres of Ab per cell line, in order 
to bind comparable amounts on each. WT cells were shown to be less prone 
to C3b deposition, evidenced by higher doses of C required to evoke similar 
levels of deposition. Inoculation of 3-MCA inducted fibrosarcomas revealed no 
differences in incidence or survival in WT or C3_/‘ cells inoculated into WT and 
C3'/_ hosts. However, the lack of C3/C3b/iC3b detected in/on tumour cells in 
C3'/_ hosts appears to rule out the possibility of tumour-derived C3 in this 
model.
Experiments described in this Chapter were designed to establish and 
characterise novel clonal lines generated via 3-MCA tumour induction. Clonal 
lines of WT genotype, and those deficient in C components and CReg were 
generated and characterised in vitro. The in vivo characterisation of these 
lines remains incomplete yet represent valuable tools with which to continue 
investigation into the role of C in tumour growth and progression. Differences 
in tumour phenotype observed in WT or C-deficient host mice will be 
significant while data presented in this thesis demonstrates the validity of 
tumour induction and inoculation in the various mouse colonies available at 
Cardiff University as a means to investigate the important but poorly 
understood relationship between tumour cells and the C system.
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7. Discussion
7.1. General Discussion
Experiments described in this thesis were devised to investigate whether 
components of the C system contribute to or restrict tumour growth. The 
hypothesis that C may promote tumour survival and/or proliferation is a 
relatively new concept and little convincing evidence is available to support 
this idea, in this thesis, two distinct techniques for investigating the hypothesis 
were employed. Firstly, a WT fibrosarcoma line was inoculated in WT mice, 
and mice lacking C1q, C3 or two potent CRegs (CD55, CD59). Further, the 
same line was used to assess the effect of C5-neutralisation on fibrosarcoma 
growth via use of a mAb. These experiments were performed to investigate 
the effects of specific C deficiencies on the in vivo incidence and growth of an 
established and pre-characterised tumour line. In order to evaluate the impact 
of C on tumour development in vivo, a second technique was employed. This 
involved injection of a chemical carcinogen (3-MCA) in WT mice and mice 
lacking C1q, C3 and the two CRegs. Comparisons of tumour incidence and 
progression in these groups of animals provided important insights into the 
roles of these proteins in de novo tumour development. A crucial further 
objective to 3-MCA induction of tumours was the generation of novel tumour 
cell lines of the same genotype to the host mouse. Thus, tumour cell lines with 
and without the ability to synthesise specific C-components or CReg were 
generated from excised tumours. These were characterised in vitro and re­
inoculated into WT and C3‘7' hosts in order that the impact of systemic C and 
tumour-derived C could be evaluated independently.
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Results detailed in this thesis can be summarised into three key findings of 
particular significance:
1) The C component C5 can promote tumour progression following 
inoculation of an established fibrosarcoma line in vivo.
2) Both C components C1q and C3 can promote development of cfe 
novo tumours following 3-MCA tumour induction in vivo.
3) CD55‘7\CD59'7‘ hosts exhibit significantly impaired development of 
cfe novo tumours following 3-MCA tumour induction in vivo.
7.2. A pro-tumour role for the C5 protein
Experiments detailed in Chapter 4 describe the use of an established WT 
tumour cell line, K6. This fibrosarcoma line was injected into mice and tumour 
growth monitored. In the case of C1q and C3 deficiencies, no differences in 
tumour progression were observed with tumours growing rapidly and 
reproducibly in groups of WT, C1q‘7' and C3'7' mice. However, in vivo 
neutralisation of the C component C5 revealed a pro-tumour effect associated 
with this protein. In the absence of C5, hosts exhibited a statistically 
significant retardation in tumour growth compared to mice treated with an 
isotype control antibody. This effect, together with the observed deposition of 
C3 activation fragments on tumours in both WT and C5-neutralised mice 
indicated that one or more C pathways were activated in the inoculated 
animals and that C5 cleavage or downstream events were responsible for the 
pro-tumour effect in WT animals. Release of the anaphylatoxin, C5a, or 
deposition of the MAC, seem the likely candidates to enhance tumour 
progression in WT mice, each of which is absent in C5-neutralised 
counterparts. Possible mechanisms responsible for the pro-tumour effects are 
described below.
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Although work in this area is at an early stage, a very recent study observed a 
similar pro-tumour role for C5 cleavage mediated through the pro- 
inflammatory effects of the C5a anaphylatoxin (Markiewski et al. 2008). In this 
model, a murine cervival carcinoma cell line (TC-1) was used to identify a role 
for C in tumour progression. Elucidation of the contributory mechanism was 
achieved by use of an antagonist for the C5a receptor (C5aR) and separately 
by the use of C5aR'7‘ mice. In each case, the pro-tumour effects were 
abrogated in the absence of C5aR signalling and tumour growth retarded. 
Further, the role of C5a and C5aR interactions in the migration and 
immunosuppressive activity of myeloid derived suppressor cells (MDSCs) was 
demonstrated. These cells were more abundant in tumours derived from WT 
animals compared with those where the interaction between C5a and C5aR 
was blocked. Accumulated MDSCs were shown to suppress the immune 
response in WT hosts by dampening CD8+ anti-tumour responses thereby 
contributing to enhanced tumour growth. Therefore, the roles of C5a as a 
chemoattractant for MDSCs and in the promotion of inflammation were 
implicated in driving tumour progression in this model. Importantly, Markiewski 
et al also reported C1q deposition on tumour surfaces and impaired tumour 
growth in C3'/_ and C4'7' animals thus implicating classical pathway activation 
in the generation of C5a and pro-tumour effects.
As described above, a pro-tumour role for C5 was also shown in the 
experiments described in Chapter 4. These data initially appear to support the 
findings by Markiewski et al and could also be attributable to a lack of C5a 
signalling, recruitment of MDSCs and impaired CD8+ T-cell responses in C5- 
neutralised mice. However, key differences are apparent between the 
observed results and a separate mechanism appears to be responsible for the 
effects in this study. Results described in this thesis appear independent of 
classical pathway activation as deficiency of C1q did not impair tumour 
growth. Although activation of any C pathway allows generation of C5a, this 
observation suggests a different mechanism of C activation by tumour cells in 
this thesis. Further, the comparable tumour progression observed in WT and 
C3'a mice suggests a protective role for C5-neutralisation independent of C 
since no evidence for C5-cleavage was provided in C3'/_ mice. If C-activation
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was crucial to the observed effects, a similar protective effect would be 
expected in C3'A mice. Data shown in 7.1 represents key similarities and 
differences between a recent study by Markiewski et al, and results obtained 
in this thesis. Both reports describe a hitherto un-suspected role for the C5 
protein in progression of tumours in vivo but appear to be via different 
mechanisms. However, a major difference between the two models is the cell 
line utilised to assess tumour growth. TC-1 is a cervical carcinoma line 
whereas K6 is a fibrosarcoma line. These lines may utilise different 
mechanisms to avoid immune clearance and may also stimulate C-activation 
via a different pathway. Generation of the C5a fragment is known to exhibit 
chemotactic effects on fibroblasts (Postlethwaite, Snyderman and Kang 
1979), and also on several other tumour cell types (Orr et al. 1983). This 
effect was shown to be C5a specific and no chemotaxis was observed 
following C3a release. This mechanism has been also implicated in enhanced 
adhesion and metastasis in a rat carcinosarcoma model (Orr, Mokashi and 
Delikatny 1982).The above reports represent a possible C-independent 
mechanism for enhanced tumour growth following C5a release and represent 
a potential mechanism independent of C3a generation. However, C5a 
generated through C activation pathways also necessitates C3a release, 
making it difficult to elucidate effects specific to C5a in this thesis. Data 
described in Chapter 4 appear consistent with the above reports and 
suggested a pro-tumour role for C5a release.
Study Host C3 cleavage C5a effects MAC
deposition
Effect on 
tumour growth
Markiewski 
et al (2008)
WT S / ✓ normal
C3'' X X X impaired
C5aR'" ✓ X s impaired
This thesis WT V V V normal
C3"'" X X X normal
C5neut s X X impaired
Table 7.1: Summarised similarities and differences in tumour progression following inoculation of 
tumour cell populations into WT mice or those lacking C-components C3 or C5.
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Whilst data presented in Chapter 4 indicate a pro-tumour role for C5 
independent of C3, the use of C3_/‘ knock-out mice and C5-depleted hosts 
may also be of significance. This is due to differences in histocompatibility, 
cells derived from a C57BI6 mouse (K6) will be genetically identical to those 
on the same background (i.e. WT). However, C1q'7' and C3‘/_ knock-out mice 
were originally generated on different backgrounds and backcrossed onto the 
C57BI6 background. Although every care was taken to minimise 
histocompatibility issues (by backcrossing a minimum of 10 generations) -  
subtle differences may remain significant and cause an immune response and 
tumour rejection. The use of a C3-depleting agent or other convertase- 
inhibiting therapies in the current model would allow comparison of littermate 
controls, eliminating histocompatibility issues and providing further control and 
support for the above findings.
7.3. 3-MCA tumour induction
Experiments described in Chapter 5 involved the use of a chemical 
carcinogen (3-MCA) to induce tumours in male mice. Tumours grew in 100% 
of WT mice injected, but growth was inhibited in C1q_/', C3'7' and CD55’7* 
.CD59/_ mice suggesting important roles for these proteins in promoting 
tumour progression in vivo.
7.3.1. Impaired 3-MCA tumour induction in C1q'7‘ hosts
For the first time, experiments performed in Chapter 5 revealed pro-tumour 
roles for the initiator of classical pathway activation C1q and the central C- 
component C3 following injection of a carcinogen. As described, C1q_/' mice 
formed tumours later and with lower incidence than WT controls. Evidence 
presented throughout this thesis suggests that fibrosarcoma cells activate C in 
vivo suggesting that tumours raised in Clq^'hosts, unable to activate the 
classical pathway, may activate C to a lesser extent and experience lower 
levels of the cellular activation events associated with C3b/MAC deposition 
and described in section 1.12. However, this hypothesis was not supported by 
data in Chapter 5 whereby comparable levels of C3b/iC3b deposition were
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observed on WT and C1q‘7” tumour tissues. Deposition of C3 activation 
fragments on tumour sections cannot be derived from classical pathway 
activation in C1q'7' hosts and either alternative or MBL pathways must be 
activated. Whilst C3 activation products may be deposited via the same 
pathway in WT and C1q‘7" tumours, it is also possible that deposition on WT 
tumours is derived from the classical pathway and derived from alternative 
pathway activation on C1q'7' tumours through a different mechanism. 
Deficiency of C1q is linked to impaired clearance of apoptotic cells and 
consequent activation of the alternative pathway (Matsui et al. 1994, 
Mevorach et al. 1998). In order to determine the mechanism of C activation in 
C1q'7' tissues (i.e. tumour activated or apoptotic cell activated), assessment of 
apoptotic cell numbers in C1q‘7‘ and WT cell populations is needed and may 
be achieved via immunohistochemical techniques. Commonly used markers 
for labelling apoptotic cells include caspase 3, a cysteine proteinase enzyme 
central to the apoptotic pathway. Alternatively, an established method exists 
for detection of DNA fragmentation known as terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) (Gavrieli et al. 1992). This 
technique may be adapted to accurately identify cells in the latter stages of 
apoptosis. Co-localisation of C3b deposition with apoptotic cells would 
suggest these to be responsible for C-activation while decreased infiltration of 
phagocytic cells may also be observed in C1q'7' mice compared to WT 
controls. Elucidation of the mechanisms of C activation by tumours or 
apoptotic cells is a critical further experiment and is necessary in order to 
better interpret the role of C1q in tumour progression.
A role for C1q in controlling tumour growth has also been shown independent 
of CDC. A murine tumour study previously found that local C1q biosynthesis 
was required for both Ab-mediated and Ab-independent tumour cytotoxicity 
through activation of macrophages (Leu et al. 1990). Additionally, a recent 
report that C1q can induce apoptosis in human prostate cancer cells also 
argues against a pro-tumour role for C1q (Hong et al. 2009). These reports of 
anti-tumour roles for C1q are in contrast to data presented in this thesis and 
predict enhanced tumour growth in C1q‘7‘ mice. These effects are either
260
irrelevant in the 3-MCA tumour induction model, or are outweighed by factors 
promoting tumour growth in WT mice.
7.3.2. Impaired 3-MCA tumour induction in C3'7' hosts
A role for the central component C3 was also demonstrated in facilitation of 
tumourigenesis following 3-MCA injection. This finding appears to support 
observations in C1q A mice and may also be linked to impaired classical 
pathway activation in C3"/_ mice and suggests a pro-tumour role for the C3 
protein. This observation is particularly important given the diverse roles for 
the C3 protein in both innate and adaptive immunity, in particular the 
contributions to optimal T-cell and B-cell responses (Kerekes et al. 1998), 
(Carter and Fearon 1992). These mechanisms are discussed fully in section 
1. 4). Given these roles, any pro-tumour role for C3 would be expected to be 
offset or eclipsed by significantly impaired immunosurveillance in C3_/' mice 
resulting in enhanced tumour progression compared to WT controls. 
However, this was not the case and the tumour progression was restricted in 
C3"/_ hosts. Thus, impairment of immune responses associated with lack of 
the C3 molecule either did not affect tumour growth, or the effects were 
significantly outweighed by the absence of pro-tumour effects of C3 present in 
WT hosts. Clear evidence demonstrating the importance of C in tumour 
progression is provided and necessitates a change in conventional thinking 
and significant further study in this area. As yet, there is scant other evidence 
to support possible mechanisms for a pro-tumour role for C3, however, a 
study on mouse lung carcinoma cells demonstrated enhanced proliferation 
following C3 activation, surface deposition and internalisation thought to be 
mediated via a stimulatory growth signal (di Renzo et al. 1999). Further work 
involving the use of anti-C3 Abs proved a direct role for C3 in enhanced 
tumour growth. Internalisation of C3 products was followed by increased 
protein kinase activity with the PKC family crucial to proliferative effects 
observed (Longo et al. 2005). Activation of cellular pathways and increased 
phosphorylation by various tyrosine kinases may lead to a multitude of 
downstream effects capable of stimulating cells and promoting tumour growth. 
The reports detailed in section 1.12 whereby C3b and MAC deposition may
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activate these pathways represent a possible explanation for the enhanced 
tumour progression observed in WT compared to C3'/_ hosts.
Whilst both C components C1q and C3 were shown to be important for driving 
tumour progression following induction by 3-MCA, pro-tumour effects for 
these proteins were not observed in Chapter 4 following inoculation of 
cultured fibrosarcoma cells. In these experiments, C5 only was shown to 
contribute to enhanced tumour progression with comparable growth in WT, 
C1q_/' and C3‘/_ hosts. As previously discussed in Chapter 4, the limited 
timescale of these experiments (<4 weeks as opposed to <4 months in 3- 
MCA experiments) may be insufficient for pro-tumour effects to become 
apparent. Alternatively, differences between the two tumour growth models 
may be responsible and suggesting a role for C in promotion of developing 
tumours, but not in established populations i.e. the early events related to 
tumourigenesis may be aided by C activation whereas developed tumour cells 
may grow sufficiently well in the presence or absence of C. In order to 
investigate this hypothesis, alternative models could be employed utilising 
different cell types or tumour induction models i.e. varying the tumour 
incubation time by using a less aggressive cell line. For example, the murine 
melanoma cell line B16 is also derived from a C57/BL6 mouse (thus avoiding 
antigen differences) and exhibits a longer latency period that K6 with slower 
growth and hosts remaining tumour free up to 3 weeks post inoculation with 
10s cells (Cuff etal. 2010).
7.3.3. C as a ‘double-edged sword’ in tumour immunity
An important consideration when evaluating C-related effects is that depletion 
or deficiency of a protein not only abrogates the effects associated with 
(deposition or cleavage of) that protein, but also affects all downstream 
activation events. In this way, C3_/' mice show no C3b deposition on tumour 
cells, but tumour cells will also not activate the terminal pathway. Therefore 
C5a release and MAC deposition are also absent in C3'7' hosts, and attributing 
a pro-tumour role to a single C-component is difficult. Cellular activation 
events following C3b / MAC deposition represent a possible mechanism for
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pro-tumour effects associated with C. These effects are discussed in section 
1.12 and represent ways by which nucleated cells exhibit increased protein 
kinase activity following sublytic C deposition and subsequent recovery of 
targeted cells. Further, cells exposed to sublytic doses of C may acquire 
increased resistance to subsequent C deposition, known as C-induced 
protection. The concept of induced protection was not studied in this thesis 
and it’s role remains unclear in vivo. However, this phenomenon represents a 
significant mechanism which may contribute to a pro-tumour role for C and 
warrants renewed investigation. Ideally, tumour ceils would be treated with 
different levels of C deposition in vivo with proliferative rates, CReg 
expression and tendency to metastasise assessed. This may be achieved via 
the use of differing Ab doses to activate classical pathway although 
considerable care must be given to control for non-C effects i.e. ADCC. 
Further in vitro work is also needed to further elucidate effects and 
mechanisms associated with sublytic C attack. Considerable work in this area 
allowed determination of numerous cell effects (discussed in Section 1.12) 
associated with sublytic C deposition and recovery, however, further study in 
this area to investigate specific effects and also explore whether tumour cells 
can exploit these mechanisms or they actually exhibit equivalent outcomes to 
non-transformed nucleated cells. In order to study the effect of in vitro 
sublytic attack, cells may be treated with C prior to inoculation into WT hosts, 
with differing doses of C tested and in vivo growth of tumour cells monitored. 
Fibrosarcoma cells could be used to investigate this hypothesis, although data 
described in Chapter 6 show these cells to be highly resistant to CDC. 
Consequently, a cell line sensitive to C in vivo would be extremely interesting 
to assess whether initial treatment could render the inoculated cells more 
resistant and aid progression. Further generation of fibrosarcoma cells as 
described in this thesis may produce such a cell line, whilst other tumour cell 
types may also be more suitable. These studies could then be extended to 
test for effects of specific components as detailed in this thesis, this would 
include deposition of C3b fragments in the absence of MAC e.g. C5-depleted.
An inherent problem with the use of C-deficient animals is the inability to 
attribute observed effects to a single mechanism. This is due to the cascade
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nature of the C system which means that deficiency in a certain C-component 
may yield effects attributable to that protein or to any of the numerous 
downstream effects. Thus, both pro-tumour and anti-tumour effects of C will 
be affected by deficiency in any C component. In reality, an overall pro-tumour 
effect of C1q and C3 deficiency is shown in Chapter 5 but this effect is 
comprised of a number of variables and an overall representation of the 
‘balance’ between pro-tumour and anti-tumour responses is apparent. Figure 
7.2 outlines several of the major contributory factors involved with C1q and C3 
deficiency and in each case, the pro-tumour role for C (in WT hosts) 
outweighs the various immune mechanisms contributing to anti-tumour 
responses. Isolation of clearly defined roles for individual proteins (e.g. C5a) 
is necessary to properly address this emerging hypothesis and evaluate 
possible therapeutic strategies to counteract pro-tumour effects associated 
with C.
Impaired CDC 
Impaired opsonisation 
Impaired chemotaxis (immune cells) 
Impaired phagocytosis
Impaired C3b deposition
Impaired MAC deposition
Impaired chemotaxis (suppressive cells)
Pro-tumour effects Anti-tumour effects
Figure 7.2: Schematic diagram representing ‘balance’ of pro- and anti-tumour 
effects associated with deficiency of C1q or C3 in 3-MCA tumour induction.
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The inflammatory response is an important factor in tumour development and 
has long been thought to contribute to cancer progression. Several studies 
have found a decreased cancer risk in human patients prescribed anti­
inflammatory drugs over a long period of time (Garcia-Rodrlguez and Huerta- 
Alvarez 2001, Meier, Schmitz and Jick 2002). As described previously, 
release of anaphylotoxic protein fragments C3a and C5a are consequences of 
C activation with potent pro-inflammatory effects attributed to both. In this 
way, activation of C may contribute to pro-tumour effects through increased 
inflammation not present in C5-depleted hosts. The protective effects 
observed associated with C1q and C3 deficiency were strong and statistically 
significant yet appear to be mediated through separate mechanisms. Whilst 
the work in this thesis aims to investigate pro and anti-tumour effects of C, the 
observed results point to a strong role for C in tumour progression despite 
impairment of various immune mechanisms. The classical pathway of C is 
known to be important for induction of optimal immune responses. C1q has 
been shown to be important in optimal T-cell responses with defective 
cytokine production noted in C1q'7' mice (Cutler et al. 1998). Additionally C3 is 
strongly implicated in optimal T-cell responses (see Section 1.4) (Arvieux, 
Yssel and Colomb 1988, Kerekes et al. 1998). However, both C1q'/_ and C3'7' 
mice exhibited retarded tumour growth even with impaired 
immunosurveillance mechanisms. This indicated strong pro-tumour roles for 
these proteins able to overcome impairment to anti-tumour responses and 
develop statistically significant effects against tumour progression.
Deposition of C3b/iC3b and MAC was observed on tumour samples grown in 
WT, C1q'/_ and CD55'/'.CD59/' mice. The tissue analysed from these mice 
was from progressively growing tumours and therefore those not cleared by 
immune mechanisms. Preferably, host mice in which tumours grew initially, 
but were cleared by C-responses would also be analysed. These C-sensitive 
cells would be isolated and characterised (e.g. CReg expression, MAC 
shedding, C3 secretion) to identify differences in cleared and non-cleared 
tumour cell populations. Thus, mechanisms by which tumour populations 
were able to escape immunosurveillance could be identified. Unfortunately, 
such evaluation is inherently difficult as palpable tumour populations rarely
265
i
arise in these animals and cannot be excised and evaluated. Importantly, 
tumours in C3‘7' hosts were not subjected to C3b or MAC deposition, nor could 
C3a or C5a be generated. A role for C5a-mediated recruitment of MDSCs (in 
WT hosts) is therefore possible in this model as described above and 
demonstrated by Markiewski et al (2008). Markiewski’s study showed 
retarded tumour progression in C3‘7' mice through impaired recruitment of 
MDSCs in the absence of C5a. Unfortunately, it was not possible to 
investigate the effects of C5 deficiency/depletion using 3-MCA to induce 
tumours in this study. This was due to the large quantities of mAb required to 
fully deplete host mice, and the extended time period (>90 days) before 
tumours arise in this model. For this reason, knock-out animals rather than 
antagonists or depleting antibodies are more appropriate to examine effects 
on 3-MCA tumour induction. However, depletion of C components could be 
achieved over a shorter time span e.g. to examine the effects of C5 during a 2 
week window immediately following injection of the carcinogen. This could 
allow assessment of the role of C5 in the early events associated with 
carcinogenesis. Investigation of C5-deficiency in the 3-MCA model would be 
an important experiment to consider and examine the role of C5a in 
inflammation during tumour development and immunosurveillance. A pro­
tumour effect would be expected to support findings in Chapter 4 and may 
help elucidate a mechanism for the effects of C3-deficiency observed in 
Chapter 5.
7.3.4. CD55 and CD59 in tumour progression
Also investigated in Chapter 5 was the effect of CReg deficiency on 3-MCA 
induced tumours. Mice deficient for both CD55 and CD59 were injected with 
3-MCA and found to be resistant to tumour induction. Various tumour cells are 
thought to abundantly express CReg in order to protect themselves from C- 
mediated lysis (Fishelson et al. 2003), thus, the inability to express such 
proteins may be expected to sensitise emerging tumour cells to CDC. 
However, characterisation of tumour populations revealed that CD55 was not 
expressed on WT, C1q'7' or C3'7* tumour cells. This observation was made 
immediately post excision of tumour cells with the lack of CD55 expression
also maintained following generation of in vitro populations and clonal cell 
lines. Therefore, CD55 initially appears not to contribute to tumour 
progression in this model. Conversely, the expression of CD59 was 
demonstrated in WT, C1q'/_ and C 37' groups immediately following tumour 
excision. This suggests that tumour expressed CD59 is more important in this 
model and could be responsible for the preferential tumour growth observed 
in WT compared to CD55'/'.CD59‘/' hosts. In these mice, tumour cells did not 
materialise or were cleared effectively and the lack of CD59 expression is 
likely to sensitise fibrosarcomas to CDC through inability to regulate the 
terminal C pathway. However, alternative roles for these CReg other than 
protection from CDC have recently been demonstrated which may are 
important when considering the observed results. Although CD55 was not 
present on excised tumour cells from WT animals, expression on other (non­
tumour) cells may instead be significant. Deficiency of CD55 has been shown 
to allow stronger CD4+ and CD8+ T-cell responses to antigen (Liu et al. 2005, 
Fang et al 2007), which could lead to enhanced clearance of tumour cells in 
CD55'7' mice. A similar down-modulatory role for CD59 has been shown in 
suppression of CD4+ T-cell responses leading to decreased proliferation of 
these cells (Longhi et al. 2005). Again, CD59_/' mice may therefore exhibit 
enhanced clearance of tumour cells and protection from 3-MCA tumour 
induction. The global lack of these two proteins could therefore lead to 
enhanced anti-tumour immune responses and tumour clearance dependent 
on C activation, but not via CDC. These novel roles for CReg are an area 
worthy of significant further study and are yet to be investigated in the context 
of tumour immunology. The respective effects which may contribute to the 
lower tumour incidence in CD55'/‘.CD59'/' mice are summarised in Figure 7.3. 
Significant further work would be required to investigate this hypothesis with 
differing contributions of CD4+, CD8+, NK-cells expected depending on the 
tumour model used. Infiltration of these cells could be assessed by 
immunohistochemistry or flow cytometry, however, careful consideration must 
be given to the activities of these cells (e.g. large numbers of cells may 
suggest a response, but activity may be suppressed and cell presence 
irrelevant). Activation markers could help identify anti-tumour responses, while 
isolation and in vitro characterisation for cytokine production and/or responses
267
to tumour antigen would also be important. The precise immunological 
functions of CD55 are yet to be established with a role for this protein also 
reported in enhancement of T-cell responses. Cross-linking of CD55 using 
mAbs has been shown to activate T-cells (Tosello et al. 1998). It has been 
suggested that the enhanced T-cell responses are caused by abrogation of 
CD55 CReg function, leading to increased production of C activation 
fragments. This is consistent with the findings of Liu (2005) and Heeger 
(2005) who noted enhanced T-cell responses in CD55'7' mice. However, a 
further demonstration of CD55-mediated enhancement of T-cell responses (in 
conjunction with TCR engagement) found increased activation of CD4+ T- 
cells via a non-neutralising mAb specific for CD55 suggesting a role 
independent of C deposition and diverse roles for the CD55 protein on T-cells 
(Capasso et al. 2006)
Data described in this thesis suggested possible roles for CD55 or CD59 in 
promoting tumour progression, the reasons underlying this difference must be 
determined. If enhanced T-cell responses are responsible for tumour 
clearance in CD55‘/\CD59‘/‘ hosts, this could represent a crucial strategy in 
harnessing existing host immune mechanisms to clear tumour cells. Initial 
investigation of CD4+ infiltrates within tumours did not identify a difference 
between groups though investigation of T-cell phenotype (Theiper, Treg, CD8+) 
and anti-tumour activity of these cells would provide crucial data as to the 
immune effectors contributing to the observations. Further, the use of single 
knock-outs (i.e. CD55*7' and CD59'7* separately) is important to examine the 
effects of individual CReg deficiencies and allow dissection of the relative 
contributions of CD55 and/or CD59 to pro-tumour effects in WT mice. Whilst 
various approaches for targeting CReg on tumour surfaces are available and 
in development (Ziller et al. 2005, Macor et al. 2007) perhaps a more 
successful strategy may include targeting CReg expressed on immune cells 
to temporarily increase their anti-tumour functions. When combined with 
traditional tumour therapy e.g. excision, radiotherapy and chemotherapy 
treatments, enhancement of the efficacy of circulating immune cells may help 
prevent relapse or metastasis and improve patient prognosis. However, such 
an approach is likely to have significant autoimmune consequences and
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would require extensive research to assess, optimise and control potential 
effects.
Enhanced C3b/MAC deposition (?)
Impaired CReg capacity 
Enhanced CDC (?) 
Enhanced T-cell immunity
Pro-tumour effects Anti-tumour effects
Figure 7.3: Schematic diagram representing ‘balance’ of pro- and anti-tumour effects 
associated with deficiency of CD55 and CD59 in 3-MCA tumour induction.
7.4 Further observations
Further to the three key findings described in this thesis, a number of other 
observations provided useful insights into the role of C in tumour progression. 
Experiments detailed in Chapter 6 further confirmed the observation from 
previous Chapters that fibrosarcoma cells do not express the CReg CD55.
This absence is somewhat surprising but may be linked to the abundant 
expression of Crry detected on all tumour cells analysed, which has an 
overlapping CReg function with CD55. While all tumour populations 
expressed CD59 in vivo, only C3'/_ lines were shown to conserve this 
expression in vitro. Preliminary experiments were performed in order to 
identify differential growth of these cell lines in C-sufficient, and C-deficient 
hosts. Re-inoculation of WT and C3'7' lines failed to reveal a difference in 
tumour progression in either WT or C3'/_ hosts, although increased group 
sizes would be required in order to confirm this observation. Unforeseen 
problems associated with tumour growth in this model and time constraints 
prevented a full investigation of host and tumour derived C components and 
their in vivo effects. These experiments remain incomplete and represent an 
invaluable opportunity to assess the effect of tumour cell C deficiencies on
tumour growth. Further, assessment of CReg expression following re­
inoculation may reveal that WT cells up-regulate CD59 to previous levels 
when returned to an in vivo setting. Clonal fibrosarcoma cell lines (WT, C1q'7', 
C3"7' and CD55'7'.CD59‘7') were generated and extensive study of the 
progression of these cells in WT and C-deficient hosts are important 
experiments with the potential to elucidate key mechanisms by which C can 
promote tumour progression in vivo. The secretion of C-components e.g. C1q 
and C3 by tumour cells may play important roles in tumour progression and 
represent a clear strategy by tumour cells to induce cellular activation 
mechanisms. Cell lines sufficient and deficient in proteins are important tools 
to address the contributions of host and tumour derived C component 
secretion to tumour progression. The re-inoculation of CD55'7\CD59'7’ cells 
also represents an important further experiment with interesting 
consequences. These cells would ordinarily be expected to be sensitised to 
CDC through impaired regulation of activation pathways (CD55) and the 
terminal pathway (CD59). However, a role for tumour expressed CD55 was 
not shown for these fibrosarcoma lines, and CD59 only was detected on WT 
tumour cells. Cells lacking these CReg may be poorly adapted to in vivo 
growth, cleared by CDC and account for the poor tumour growth in CD55‘7' 
.CD59‘7‘ described in Chapter 5. However, in light of more recent 
immunological roles shown for CD55 and CD59 (reviewed by Longhi et al. 
2006), these effects may be independent of CDC. Therefore, these cells may 
up-regulate different CRegs, or utilise alternative mechanisms to avoid lysis 
upon re-inoculation into C sufficient animals thus remaining protected from C 
effects and able to proliferate rapidly. Responses of these cells to C 
deposition would provide crucial insights into the value of C as a potential 
anti-tumour effector mechanism.
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7.5. C3 secretion
The secretion of C components by fibroblast cells (Garred et al. 1990) , and 
several tumour cell types (Kitano and Kitamura 1993, Jean et al. 1997) has 
previously been demonstrated. The central component C3 is the most 
commonly found C-component in culture supernatants and may be an 
important factor in the relationship between tumour cells and C. In order to 
address the relative contributions of host and tumour derived C components 
to tumour progression, cells which synthesise and secrete C components are 
required. Synthesis or secretion of C3 by WT cells generated by 3-MCA 
tumour induction was not observed in this study, but may require stimulation 
before C3 can be detected. This may be achieved in vitro via treatment with 
various stimulatory cytokines e.g. IL1, IL6 and IL13 (Katz and Strunk 1989, 
Katz, Revel and Strunk 1989, Katz et al. 1995). However, the absence of 
C3b/iC3b deposition on WT tumour cells in C3'/_ hosts as described in 
Chapter 6 suggests that these cells were not stimulated to secrete significant 
C3 in vivo with no C3b/iC3b detected on tumour sections following re­
inoculation. This may be due to very low amounts of C3 being secreted, or 
that C3 was not activated and was unable to deposit on cells. Generation of 
tumour cell lines which secrete C3 (and those generated by identical methods 
in C3'7' hosts) would provide an invaluable tool with which to investigate the 
role of tumour derived C and enhanced proliferative or metastatic effects 
associated with such a phenotype. A number of C3 cleaving proteins have 
been identified which are secreted by tumour cells, these cysteine proteinase 
enzymes have C3 inactivating capacity and have been found to be co­
secreted with tumour derived C3. This represents a possible mechanism by 
which tumour cells may promote their own progression, through C3b 
deposition and subsequent cellular activation, yet remain protected from CDC 
and opsonisation by enhanced C3 cleavage capacity. Up-regulated or 
enhanced C3 inactivation may be a feature of tumour cells secreting C3 and 
remains an area worthy of further study. While C3 secretion is the best 
studied and provides the most likely mediator of pro-tumour effects, 
investigation of various other C-component and CReg expression or secretion 
is worthwhile and may yield interesting results.
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7.6. Further experiments
In addition to WT, C1q_/', C3'/_ and CD55'/'.CD59‘/‘ animals and tumour 
populations generated from these hosts, a number of other knock-out mice 
would be extremely useful to further dissect the contributions of individual C 
components to tumour progression. The model employed in this thesis 
provided a powerful and reproducible method allowing comparison between 
WT and C-deficient animals. Differences observed became statistically 
significant with manageable group sizes and provided interesting 
observations. Of particular interest would be mice deficient in C2, C4 or fB, 
this would allow assessment of the relative contribution of the classical (C2 or 
C4) and alternative (fB) activation pathway to C activation, deposition and 
tumour progression. Whilst C1q remains the most significant C-component 
linked with apoptotic clearance, further investigation of apoptosis in the 
tumour micro-environment and effects on tumour growth could be achieved by 
study in C 27' or C4*7' mice given the reported roles for classical pathway 
components in clearance of ACs (Taylor et al. 2000). Additionally, mice 
deficient in a terminal pathway component e.g. C6 would provide an excellent 
opportunity to assess the lytic pathway i.e. effects of MAC deposition. 
Crucially in this deficiency, release of the anaphylatoxin C5a is possible, but 
no further deposition of C components onto target membranes can occur. 
Mice deficient in fB and C6 are available in house, currently being back- 
crossed onto a C57BI6 background and will provide exciting opportunities to 
extend this work when properly controlled with WT mice on the same 
background. Additionally, the respective contributions of the CReg, CD55 and 
CD59, to the protective effect can also be elucidated via experiments with 
single knock-outs. Such experiments would involve induction of tumours (via 
3-MCA) in WT, CD55'7' and CD597' tumours. A statistically significant 
difference would be expected between WT and deficient groups depending on 
whether CD55 and/or CD59 was responsible for the pro-tumour effect in WT 
hosts observed in Chapter 5. At present, effects cannot be attributed to either 
protein with evidence to suggest both can contribute to enhanced tumour 
progression.
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An exciting recent development offers an opportunity to extend this study in 
Crry'7' mice allowing investigation of both the potent C-regulatory (Section 
1.6.2.4) and immunological roles (Section 1.7.3) of this crucial protein. 
Previously, mice bred to this genotype died in utero and could be studied only 
by cross-breeding to a C3'7' background. However, Crry'7' mice have recently 
been generated following inhibition of the terminal pathway (Ruseva et al. 
2009), these animals are able to synthesise and deposit C3 activation 
fragments. Clearly, Crry is of vital importance in mice and was expressed on 
all tumour sections analysed in this study. A role for Crry expression has been 
shown in promotion of tumour metastasis in a rat model of colorectal 
carcinoma, with significantly decreased outgrowth following blockade of Crry 
(Gelderman et al. 2004). The Crry protein appears important in murine 
tumours, and fibrosarcomas deficient in this CReg would be invaluable to 
investigate resistance to CDC and Crry contribution to tumour progression.
Further roles in immune cell signalling are becoming apparent with promotion 
of differentiation and activation demonstrated for mouse CD4+ T-cells 
following co-ligation of CD3 and Crry (Fern£ndez-Centeno et al. 2000, 
Jimenez-Perianez et al. 2005). Another important finding was provided by 
studies whereby transfection of rat adenocarcinoma cells with Crry enhanced 
tumourigenicity and decreased ADCC through impaired NK-cell responses 
(Caragine et al. 2002). Importantly, this function was shown to be independent 
of C-opsonisation and revealed a novel role for Crry in mediating NK-cell 
immunity. Therefore the role of Crry in tumour progression extends outside it’s 
role in regulating complement, and Crry'7' mice will allow further investigation 
into a purported role in tumour progression in rodents and how that may 
translate into human studies.
Experiments described in this thesis were designed to investigate the effects 
of specific C components or CReg on tumour progression. Further, several 
key characteristics were identified and assessed including expression of the 
CRegs CD55, CD59 and Crry. However, various other CRegs exist which 
may contribute, or be crucial to tumour cell survival and/or growth and 
represent important future experiments to further the characterisation of these
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cells and lead to better understanding of the relationship between 
fibrosarcoma cells and the C system. Expression of CR1 is normally restricted 
to B-cells and DCs in mice (Kinoshita et al. 1988), but retains C regulatory 
activity and could potentially be utilised by tumour cells, while fluid phase 
CReg such as fH, fl or C4bp could also serve to regulate classical and 
alternative pathway activation respectively. A number of cell surface markers 
may also provide useful indications of mechanisms affecting tumour growth in 
this model. For example, reduced MHC Class I expression has been 
implicated in escape from immunosurveillance through impaired antigen 
presentation and T-cell mediated immunity (reviewed by Bubenik J et al. 
2004). Additionally, expression of C component receptors (e.g. C1qR, C3aR, 
C5aR) by both tumour cells, and infiltrating immune cells could be of 
significance in order to elucidate contributory pro-tumour or anti-tumour 
effects. Such characterisation was performed by Markiewski et al and was 
able to identify the recruitment of immunosuppressive cells (MDSCs) by 
chemotaxis through expression of C5aR.
As described in section 1.10, and as demonstrated in Chapters 4, 5 and 6, 
fibrosarcoma cells are able to activate the C system which is therefore 
considered a potential anti-tumour effector mechanism (reviewed by Macor et 
al. 2007). A major advantage of utilising C in Ab-targeted anti-tumour therapy 
involves the local biosynthesis of C components in the tumour vicinity and the 
enhanced penetration of small, soluble components into tumour masses 
compared with impaired penetration by immune cells, thus the localisation of 
C components to targeted tumour cells is easier than that of other ADCC 
effector cells e.g. NK-cells. Additionally, a crucial feature of the classical C 
pathway is the ability to localise activation to the site of Ab binding. As such, 
mAbs specific for tumour antigens may localise C deposition to tumour 
surfaces and cause tumour cell death by CDC or opsonisation. However, as 
previously described tumour cells possess numerous mechanisms to evade 
C-mediated cytotoxicity, the best studied being expression of CReg. As such, 
mAb immunotherapy remains an inefficient yet promising anti-tumour 
treatment. A number of mAbs have been developed and approved for use in 
human anti-cancer therapy. Of the mAbs used to target neoplastic cells,
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relatively few have been shown to activate C. However, the anti-CD20 mAb 
Rituxumab is known to activate C on non-Hodgkins lymphoma cells and 
contribute to cell destruction via CDC (Di Gaetano et al. 2003). Another mAb 
specific for CD52 (Alemtuzumab) is also dependent on C activation to 
mediate anti-leukaemia function (Zent et al. 2004). Both mAbs have been 
approved for in vivo use as an adjuvant to conventional therapies e.g. 
surgery, chemotherapy. In order to fully maximise the potential of mAb 
immunotherapy, strategies to improve the efficiency and enhance C activation 
have been sought. Such strategies are outlined in Section 1.10 and include 
chemical engineering of antibody constructs (Harris et al. 1997), and 
preferential selection of lgG1 and lgG3 sub-classes in order to maximise C 
activation (Idusogie et al. 2001). Targeted inhibition of CReg activity on 
tumour cell surfaces has also been used to improve therapeutic efficacy. 
Thus, reducing CReg activity in vitro using cytokines (Blok et al. 1998), siRNA 
(Zell et al. 2007), and mAbs were shown to sensitise tumour cell lines to CDC 
(Harris et al. 1998, Ziller et al. 2005). Therefore, bi-specific mAbs recognising 
both a tumour antigen and a CReg represent a promising strategy able to 
simultaneously activate C and sensitise target cells to CDC. Work in this area 
is ongoing with a number of in vitro studies providing promising evidence for 
enhanced killing of tumour cells. Enhanced C3b deposition and CDC have 
been observed in a colorectal (Gelderman et al. 2002b), and cervical 
carcinoma model (Gelderman et al. 2002a) following bi-specific targeting of a 
tumour antigen and CReg. Additionally, a spheroid model of renal carcinoma 
metastases showed significant killing and clearance of micrometastases 
following targeting using a bi-specific mAb against G250 antigen and CD55 
(Sier et al. 2004). Evidence to support the use of these Abs in vivo is scant, 
though CDC, along with ADCC, remain promising therapeutic strategies for 
targeting tumour cells and enhancing immune responses for clearance of 
tumours in humans. This technique may be used as a standalone therapy or 
in conjunction with conventional methods such as surgery and chemotherapy 
to improve treatment efficacy and reduce potential metastases.
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7.7. Conclusions
Thus far, strategies to enhance C activation on tumour cells either by mAb 
targeting or CReg inhibition have been performed on the premise that C 
contributes to tumour cell clearance and improves patient prognosis. 
However, more recent data presented by (Markiewski et al. 2008), and in this 
thesis point to a pro-tumour role for C-activation suggesting that careful 
consideration and further research is needed to investigate potential pro­
tumour consequences resulting in enhanced tumourigenicity and poorer 
patient prognosis. Such reports are contrary to dogma, challenge current 
thinking and necessitate a radical rethink and renewed investigation into the 
role of C in tumour progression in order to acquire a true representation of the 
doubie-edged sword role played by the C system in tumour immunology.
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